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Abstract 
Mycoplasmas are evolutionarily advanced prokaryotes which have acquired the elite status of “next 
generation” bacterial pathogens and necessitate new paradigms in completely understanding their disease 
potential. The recurrent failure to eradicate mycoplasmal diseases from humans and animals through the 
use of antibiotics and other techniques have led to the conclusion that the most promising approach would 
be the development of an effective vaccine with which to control mycoplasma infections. The identification 
of three species of Mycoplasma which infect South African ostriches, causing huge losses to the South 
African ostrich industry each year, has thus prompted a search for new vaccination strategies with which to 
control and eradicate them. This study investigated the use of three potential DNA vaccines, utilizing the 
adherence-associated Ms01 OppA protein as antigenic determinant to generate antibody responses against 
the ostrich-infecting Ms01 organism. A vaccine trial in which the antigenic potential of the pCIneo, 
VR1012 and VR1020 DNA vaccines were evaluated in ostriches, necessitated the development of an 
enzyme-linked immunosorbent assay (ELISA) for serological analysis. To this end, the Ms01 oppA gene 
was isolated, cloned into a prokaryotic expression vector and expressed as a recombinant GST-fusion 
product in Escherichia coli. The successful expression and purification of the recombinant protein enabled 
its subsequent utilization as antigen in the generation of an ELISA. The ELISA displayed a high signal to 
background ratio. Using this ELISA, it could be shown that ostriches already possessed antibodies to the 
Ms01 organism prior to vaccination, a probable result of previous exposure. The expected antibody 
response pattern could not be detected in ostriches in response to the vaccinations, and therefore no final 
conclusion as to the immunostimulatory capabilities of the DNA vaccines could be drawn. Further 
vaccination trials in which ostriches that do not possess immunity to ostrich mycoplasmas, are required in 
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Opsomming 
Mikoplasmas is evolusionêr gevorderde prokariote wat as nuwe generasie bakteriese patogene beskou word 
en nuwe paradigmas word benodig om hulle siekte potensiaal te verstaan. Die herhaaldelike mislukking om 
mikoplasmatiese siektes van mense en diere deur die gebruik van antibiotika en ander tegnieke het tot die 
gevolgtrekking gelei dat die mees belowende benadering tot die beheer van mikoplasma infeksies, die 
ontwikkeling van ‘n effektiewe entstof is. Die identifisering van drie spesies van Mycoplasma wat Suid-
Afrikaanse volstruise infekteer, en groot verliese in die Suid-Afrikaanse volstruisbedryf veroorsaak, het tot 
‘n soektog na nuwe entstof strategieë gelei waarmee hulle beheer en uitgewis kan word. Hierdie studie het 
die gebruik van drie potensiële DNA entstowwe ondersoek, wat die selaanhegtings-geassosieerde Ms01 
OppA proteïen as antigeniese determinant benut, om antiliggaam response teen die volstruis infekterende 
Ms01 organisme te genereer. ‘n Entstof proef is onderneem waarin die antigeniese potensiaal van die 
pCIneo, VR1012 en VR1020 DNA entstowwe geëvalueer is in volstruise, en het die ontwikkeling van ‘n 
ELISA vir die serologiese analise daarvan genoodsaak. Vir die ontwikkeling van die ELISA, is die Ms01 
oppA gene geïsoleer, gekloneer in ‘n prokariotiese ekspressie vektor en uitgedruk as ‘n rekombinante GST 
fusie produk in Escherichia coli. Die suksesvolle uitdrukking en suiwering van die rekombinante proteïen 
het die daaropvolgende gebruik daarvan as antigeen in die ontwikkeling van die ELISA moontlik gemaak. 
Die ELISA het ‘n groot sein tot agtergrond verhouding getoon. Die resultate wat met hierdie ELISA verkry 
is, het getoon dat die volstruise in hierdie inentingsproef blykbaar reeds voor immunisering antiliggame 
teen die Ms01 organisme besit het, wat op vorige kontak met die organisme dui. Die verwagte antiliggaam 
responspatroon kon dus nie in hierdie volstruise waargeneem word nie, en om dié rede kon geen finale 
afleiding oor die immuunstimulerende vermoëns van die DNA entstowwe gemaak word nie. Verdere 
inentingsproewe van volstruise wat nie vorige immuniteit teen volstruis mikoplasmas besit nie, word 
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Chapter 1 - Introduction 
The South African ostrich industry dominates the world ostrich trade, supplying an estimated 60% of the 
global ostrich produce. With 15 tanneries, eleven export approved abattoirs and investment activities 
exceeding R2.1 billion, the ostrich industry provides direct employment for around 20 000 workers in the 
production and processing sectors of South Africa [The South African Business Chamber, 2004; Cooper et 
al., 2007; Thompson et al., 2008]. Each year, around 230 000 slaughter birds are produced by the country’s 
558 export registered farms and, according to the South African Ostrich Business Chamber, income 
generated from export of ostrich products amounts to more than R1 billion annually [The South African 
Business Chamber, 2004; Cooper et al., 2007]. As a result of this, the ostrich industry is one of the top 
twenty agro-based industries in South Africa and thus of significant economic importance to the country 
[The South African Business Chamber].  
The high profit potential of ostrich farming is brought about by the assortment of products which may be 
obtained from a single bird [Jefferey, 1996]. The South African ostrich industry generates 45% of its total 
income from ostrich meat, 45% from ostrich skin and 10% from ostrich feathers [Cooper et al., 2007]. The 
vast majority (90%) of leather and meat is exported, making the South African ostrich industry heavily 
reliant upon the export of ostrich leather and meat products to trade partners in Europe, USA and Japan 
[Thompson et al., 2008]. Ostrich leather is a fashionable product utilized in the making of clothes, boots 
and upholstery. Four square meters of hide may be produced from a single adult bird, with one hide making 
three pairs of boots [Jefferey, 1996]. Ostrich feathers are popular in the fashion industry, but are also 
utilized for the production of cleaning products and other items. Ostrich meat, due to its low fat (<2%), 
cholesterol and calorie content, but high protein content, is considered to be the healthiest of the red meats 
and has, in recent years, grown in popularity due to increasing numbers of health conscious consumers 
[The South African Business Chamber, 2004; Jefferey, 1996]. Approximately 4 000 tonnes of ostrich meat 
is exported every year to the European Union, whose market is responsible for 60-70% of the global ostrich 
meat consumption [Cooper et al., 2007; Thompson et al., 2008].  
The advantageous natural conditions, in addition to its historic advantage, should enable South Africa to 
maintain its leading role in the global ostrich trade market. However, recent bans (August 2004 to 
September 2005 and again July 2006 to November 2006, as well as from July 2011 to December 2011) on 
ostrich meat exports, due to avian influenza outbreaks, have highlighted the requirement for effective 
disease control measures [Thompson et al., 2008]. A ban on ostrich meat exports may result in losses of at 
least R50 million per month during peak season, making job losses inevitable. In addition, the South 
African ostrich industry is already suffering losses of up to 30% as a result of respiratory disease in feedlot 
ostriches [Pretorius, 2009]. The recent isolation of three ostrich-specific mycoplasmas; Ms01, Ms02 and 
Ms03, which cause respiratory disease in South African ostriches has thus, in addition to causing dramatic 
production losses, raised concerns regarding the transmission of these mycoplasmas to other countries 
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through contaminated meat products, which may consequently place constraints on the export of ostrich 
products, resulting in a significant impact on the economy of the country [Botes et al., 2005].  
A limited range of antibiotics, together with strict biosecurity practices, are currently the only measures 
aimed at the control of ostrich mycoplasma infections [Pretorius, 2009]. Although other avian mycoplasma 
vaccines have been employed as an attempted control measure, none have proven even slightly effective, as 
shown in a study by Pretorius [2009]. Needless to say, mycoplasma infections still occur at unacceptable 
frequencies in South African ostriches. Accordingly, the South African ostrich industry has launched an 
investigation into vaccination strategies with which to combat ostrich mycoplasma infections in South 
Africa. The investigation includes conventional whole-organism vaccine development studies, undertaken 
at Onderstepoort Veterinary Institute in Pretoria, as well as the more novel DNA vaccine development 
strategy described in this thesis.  
For these reasons, the objectives of this study were: 
 To produce a recombinant Ms01 OppA protein by cloning the Ms01 oppA gene into a prokaryotic 
expression vector, expressing the gene in Escherichia coli and purifying the expressed protein.  
 To generate two enzyme-linked immunosorbent assays (ELISAs), in which ELISA plates were 
coated with recombinant Ms01 OppA protein and the Ms01 whole organism, respectively, for 
serological analysis of immune responses to Ms01 vaccines in ostriches. 
 To conduct a vaccination trial in which the ability of DNA vaccines, consisting of the Ms01 oppA 
gene cloned into the pCIneo, VR1012 and VR1020 vaccine vectors respectively, to elicit antibody 
responses against the Ms01 organism in ostriches could be evaluated. 
Chapter 2 of this thesis provides a literature review of the phylogeny, taxonomy, evolution, 
distribution, molecular biology, morphology and pathogenesis of mycoplasmas. An overview of the 
utilization of DNA vaccines as well as a brief overview of the Ms01 OppA protein concludes the 
literature review. Chapter 3 describes the cloning, expression and purification of the Ms01 OppA 
protein. A description of the DNA vaccination trial undertaken and the ELISAs used to analyze the 
samples taken during the trial is provided in Chapter 4. Chapter 5 contains the conclusions drawn from 
this study as well as future perspectives. The thesis is concluded with a list of references followed by 
addenda which include the nucleotide sequence of the Ms01 OppA protein and the raw data of the 
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Chapter 2 - Literature review 
2.1 The Ostrich  
Ostriches are part of a group of flightless birds known as ratites [Al-Nasser et al., 2003]. Other members of 
this group include the emu, the cassowary, the rhea, the kiwi and the extinct moa [Al-Nasser et al., 2003; 
Sales, 2009]. Ratites are characterized by their smooth, broad, bowl-shaped sternum or breastbone which 
lacks a keel [Al-Nasser et al., 2003]. A keel is an adaptation for the attachment of breast or flight muscles 
in other birds.  
Ostriches, which are currently the largest living birds on the planet, can range between 1.7 and 2.7 m in 
height and can reach adult body weights of between 70 and 130 kg [Cooper et al., 2007; Sales, 2009]. 
Ostrich eggs can weigh up to 2 kg, but are the smallest egg of any bird, relative to the size of its parent 
[Adams and Revell, 2008]. Female ostriches are grayish-brown, while males attain a black and white 
plumage when they reach the age of two [Cooper et al., 2007].  
Ostriches, which can be seen in Figure 2.1, are classified under the class: Aves, family: Struthionidae, 
species: Struthio camelus [Al-Nasser et al., 2003]. There are four living subspecies of ostrich [Sales, 2009]. 
These include Struthio camelus australis, which can be found south of the Zambezi and Kunene rivers in 
Southern Africa, Struthio camelus molybdophanes, from Somalia and Ethiopia, Struthio camelus camelus, 
found along the west coast of the Red Sea and the Sahara desert and Struthio camelus massaicus, found in 
Tanzania and eastern Kenya [Sales, 2009]. The Arabian ostrich, which used to be another subspecies of 
ostrich, Struthio camelus syriacus, was hunted to extinction between 1945 and 1966 [Al-Nasser et al., 
2003; Sales, 2009]. There is, however, a hybrid of Struthio camelus australis and Struthio camelus syriacus 
in existence, known as Struthio camelus var. domesticus [Al-Nasser et al., 2003].  
 
Figure 2.1 A photograph of ostriches farmed in South Africa [Southern Africa direct , 2008]. 
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Ostriches are native to the savannas of Africa and can be found both north and south of the equatorial forest 
zone [Sales, 2009]. These birds, which can live up to 75 years, have a pair of powerful legs that allow them 
to reach speeds of up to 70 kilometers per hour [Sales, 2009; Adams and Revell, 2008]. While foraging for 
food, ostriches can range over an area with a radius of up to 20 kilometers in their native habitat. 
2.2 The South African Ostrich Industry 
The Western Cape Province currently represents 70-80% of the South African ostrich industry, with the 
main production and processing sites being located in the semi-arid Klein Karoo region [Cooper et al., 
2007; Thompson et al., 2008]. Fifteen to twenty percent of slaughter ostriches are, however, also reared in 
the Eastern Cape Province [Cooper et al., 2007].  
2.3 History of the ostrich industry 
Ostrich farming was first initiated in 1866, when the first eggs of domesticated ostriches were hatched in 
South Africa [Sales, 2009; Douglas, 1906]. Ostriches had long been hunted mainly for their feathers, but at 
around 1859 it became apparent that wild ostriches would soon become extinct if buyers in Europe were to 
depend solely upon ostriches being hunted in remote parts of Africa [Sales, 2009]. This resulted in the idea 
of farming with ostriches and in turn, led to the first ostriches being domesticated.  
In 1880, South Africa was exporting 73 965 kg of feathers, of which only one-eighth was obtained from 
wild birds [Douglas, 1906]. A census done in 1891 reported that the number of tame birds in the country 
amounted to 154 880. By 1904, this figure had more than doubled to 357 970 and in 1910 the South 
African ostrich industry was booming with 764 736 breeding birds, producing 336 854 kg of feathers 
annually [Sales, 2009; Douglas, 1906]. While attempts had been made to initiate the farming of ostriches in 
New Zealand, Egypt, California, South America and Australasia, these efforts eventually failed. The Cape 
colony, to which ostrich farming was practically confined at this stage, remained to be a continuous success 
from the beginning. The ostrich industry, however, did not remain free of problems. Excessive supply of 
feathers, changing fashions, poorly coordinated marketing and the disruption of export brought on by 
World War I (1914-1918) resulted in a rapid collapse of the ostrich industry in the second decade of the 
twentieth century [The South African Business Chamber, 2004]. Thus, by 1930 only 23 000 farmed 
ostriches were left in South Africa. The ostrich industry, however, gradually recovered after World War II 
(1939-1945) and expanded to include the production of leather [South Invest, 2011]. A one-channel 
cooperative marketing system was launched in South Africa in 1959 and in 1964 the first abattoir was 
established in the country [The South African Business Chamber, 2004]. This was followed by the erection 
of a tannery in 1970. The turn of the century brought with it a growing consumption of ostrich meat and 
previously low prices steadily increased. In 2003, it was estimated that there were just under 500 000 
commercially bred ostriches in the world, of which about 350 000 were in South Africa [South Invest, 
2011]. Presently South Africa continues to dominate the global ostrich market. 
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2.4 Mycoplasmas 
2.4.1 Phylogeny, Taxonomy and Evolution of Mycoplasmas 
Mycoplasmas are a genus of bacteria which fall within the class Mollicutes [Rottem, 2003; Bradbury, 
2005]. The name Mollicutes refers to the fact that these organisms are surrounded only by a thin trilaminar 
membrane and lack the conventional cell wall which normally surrounds other bacterial cells [Bradbury, 
2005]. The word Mollicutis is derived from the latin words ‘mollis’ which means ‘soft’ and ‘cutis’ which 
means ‘skin’.  
Mollicutes are divided into five phylogenetic units, based upon their 16S rRNA sequences, with the best 
studied genera found in the orders Entomoplasmatales (Entomoplasma, Spiroplasma, Mesoplasma), 
Anaeroplasmatales (Asteroleplasma, Anaeroplasma), Acholeplasmatales (Acholeplasma) and 
Mycoplasmatales (Mycoplasma, Ureaplasma) [Razin, 1998; Prescott et al., 2002]. Although they were 
initially thought to be the primitive forerunners of the more complex pathogens, Mollicutes are now known 
to be phylogenetically related to Gram positive bacteria and are thought to have developed from these 
organisms by means of genome reduction [Rottem, 2003; Bradbury, 2005; Prescott et al., 2002]. A 
phylogenetic scheme, based upon the 16S rRNA sequences of the Mollicutes, which was suggested by 
Maniloff [cited by Bradbury, 2005] indicates that Mollicutes diverged from Streptococci around 
600 million years ago, with the loss of some nonessential genes, including those involved in cell wall 
synthesis [Razin, 1998; Bradbury, 2005]. Around 500 million years ago, Mollicutes split into two branches, 
the AAA branch and the SEM branch. The AAA branch consists of Anaeroplasma, Acholeplasma and 
Asteroleplasma, while the SEM branch comprises the Spiroplasma, Entomoplasma, and Mycoplasma 
[Razin, 1998]. Maniloff [cited by Bradbury, 2005] goes on to suggest that during the degenerate evolution 
of these two branches, genome reduction occurred independently, and that the Acholeplasmas and 
Anaeroplasmas were the first to evolve by reductive evolution. He further states that the Spiroplasmas 
originated during an early split from the Acholeplasmas, and that Mycoplasmas and Ureaplasmas evolved 
from the Spiroplasmas. The conversion of the UGA codon from a stop codon to a tryptophan codon is 
thought to have occurred during the early evolution of the SEM branch.  
The term ‘mycoplasma’ was initially used to signify an intimate connection between plant-invading fungi 
or other microorganisms and their host cells by A.B. Frank in 1889, and then again by Jakob Erikson in 
1897 [Krass et al., 1973]. However, in 1929 it was used for the first time as a reference to the bovine 
pleuropneumonia organism by Nowak, who wrote in a paper on the morphology, nature, and life cycle of 
the organism: “the term Mycoplasma peripneumoniae seems to agree better with the nature and the 
morphology of the microbe” [Krass and Gardner, 1973; Hayflick and Chanock, 1965]. This followed the 
initial use of the term Asterococcus mycoides, designated by the Linnean system in 1910, but which was 
discarded due to its use for a genus of algae in 1908. Two other terms, Micromyces and Coccobacillus, had 
also previously been suggested, but were discarded for the same reason [Hayflick and Chanock, 1965]. 
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Nowak later explained about his chosen name for the bovine pleuropneumonia organism: “The name 
mycoplasma seems suited both to its unusual protoplasmic nature and also to its remarkable mycelial 
morphology,” [cited by Krass and Gardner, 1973]. The legitimacy of the term ‘mycoplasma’ was then 
subsequently confirmed in separate papers by Edward and Freundt in 1955 and by the Editorial Board of 
the International Committee on Nomenclature of Bacteria prior to that. Thus, the term mycoplasma was 
taxonomically approved, interestingly, without particular reference to its prior use by Frank or Edward in 
mycology. However, this does not disqualify its legitimacy. 
The International Committee on Systematic Bacteriology, Subcommittee on Taxonomy of Mollicutes has 
set out the minimum standards for classification as a Mycoplasma [Minion, 2002]. Although classification 
is problematic due to the few physiological and biochemical properties that can be used for differentiation, 
characteristics such as permanent lack of cell walls, cell size, genome size, colony formation and G+C 
content are often used. Biochemical characteristics such as fermentation of glucose or arginine, optimal 
growth temperature, morphology, serology and host origin are also considered. Phylogenetic analyses using 
16S rRNA sequences are now, however, the defining phylogenetic tool used in the classification of 
Mollicutes.  
In 2005, Botes et al. [2005] identified three novel species of Mycoplasma through the use of 16S rRNA 
sequencing. Until then, the poultry mycoplasmas, specifically Mycoplasma gallisepticum, was thought to 
be responsible for the huge losses caused by ostrich mycoplasmosis. Phylogenetic analysis indicated that 
the newly identified mycoplasmas fall within the Hominis group and that they are phylogenitically distant 
from one another, as can be seen in Figure 2.2. Since Mycoplasmas are usually named according to the host 
they inhabit, these Mycoplasmas should be named Mycoplasma struthiolus, in reference to their host 
Struthio camelus. However, due to the fact that these Mycoplasmas have not yet formally been 
characterized, they are temporarily referred to as Ms01, Ms02 and Ms03.  
2.4.2 History of mycoplasmas 
While Louis Pasteur was the first to recognize the mycoplasmas as a microbial entity, he was unable to 
culture these organisms in nutrient broth or to examine them under a microscope [Hayflick and Chanock, 
1965]. It was Nocard and Roux who, in 1898, first succeeded in cultivating the microbial agent associated 
with contagious bovine pleuropneumonia on a medium similar to that used to grow bacteria [Bradbury, 
2005; Hayflick and Chanock, 1965; Bigland, 1969]. By 1910, the morphology of the pleuropneumonia 
organism (PPO) had been described and before long, microorganisms with similar properties were being 
isolated from other sources and referred to as pleuropneumonia-like organisms (PPLO) [Hayflick and 
Chanock, 1965]. It was soon found that PPOs were filterable through Berkefeld V filters and in 1929, with 
the aid of filtration studies using the Gradocol membrane, the size of the minimal units required for 
reproduction was estimated to be between 125 to 150 μm. Resultantly, despite the knowledge that this 
microbe, now referred to as Mycoplasma mycoides subspecies mycoides, could multiply in a cell-free 
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medium, it was deemed to be a virus for 25 years [Bradbury, 2005; Hayflick and Chanock, 1965; Bigland, 
1969]. That same year, Julien Nowak was the first to refer to the PPO as a Mycoplasma (peripneumonia). 
The first reported isolation of an avian mycoplasma is believed to have occurred in 1936, when Nelson was 
investigating different causes of ‘infectious coryza’ and found cocco-bacilliform bodies in a mild 
respiratory disease condition of chickens [Bigland, 1969]. Chronic respiratory disease in avians was 
documented for the first time in Alberta in 1952 and involved six flocks of chickens and two flocks of 
turkeys, of which the number of chicken flocks affected had risen to ninety, by 1953. The first isolation of 
M. gallisepticum occurred in 1952 while Markam and Wong were investigating chronic respiratory disease 
in chickens, and between 1953 and 1957 Crawley and Faley isolated the microbe, developed the 
hemagglutination inhibition test, and made the earliest suggestions on how to control chronic respiratory 
disease in poultry. 
Thus, the existence of a new group of saprophytic and parasitic microorganisms, distinguished from 
viruses, bacteria and rickettsias by their unusual properties, had officially been documented (following the 
isolation of mycoplasmas from various sources, including humans, animals and sewage), and in 1989, 
almost one hundred years after the first known species of mycoplasma was isolated, a filterable virus-like 
agent found in AIDS and other patients, was found to be a strain of Mycoplasma fermentans by Lo et al. 
[cited by Bradbury, 2005; Hayflick and Chanock, 1965; Bigland, 1969]. 
Interestingly, not long ago many rickettsias were reassigned from the genera Eperythrozoon and 
Haemobartonella to the genus Mycoplasma [cited by Bradbury, 2005]. This move was based upon the 16S 
rRNA similarity shared by the organisms. Another interesting fact is that already in 1983, Whitcomb and 
Bove [cited by Bradbury, 2005] remarked about the abovementioned organisms: ‘although they have been 
classified as rickettsiae, ultrastructural studies have clearly established their mycoplasma-like nature’ [cited 
by Bradbury, 2005]. 
2.4.3 Distribution of Mycoplasmas 
Mycoplasmas are globally distributed and are considered to be principal pathogens in animal production 
units in each country of the world [Minion, 2002]. Although most mycoplasmas only thrive within a 
narrow host range, they are known to inhabit plants, fish, insects, reptiles, birds and mammals [Prescott, et 
al., 2002; Minion, 2002, Dubvig, K., and Voelker, 1996]. Notably, one article stated that “It appears as 
though the main factor for adding an animal or plant to the list of hosts is the willingness of a 
mycoplasmologist to invest the effort and funds required to isolate and taxonomically characterize the 
mycoplasmas from the tested host” [Razin et al., 1998].  
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Figure 2.2 A phylogenetic tree of mycoplasma species based on a parsimony analysis of 16S rRNA gene sequences. 
This tree represents one of eight of the shortest trees retrieved in a heuristic search (CI = 0.381, RI = 0.696). The 
branches that collapse in the strict consensus tree are indicated with arrows. Branch lengths and bootstrap values are 
indicated above and below the line respectively. 
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2.4.4 Molecular biology of mycoplasmas 
A mycoplasma cell essentially consists of three simple, yet unique structural organelles which have 
intrigued membrane and cellular biologists for several years and more recently attracted the attention of 
molecular biologists [Bradbury, 2005]. These organelles include a cell membrane, a circular double-
stranded DNA molecule and ribosomes. Molecular biologists have been particularly fascinated with the 
mycoplasmas, because the loss of non-essential genes by these organisms is thought to hold the key to the 
minimal gene requirements capable of supporting life.  
2.4.5 Cell size, morphology and reproduction 
With diameters ranging between 200 and 800 nm in length, mycoplasmas are the smallest free-living, self-
replicating organisms known to man [Razin et al., 1998; Rottem, 2003; Bradbury, 2005; Zuo, et al., 2009]. 
Due to their lack of a cell wall, the dominating shape of a mycoplasma cell is that of a sphere [Razin et al., 
1998; Rottem, 2003]. Several mycoplasmas are, however, known to display a variety of morphologies 
which may include flask-like cells with terminal tip structures, as well as filamentous and ring forms 
[Prescott, et al., 2002; Razin et al., 1998; Rottem, 2003]. Mycoplasmas grow optimally at 37°C and 
typically form small, circular, smooth colonies with fairly flat edges and a denser elevation in the middle, 
which has been likened to the shape of a fried egg [Kleven, 2008].  
 
Figure 2.3 An electron micrograph of an individual mycoplasma cell [Bradbury, 2005].  
2.4.6 Genome structure and organization 
2.4.6.1 Genome size 
Mycoplasmas have the smallest reported genomes of any self-replicating living organism, with sizes 
ranging from 580 kb in M. genitalium to 1380 kb in M. mycoides subsp. mycoides [Dubvig and Voelker, 
1996; Razin et al., 1998; Rottem, 2003]. The striking differences between the genome sizes of 
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mycoplasmas, and that of other microorganisms, are illustrated in a comparison between the genome sizes 
of Mycoplasma genitalium (580 kb), Haemophilus influenza (1 830 kb) and Escherichia coli (4 720 kb) 
[Bradbury, 2005]. The tiny genomes of mycoplasmas are thought to be the result of a loss of many 
dispensable genes, which accounts for their parasitic lifestyle, as explained later in this chapter. The 
considerable variation observed in the genome sizes of mycoplasmas, not only within the same genus, but 
between different strains of the same species, is thought to be the result of repetitive DNA elements which 
are scattered throughout the chromosome of mycoplasma cells [Dubvig and Voelker, 1996]. These 
repetitive elements are thought to consist of either insertion elements or segments of genes encoding major 
surface antigens, as discussed later in the thesis [Razin et al., 1998; Dubvig and Voelker, 1996].  
2.4.6.2 Base composition and codon usage 
Mycoplasma genomes have a G+C base composition of between 23-40%, with less than 35% of G+C base 
pairs comprising the genomes of most species [Kleven, 2008; Dubvig and Voelker, 1996]. This low G+C 
content is thought to be the eventual consequence of ineffective uracil-DNA glycosylation activity in the 
mycoplasmas, which gradually led to G+C base pairs being replaced by A+T base pairs [Dubvig and 
Voelker, 1996]. This extreme bias in base composition has resulted in a similar bias in codon usage. As 
such, 90% of codons in most mycoplasmas have an A or T in the third nucleotide position. Considering the 
above, it should not be surprising that mycoplasmas employ an alternative genetic code. The TGA codon, 
which serves as a stop codon in most organisms, codes for tryptophan in the mycoplasma genome, instead 
of the TGG codon utilized in the “universal” genetic code. This adaptation in codon usage has resulted in 
obvious practical implications when cloned mycoplasmal genes are expressed in heterologous systems. 
Specifically, the TGA codons (encoding tryptophan) in mycoplasmas will be read as termination codons in 
E. coli and other organisms which employ the universal genetic code, thus resulting in the expression of 
truncated gene products.  
Codon bias is, however, not restricted to the third nucleotide position and may also occur in the first and 
second positions, which results in a significant effect on the amino acid composition [Dubvig and Voelker, 
1996]. Accordingly, mycoplasmas have less CCN, GGN, CGN and GCN codons compared to E. coli, 
which has a G+C base composition of around 50%, and consequently express proteins with fewer Pro, Gly, 
Arg and Ala residues than the latter. Likewise, mycoplasmas have an elevated proportion of TTY, AAN, 
ATN and TAY codons, and therefore a greater abundance of Lys, Asn, Phe, Ile and Tyr residues. 
Conservative amino acid substitutions resulting from a change in G-C base pairs to A-T base pairs make 
the bias in the amino acid composition of mycoplasmal proteins especially obvious. The fact that 
mycoplasmas frequently have Lys residues (codons AAG and AAA), in the amino acid positions where 
other organisms normally have Arg residues (codons AGG, CGN and AGA) in conserved proteins, serves 
as a good illustration of this point.  
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2.4.7 Protein production 
2.4.7.1 Transcription 
As a result of their small genomes, mycoplasmas lack several genes which regulate gene expression 
[Beneina, 2002]. Mycoplasmas generally possess RNA polymerase promoter areas similar to the -10 
(Pribnow box) and -35 consensus sequence of promotors recognized by the vegetative sigma factor σA 
[Dubvig and Voelker, 1996]. The -10 consensus sequence in E. coli and Bacillus subtilis is TATAAT, 
whereas in the Ms01 oppA gene this sequence, which was identified 21 bp upstream of the translation 
initiation codon, is TAACAT [Pretorius, 2009; Dubvig and Voelker, 1996]. Similarly the -35 consensus 
sequence in E. coli and B. subtilis is TTGACA, whereas the corresponding sequence, identified 42 bp 
upstream of the translation initiation codon, is TCGGTT in Ms01.  
While most mycoplasmal transcription signals resemble the classical eubactorial ones, mycoplasmal RNA 
polymerases share a peculiar resistance to rifamycin with Clostridium acidiurici, C. innocuum, and C. 
ramosum; their phylogenetic relatives [Razin et al., 1998; Rottem, 2003]. The core RNA polymerase is 
encoded by the conserved genes rpoA (α subunit), rpoB (β subunit) and rpoC (β’ subunit), and sequencing 
analysis of the rpoB gene of M. gallisepticum indicate that minor changes in the amino acid sequences in 
the RIF region (region responsible for rifamycin binding) of the β subunit may confer rifamycin resistance. 
With regards to the direction of transcription, significant consistency has been observed, with only 15% of 
proposed open reading frames (ORF) in mycoplasmas being transcribed against the usual direction of 
transcription [Razin et al., 1998]. The termination factor Rho appears to be absent from all mycoplasmal 
genomes analyzed thus far, indicating that termination of transcription may occur independently of this 
factor. Similar to other bacteria, however, a stem-loop structure, composed of characteristic terminator 
sequences in which short, interrupted palindromic regions are followed by a run of uracil residues, serves to 
stop transcription in mycoplasmas.  
2.4.7.2 Translation 
The transcription of most mycoplasmas’ messenger RNA (mRNA) resembles that of the Gram-positive 
bacteria, with the exception of the TGA codon which encodes tryptophan in mycoplasmas and serves as a 
stop codon in other bacteria [Dubvig and Voelker, 1996]. Nucleotide sequence analysis indicate that the 
coding regions of most mycoplasmal genes begin with an ATG start codon, while TTG and GTG serve as 
alternative start codons. This is a trait shared by most prokaryotes, since better interaction occurs between 
the ATG initiation codon and the initiation transcript RNA (tRNA) than with other initiation codons 
[Pretorius, 2009]. 
Most mycoplasmal mRNAs contain a ribosome-binding site, usually situated four to ten bases upstream of 
the translation initiation codon, which is comparable to the Shine-Delgarno sequence of Gram positive 
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bacteria [Dubvig and Voelker, 1996]. This sequence, situated five bases upstream of the translation 
initiation codon of the oppA gene, was identified to be 5’-TAGGAGAA-3’ in Ms01 [Pretorius, 2009]. A 
characteristic mycoplasmal ribosome-binding site is usually composed of a subset of around five bases of 
the sequence 5’-AGAAAGGAGG-3’, to which the 16S ribosomal RNA (rRNA) anneals [Dubvig and 
Voelker, 1996]. Interestingly, however, the 3’ end of mycoplasma 16S rRNA molecules is seven 
nucleotides longer than characteristic Gram negative 16S rRNA molecules and four nucleotides longer than 
typical Gram positive 16S rRNA molecules, probably suggesting that mycoplasmas require a Shine-
Delgarno sequence with stronger complimentarity to 16S rRNA, than other bacteria. Nevertheless, not all 
mycoplasmal species were found to contain a Shine-Delgarno-like sequence, which indicates that 
alternative sequences may function as ribosomal binding sites in many mycoplasmas [Razin et al., 1998]. 
Indeed, the tuf gene of M. genitalium, which lacks a Shine-Dalgarno sequence, yet is highly expressed, was 
found to contain a novel ribosome-binding site which is thought to anneal to a highly conserved region of 
the 16S rRNA molecule corresponding to nucleotides 1082–1093 of the 16S rRNA of E. coli [Dubvig and 
Voelker, 1996]. 
Usually there is one amino acyl-tRNA synthetase for each amino acid of the 20 activating enzymes 
typically present in eubacteria. Mycoplasmas appear to lack only glutaminyl-tRNA synthetase [Razin et al., 
1998]. This is a trait mycoplasmas share with Gram positive bacteria, in which the tRNAGlu is initially 
charged with glutamate, which is subsequently converted into glutamine by an aminotranferase enzyme. An 
aminotransferase enzyme has, however, not yet been identified in mycoplasmas, but genes encoding the 
elongation factors, for example fus, efp, tsf, and tuf, have been identified. Six of the eight codon family 
boxes of M. mycoides and M. capricolum were found to be read by single isoacceptor tRNA with an 
unmodified uridine in the first position of the anticodon (wobble position).  
Mycoplasmas only possess one peptide release factor (RF), specifically RF1, which recognizes the TAG 
and TAA stop codons [Razin et al., 1998]. Since the TGA codon is used to encode tryptophan in 
mycoplasmas, the use of RF2, which recognizes TGA and TAA stop codons, is not required by these 
organisms. In addition, considering their A+T-biased genome, it is not surprising that a preference to the 
use of TAA stop codons rather than that of TAG codons has been observed in mycoplasmas with a very 
low G+C genome composition. Likewise, the oppA gene of Ms01 is terminated by the TAA stop codon.  
2.4.7.3 Post-translational modification 
Due to their lack of a cell wall, mycoplasmas do not have a periplasmic space and proteins that are not 
cytoplasmic are either secreted or membrane bound [Dubvig and Voelker, 1996]. Mycoplasma proteins are 
directed into a secretory pathway for transport across the membrane by typical eubacterial signal peptide 
sequences ((-4)-VAASC-(+1)) [Heinrich, 1999]. Mycoplasmas, however, possess an extremely high 
number of lipoproteins when compared to other bacteria [Dubvig and Voelker, 1996]. Lipoprotein 
processing often involves cleavage of the signal peptide sequence N-terminal to a cysteine residue to which 
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a diacylglycerol moiety of glycerophospholipid has been transferred to the sulfhydryl group [Razin et al., 
1998; Dubvig and Voelker, 1996]. The prolipoprotein (lipoprotein precursor) is cleaved N-terminal to the 
modified cysteine by a signal peptidase II enzyme, resulting in the cysteine becoming the first amino acid 
of the processed protein. Thus, many mycoplasmal lipoproteins have a consensus signal peptidase II 
cleavage site, followed by a cysteine residue, including the oppA gene of Ms01, in which a signal peptidase 
II recognition site and lipoprotein attachment site (22LVAAACNSKSA32) has also been identified 
[Pretorius, 2009].  
Isoprenylation and phosphorylation are additional examples of protein modifications which occur in 
mycoplasmas [Dubvig and Voelker, 1996]. Although the mechanism of isoprenylation and the function of 
modified proteins are not yet known, phosphorylation of cytoadherence accessory proteins by ATP-
dependent serine-threonine kinases are thought to regulate activities such as cytoadherence, cell division 
and gliding motility. 
2.4.8 Metabolism 
The small genomes of mycoplasmas have availed them limited coding capacity, and consequently 
precludes several metabolic activities typically present in most bacteria, which accounts for these 
organsisms’ parasitic way of life [Razin et al., 1998; Prescott et al., 2002; Dubvig and Voelker, 1996]. 
Genome analyses have indicated that mycoplasmal genomes encode numerous proteins associated with 
metabolite transport and catabolic activities, whereas few anabolic proteins are coded for. This indicates 
that mycoplasmal metabolic activities are primarily associated with energy production rather than the 
provision of substrates for biosynthetic pathways [Razin et al., 1998]. Therefore, although these organisms 
do perform complex protein synthesis, they have to rely on their host (or growth medium) for the provision 
of several essential nutrients, including fatty acids, vitamins, amino acids, sterols, purines and pyramidines 
[Bradbury, 2005; 17, 18].  
Mycoplasmas may be divided into fermentative and nonfermentative species [Razin et al., 1998; Prescott et 
al., 2002]. Fermentative mycoplasmas generate ATP through glycolysis and the pyruvate dehydrogenase 
pathway, with lactic acid production, whereas most nonfermentative species, such as M. hominis and M. 
arthritidis, as well as some fermentative species, utilize the arginine dihydrolase pathway, resulting in the 
production of ATP, ammonia, ornithine and carbon dioxide [Razin et al., 1998; Prescott et al., 2002; 
Dubvig and Voelker, 1996]. At least some mycoplasmas appear to have a functional pentose-phosphate 
pathway, but none seem to have a complete tricarboxylic acid cycle or any quinines or cytochromes. Their 
electron transport chain system is flavin terminated [Prescott et al., 2002; Dubvig and Voelker, 1996]. 
Therefore, substrate-level phosphorylation is most probably the major route of mycoplasmal ATP 
production, resulting in low yields and fairly large quantities of metabolic end products, sometimes 
completely depleting the host of the specific substrate metabolized [Razin et al., 1998; Dubvig and 
Voelker, 1996].  
Stellenbosch University  http://scholar.sun.ac.za
 14 
2.4.9 In vitro culture 
Despite their inefficient energy yielding pathways and fastidious nutritional requirements, mycoplasmas are 
able to grow in the absence of host cells [Razin et al., 1998]. Although mycoplasmas are notoriously 
difficult to cultivate, complex media, typically based on beef heart infusion, yeast extract, serum with a 
range of supplements, as well as peptone, are used to overcome the assimilative difficulties of these 
organisms. Mycoplasmal cultivation using complex undefined media has, however, hindered the 
preparation of mycoplasmal antigens free of serum components, the molecular description of mycoplasmal 
metabolic pathways, and the genetic analysis of mycoplasmas. Ongoing efforts, with the aim of reaching a 
defined growth medium have seen partial success, with defined media supporting the growth of some 
species having been described.  
2.4.10 Membrane characteristics 
Mycoplasmas lack intracytoplasmic membranes and thus possess only one type of membrane, namely the 
plasma membrane [Razin et al., 1998; Razin, 1978]. Consisting of mostly lipids and proteins, the gross 
chemical composition of mycoplasmal plasma membranes resembles that of most prokaryotes.  
2.4.10.1 Membrane Lipids 
Nearly all mycoplasmal lipids are found in the cell membrane and, similar to other biological membranes, 
include phospholipids, glycolipids and neutral lipids [Razin et al., 1998; Razin, 1978]. The acidic 
phospholipids, phosphatidylglycerol and to a lesser degree diphosphatidylglycerol, can be found nearly 
everywhere in the mycoplasmal membrane, whereas a large part of the membrane in many, but not all 
mycoplasmas, may also consist of glycolipids. The fatty acid residues of membrane phospholipids, 
glycolipids and cholesterol make up the main portion of the hydrophobic core of the membrane. However, 
as previously stated, mycoplasmas are incapable of synthesizing fatty acids and as a result are dependent on 
their host for their supply.  
The majority of mycoplasmas require cholesterol for growth, a trait which is unique among the prokaryotes 
[Razin et al., 1998; Razin, 1978]. The cell membranes of these sterol-requiring Mollicutes generally 
contain much greater levels of cholesterol than Mollicutes which do not require cholesterol for growth. 
These cholesterol levels are similar to those found in eukaryotic cell membranes. 
Glycosyl diglycerides containing from one to five sugar residues is another common constituent of many 
mycoplasmal cell membranes [Razin, 1978]. Immunogenic lipopolysaccharides with chemical 
compositions unrelated to those found in Gram negative bacteria have also been found in many 
mycoplasmal species. 
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2.4.10.2 Membrane Proteins 
More than two thirds of the mass of mycoplasmal membranes is accounted for by proteins, the rest 
consisting of membrane lipids [Razin et al., 1998]. Thirty five of the 200 membrane proteins known to 
occur in M. gallisepticum are covalently modified with acyl chains. Acylation of proteins with long chain 
fatty acids is an effective means of securing surface-exposed proteins with functions outside of the cell to 
the plasma membrane. Compared to the eubacteria, mycoplasmas have a remarkably high percentage of 
genes encoding putative lipoproteins, most of which are acidic (pI < 5 to 7) and immunogenic. In the 
absence of a cell wall, surface proteins embedded or anchored (lipoproteins) in the cell membrane play an 
essential role in the interactions between the mycoplasmas and their hosts [Beneina, 2002]. Thus, 
lipoproteins are some of the leading antigens in mycoplasmas, and most of the mycoplasmal cell surface 
antigens known to undergo size and/or antigenic variation, are lipoproteins.  
The dependence of mycoplasmas on the exogenous supply of several nutrients would predict that they 
require several transport systems [Razin et al., 1998]. Mycoplasmas, however, do not have a higher 
proportion of genes dedicated to transport, than do H. influenza, E. coli and B. subtilis. The occurrence of 
only one permeability barrier in the wall-less mycoplasmas, compared to at least two barriers found in 
Gram positive and Gram negative bacteria, may be a potential reason for the small number of transport 
systems observed in mycoplasmas. The significant gene saving witnessed in this category may also be 
aided by the low substrate specificity of some mycoplasmal transport systems, for example those involved 
in the transport of amino acids. 
2.4.10.3 Membrane Transport Systems 
To date, three types of transport systems have been identified in mycoplasmas [Razin et al., 1998]. The first 
involves membrane proteins acting as specific carriers to carry out facilitated diffusion of substrates across 
the membrane. Another group is the highly efficient phosphoenolpyruvate-dependent sugar 
phophotransferase transport system (PTS). It is, however, the ATP-binding cassette (ABC) transporter 
family, which is also a transporter of oligopeptides, which is a major focus of this thesis and which will be 
discussed in greater detail.  
2.5 ATP-binding cassette transporters 
ABC transporters are unidirectional transporters which are known for their ability to couple the energy 
released during the hydrolysis of ATP to the transport of a large range of molecules, often against a 
concentration gradient, across cell membranes [Moutran et al., 2008; Nepomuceno et al., 2007]. ABC 
transporters regulate the movement of vital nutrients into and out of cells and are copiously present in all 
kingdoms of life [Nepomuceno et al., 2007; Doeven et al., 2004].  
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ABC transporters may take up as much as 5% of bacterial genomes and may function either as importers or 
exporters [Nepomuceno et al., 2007]. Importers typically amass amino acids and sugars, whereas exporters 
generally remove a number of compounds from the cytoplasm [Davidson and Maloney, 2007]. ABC 
transporters are usually composed of four functional domains: two highly conserved peripheral domains 
which attach to and hydrolyze ATP, as well as two transmembrane domains which form a permeation 
pathway across the membrane. ABC importers are substrate binding protein-dependant ABC transporters 
and as a result require the assistance of an additional domain. This domain binds and delivers substrate to 
the membrane complex. Exporters, on the other hand, whose substrates enter the translocation pathway 
directly from the cytoplasm or lipid bilayer, do not require the aid of additional binding proteins.  
Oligopeptide permease (Opp) is a multicomponent ABC transporter which is widespread amongst several 
species of bacteria and archaea and can be seen in Figure 2.4 [Moutran et al., 2008; Nepomuceno et al., 
2007]. It is a typical ABC transporter and is thus composed of the four domains which are characteristic to 
ABC transporters [Nepomuceno et al., 2007]. OppB and OppC are the two pore-forming transmembrane 
domains, while OppD and OppF are the two peripheral membrane-associated ATPase domains. Since 
oligopeptide permease is an importer, it includes an additional ligand binding domain which is referred to 
as OppA. The function of OppA is to recognize, bind and guide peptide substrates to the oligopeptide 
permease complex. OppA is therefore thought to confer affinity and specificity to the oligopeptide 
permease transport system.  
 
 
Figure 2.4 An illustration of the mechanism with which oligopeptide permeases accomplish peptide transfer. The 
respective subunits of the oligopeptide permease complex are indicated by the corresponding letters [32]. 
In 1993, Heinrich et al. [1993] identified a 100 kDa protein in M. hominis thought to be involved in the 
adherence of the mycoplasma to its host cells, a crucial step in the pathogenicity of mycoplasmas. In 
reference to its size, the protein was termed the P100 protein. Subsequently, in 1999, the same authors 
verified the identity of the P100 protein as the OppA protein, a substrate-binding subunit of the 
oligopeptide permease complex of M. hominis [Heinrich et al., 1999]. 
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2.5.1 Structure of OppA  
OppA proteins in Gram negative bacteria are free-floating periplasmic proteins [Nepomuceno et al., 2007]. 
Contrastingly, the OppA proteins of Gram positive bacteria are lipoproteins with an N-terminal cystein 
residue which is covalently bound, via a thioether linkage, to a diacylglycerol in the plasma membrane. 
Since mycoplasmas lack cell walls and are the phylogenetic relatives of Gram positive bacteria, their OppA 
proteins by implication need to be attached to the cell membrane in a manner similar to that seen in Gram 
positive bacteria.  
An N-terminal leader peptide sequence, followed by a conserved cysteine residue which is the site where 
the lipoprotein attaches to the plasma membrane of Gram positive bacteria, can normally be found at the 
beginning of the amino acid sequence of OppA [Heinrich et al., 1999, Heinrich et al., 1993]. Tam and Saier 
[cited by Peltoniemi et al., 2002] have proposed the amino acid sequence A(X)7D(X)4T(X)3R(X)3K as a 
signature for oligopeptide permeases, while amino acid sequence alignments by Heinrich et al. [Heinrich et 
al., 1999] have found the consenses sequence F/Y-I/LRK to be present in most peptide binding proteins.   
While OppA is generally assumed to be monomeric, many early reports have indicated that these substrate 
binding proteins may actually be dimers [31. Davidson and Maloney, 2007]. Doeven et al. [2004] have, 
however, found that unanchored OppA is monomeric under a number of conditions and that no higher 
oligomeric aggregates are formed by membrane-bound OppA. The same authors also indicated that 
monomeric OppA is able to bind to a peptide, and in this liganded state, to OppBCDF. A single OppA 
molecule may thus, according to these authors, be adequate for peptide translocation.  
The structure of the OppA protein in mycoplasmas has not been determined yet, but much can be deduced 
from OppA proteins whose structures have been determined [Figure 2.5]. The OppA protein consists of 
three structural domains [Moutran et al., 2007]. Domains I and III are coupled by a flexible hinge and form 
a cleft in which ligand binds. This enables oligopeptides to be totally engulfed by the protein in a 
mechanism likened to that of the “Venus flytrap”. α-Helices surrounding mixed stretches of β-sheets, typify 
the bilobate ellipsoidal α/β configuration of the OppA protein in Xanthomonas citri. Domain I is composed 
of three non-contiguous sequences, consisting of residues 1 to 44, 154 to 260 and 491 to 521, which make 
up a 7-stranded mixed β-sheet with four α-helices on its sides. The rest of the non-contiguous segments (1-
44 to 154-260) of this ensemble are held in a disulphide bond between the Cys 25 and Cys 165 residues. 
Nine α-helices flanking a 7-stranded central β-sheet composed of amino acids 261 to 490, constitute 
domain III. One side of the four anti-parallel β-sheet strands which make up Domain II, is circled by seven 
α-helices to create a very hydrophobic core, while the other side of the structure is exposed to the surface of 
the molecule. Since only a portion of periplasmic receptor proteins contain domain II, OppA orthologs are 
larger in comparison to other ABC-transporter nutrient-binding proteins. 
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Figure 2.5 The structure of the OppA protein of X. citri [Moutran et al., 2007]. 
2.5.2 Function 
Besides its role in peptide translocation, the oligopeptide permease system regulates several cellular 
processes which affect the virulence and physiology of a number of species [Nepomuceno et al., 2007]. 
Oligopeptide permease is accountable for recycling as much as 50% of cell wall muropeptides in 
Salmonella typhimurium and E. coli. Moreover, a functional oligopeptide uptake system containing at least 
one active OppA ortholog has to be present in order for conjugation and transformation, which are quorem-
sensing responses mediated by peptides in Gram positive bacteria such as Streptococcus pneumonia and 
Bacillus subtilis, to occur. OppA is also thought to be involved in sporulation and in the modulation of gene 
expression in a number of Gram positive bacteria. In addition, many studies have connected the presence of 
OppA orthologs to the expression of several virulence-associated traits, for instance the expression of 
adhesins. The sensitivity of S. typhimurium and E. coli to aminoglycoside antibiotics and toxic peptides is 
thought to be augmented by the expression of OppA in these bacteria, and recently there have been 
suggestions of a link between the expression of the OppA protein and the formation of biofilm in Vibrio 
fluvialis. The ecto-ATPase activity of the OppA protein in M. hominis is, furthermore, thought to be a 
virulence associated trait utilized by mycoplasmas following colonization, as discussed in greater detail 
later in this thesis [Hopfe and Heinrich, 2008]. 
2.6 The importance of mycoplasmas in disease 
It may be surprising that, despite their simplicity, several mycoplasmal species are able to cause far-
reaching effects in both animal and plant hosts [Bradbury, 2005]. Many mycoplasmal species are well-
recognized respiratory pathogens, especially under conditions where animals such as pigs, calves, poultry 
and even laboratory rodents are intensively housed, and considerable economic loss can be caused by these 
pathogens, especially if the animals are stressed [Beneina, 2002; Bradbury, 2005]. Interestingly, there have 
even been cases in which outbreaks of Mycoplasma pneumonia have occurred amongst military recruits 
and university students, which are probably the nearest human equivalents to intensively housed and 
stressed animals [Bradbury, 2005]. 
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Whilst more than 20 species of Mycoplasma are able to infect chickens and turkeys, only four species are 
considered to be major avian pathogens [Dufour-Gesbert et al., 2006]. The disease potential of these 
veterinary important mycoplasmas, which include M. gallisepticum, M. synoviae, M. iowae and M. 
meleagridis are most clearly defined and well established amongst the avian infecting mycoplasmas 
[Beneina, 2002; Bradbury, 2005]. 
2.7 Pathogenicity of mycoplasmas 
Bacterial infection involves an intricate set of interactions between the host and the invading organism, as 
well as the environment in which the host finds itself [Bradbury, 2005]. Through evolution, the host has 
developed several strategies with which to defend itself against invading pathogens, whilst invading 
pathogens have developed numerous tactics with which to overcome the defenses of the host.  
In order to be successful, a pathogen must find a way to enter its host, reach its target tissue and perhaps 
attach itself to the target tissue [Bradbury, 2005]. A successful pathogen should be able to evade the host 
defenses, enter the target tissue (or cells depending on the organism), multiply as well as cause some 
damage to the host. It should then be able to escape from the infected host to infect new hosts. Since there 
is no information currently available on the pathogenic nature of Ms01, much of the following report is 
based upon what is currently known about other mycoplasmas, particularly M. hominis, a close 
phylogenetic relative of Ms01, as well as other significant avian mycoplasmas.  
2.7.1 Transmission and entry into the host 
Mycoplasmas are able to enter the host by means of inhalation [Bradbury, 2005]. As such, the spread of 
poultry mycoplasmosis has unwittingly been encouraged by man as a result of birds being kept at high 
stocking densities in very large populations. Although mycoplasmas are not able to thrive in the 
environment outside the host, they may survive for a number of days on materials which include cotton 
clothing, hair, crates, utensils, equipment and feathers [Bigland, 1969; Kleven, 2008]. M. gallisepticum is 
thus regularly introduced to its host by humans, rodents and free-flying birds (who in themselves are not 
infected with M. gallisepticum) and as a result, commercial poultry producers continue to struggle with the 
horizontal transfer of M. gallisepticum [Kleven, 2008]. Vertical transmission of M. gallisepticum may also 
occur through the fertile egg to the offspring (poults and chicks), and airborne transmission of M. 
gallisepticum usually occurs sporadically, but does not normally exceed a distance of two kilometers. M. 
synoviae infections are also transmitted both laterally and vertically [Kleven, 2008; Dufour-Gesbert et al., 
2006]. In addition, the spread of M. iowae and M. meleagridis occurs through the venereal route [Bradbury, 
2005]. This route of spread is often aided through the use of artificial insemination during which female 
flocks can be infected when semen from turkey stags are pooled, since contaminated semen from a single 
infected stag may potentially be distributed to an entire female flock.  
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2.7.2 Target tissues 
Mycoplasmas are usually organ and tissue specific [Razin et al., 1998]. These organisms, which may be 
commensal, parasitic or saprophytic, primarily inhabit the mucous surfaces of the respiratory tract, 
alimentary canal, joints, urogenital tracts, eyes and mammary glands of human and animal hosts [Razin et 
al., 1998; Prescott et al., 2002; Beneina, 2002].  
In avians, the epithelial surfaces are the main target tissues of mycoplasmas, those of the respiratory tract in 
particular [Bradbury, 2005]. However, some mycoplasmas also target the urogenital tract epithelial surface 
and there is speculation that, in poultry, cross infection may occur between a colonized air sac and the 
adjacent ovaries of a female. This may result in a developing embryo becoming infected and enable 
transmission to the egg, even though, as stated previously, transmission to the egg may also occur as a 
result of contaminated semen. Mycoplasmas also occasionally target the joints, a tendency typically 
displayed by M. synoviae. This, however, usually follows infection at another site, such as the respiratory 
tract. In human beings, M. hominis initially infects the urogenital tract, subsequently spreading to the 
respiratory tract as well as the joints [Razin et al., 1998].  
2.7.3 Motility 
Motility has been demonstrated in various pathogenic mycoplasmas, although this trait may be surprising in 
an organism with such a tiny genome [Bradbury, 2005]. The movement, which has been compared to that 
of a flock of sheep grazing a field, is called ‘gliding motility’. The speed of motility seems to differ 
between species when examined in vitro. The composition of the medium, the age of the culture as well as 
the incubation temperature may affect the gliding ability of the organism, while particular antibodies may 
inhibit the motility of the organism completely. Being motile helps mycoplasmas reach their target tissues 
and may also be of aid in overcoming specific physical defenses in the host, for example the mucin layer in 
the respiratory tract as well as ciliary activity, making it a virulence-associated trait [Bradbury, 2005; 
Hatchel et al., 2006]. Even though the mechanism of gliding motility has not yet been unraveled, studies 
have linked motility in mycoplasmas such as M. pneumoniae to a structure referred to as the tip organelle 
(discussed in greater detail in the next section), and have identified mutations in the adhesion protein P30 to 
be associated with a reduction of speed in such mycoplasmas. Other studies suggest the presence of a 
contractile cytoskeletal protein which aids motility and that the tip organelle is not directly involved in 
mycoplasmal motility [Dubvig and Voelker, 1996; Trachtenberg, 1998; Hatchel and Balish, 2008]. 
2.7.3 Host cell interactions 
Infection and colonization has been shown to, in several animal mycoplasmas, depend upon adhesion of the 
organism to the host tissues [Rottem, 2003]. The ability of these mycoplasmas to adhere to host tissues is 
the main virulence factor, and mutants which are adherence-deficient are avirulent. Since the adhesion of 
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mycoplasmas to the epithelial cells is an essential step in tissue colonization, it is considered to be the first 
step in disease pathogenesis [Rottem, 2003; Bradbury, 2005]. 
M. gallisepticum as well as some other mycoplasmas related to M. pneumonia, colonize eukaryotic cell 
surfaces and mucus membranes with the aid of the tip organelle, a tapered cell extension at one of their 
poles. The tip organelle functions as the leading end in gliding motility as well as an attachment organelle 
[Rottem, 2003]. Structural and functional cooperation between adhesins, interactive proteins and adherence 
accessory proteins localized in the tip organelle, mobilize and concentrate adhesins at the tip, enabling 
colonization of eukaryotic cell surfaces and mucus membranes, perhaps by means of the host sulfated 
glycolipids and sialoglycoconjugates [Baseman and Tully, 1997]. The 169 kilodalton (kDa) P1 and 30 kDa 
P30 proteins present in M. pneumonia have been identified to be critical in the cytoadherence process 
[Razin et al., 1998, Rottem, 2003]. Most mycoplasmas, including M. hominis, however, do not have a well-
defined tip organelle and little is known about the cytoadherence of such species. Studies have, 
nevertheless, identified several structures, including the P50 and the P100 protein in M. hominis, which are 
associated with cytoadherence of the organism to its host [Heinrich et al., 1999; Kitzerow et al., 1999]. 
Since mycoplasmas have no rigid cell wall, intimate contact can occur between the plasma membrane of 
the mycoplasma cell and that of the host cell [Rottem, 2003]. Under the right conditions such contact may 
lead to cell fusion. Mycoplasmas, such as M. fermentans, which are capable of cell fusion, are referred to as 
fusogenic mycoplasmas. The fusogenicity of mycoplasmas depends on the unesterified cholesterol content 
of the cell membrane and only mycoplasmas requiring cholesterol for growth are capable of fusogenic 
activity.  
Although most mycoplasmas were thought to be extracellular pathogens for many years, mounting 
evidence suggests that mycoplasmas have evolved ways (not including fusion) of entering host cells which 
are not phagocytic [Razin et al., 1998; Heinrich, 1999]. The mechanisms of host cell entry, however, still 
remain unclear. Some mycoplasmas, including M. genitalium and M. penetrans, appear to enter host cells 
with the aid of their tip organelles, but several other mycoplasmas, such as M. hominis and M. fermentans, 
which do not have tip organelles, are also capable of entering their host cells [Razin et al., 1998; Bigland, 
1969]. Adherence to host cells is, however, thought to be the first step towards host cell invasion, and 
reiterates the key role of adherence related structures on mycoplasmal cells in the pathogenicity of these 
organisms. Notably, the outcome of experimental M. gallisepticum infections in chickens were found to be 
influenced by the invasiveness of the infecting strain, a more invasive strain being found in the liver, 
kidney, heart and brain of infected birds, suggesting haematogenous spread [Bradbury, 2005]. 
2.7.4 Host evasion 
The survival of a pathogen within its host greatly depends on its ability to dodge the host’s immune system 
and the ability of some mycoplasmas to enter their host cells affords them protection from the host’s 
antibody response as well as from several drug therapies, accounting somewhat for the difficulty 
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experienced in eradicating mycoplasmas from infected hosts and to the establishment of latent or chronic 
infection states [Razin et al., 1998; Rottem, 2003; Bradbury, 2005].  
Molecular mimicry and phenotypic plasticity are, however, better documented mechanisms employed by 
most mycoplasmas to circumvent the host’s immune system [Rottem, 2003; Minion, 2002; Kleven, 1998]. 
Molecular mimicry describes antigenic epitopes which are shared by different mycoplasmas and host cells, 
and thus recognized by the host’s immune system as ‘self’ instead of ‘foreign’ and/or leads to the induction 
of autoantibodies [Rottem, 2003]. Phenotypic plasticity refers to the capacity of a single genotype to alter 
its antigenic composition in order to generate more than one alternative form of morphology, physiological 
state and/or behavior in response to environmental conditions [Kleven, 1998; Rottem, 2003]. This may be 
accomplished as a response to environmental signals or as random changes of expression of single or 
multiple genes. The adhesin-related operons in mycoplasmas serve as an example. While such operons 
contain only a single full length copy of adhesin structural genes, several truncated and sequence related 
copies of adhesin genes occur throughout the genome, with specific areas of adhesin genes existing as 
single genomic copies, in contrast to the multiple copies of other areas which are homologous, but not 
identical [Baseman and Tully 1997]. Mycoplasmas thus seem to have a reservoir of partial adhesin-related 
gene regions with which to regulate the functional and structural characteristics of adhesins through 
recombination events. It is likely that mechanisms of phase and antigenic variation, which describes “the 
reversible high frequency gain or loss of cell surface components”, occur, whereby adhesins display altered 
affinities and specificities, depending on the organization of variable and constant adhesin gene sequences 
[Baseman and Tully 1997; Rottem, 2003]. The host’s antibody response mainly targets surface components 
on pathogens and the ability to rapidly change the antigenic repertoire of its components enables the 
pathogen to avoid detection by the host’s immune system. Since mycoplasmas lack a cell wall, pilli, and 
flagella; membrane proteins are the major targets of the immune response [Rottem, 2003].  
The immunomodulatory capabilities of mycoplasmas and other bacteria are increasingly recognized, not 
only as a method of host evasion, but also as a major mechanism of virulence [Rottem, 2003]. The 
production of systemic as well as local anti-mycoplasmal antibodies of various classes and subclasses, 
stimulation of cell-mediated immunity, opsonization and phagocytosis of organisms are amongst the 
specific protective defense mechanisms utilized by the host to combat infecting mycoplasmas [Razin et al., 
1998]. However, studies have shown that specific immune reactions drawn from the host by invading 
mycoplasmas aid in the development of lesions and exacerbate mycoplasma induced disease. Mycoplasmas 
exercise a wide array of nonspecific immunomodulatory effects on the cells of the immune system and may 
induce either suppression or polyclonal stimulation of T and B lymphocytes; increase cytotoxicity of T-
cells, macrophages and natural killer cells; induce cytokines; activate the complement cascade; and 
enhance the expression of cell receptors. The ability of mycoplasmas to modulate their host’s immune 
responsiveness has aided in their pathogenicity, enabling them to suppress or evade their host defense 
mechanisms and cause chronic, persistent infections.   
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If all else fails, molecules located in the plasma membrane or outer surface of mycoplasmas, such as 
capsular polysaccharides, lipoproteins and biofilms composed of fibrillar polycarbohydrates surrounding 
cells, are thought to protect these organisms from the bactericidal effects of complement and other 
defenses, in addition to triggering inflammatory processes in the infected host [Pilo et al., 2007]. 
2.7.5 Damage to the host  
No typical principal virulence genes have been found in the genomes of the ten Mycoplasma species which 
have been sequenced completely, in contrast to other pathogenic bacteria, where virulence is mostly 
determined by toxins, cytolysins and invasions [Pilo et al., 2007]. Instead, mycoplasmas appear to use 
intrinsic metabolic and catabolic pathway functions, or proper constituents of the mycoplasmal outer 
surface, to ensure their survival and cause disease in the infected host.  
Competition for biosynthetic precursors, such as fatty acids and vitamins, is thought to upset host cell 
integrity and alter its function when mycoplasmas attach to their host [Rottem, 2003]. Nonfermenting 
Mycoplasma species such as M. hominis and M. arthritidis serve as examples [Dubvig and Voelker, 1996]. 
Such mycoplasmas rapidly deplete the host’s arginine reserves, affecting host protein synthesis, host cell 
division, and growth; and additionally inducing chromosome breakage, reduction in chromosome number, 
the appearance of new and/or additional chromosome varieties, and multiple translocations [Rottem, 2003]. 
The depletion of L-arginine has also been shown in many studies to stimulate several immunosuppressive 
effects in immune cell systems in vitro [Razin et al., 1998]. In addition, mycoplasmas can interfere with 
membrane receptors and alter transport mechanisms of the host cell, for example interference with K+ 
channels of ciliated bronchial epithelial cells by M. hyopneumoniae, when they attach to the surface of the 
host [Rottem, 2003].  
Despite the fact that they are not associated with toxins, mycoplasmas are known to excrete cytolytic 
enzymes, cytotoxic metabolites, and peroxide and superoxide radicals which damage the host cell 
membrane [Razin et al., 1998; Rottem, 2003]. Potent membrane-bound phospholipases present in many 
mycoplasmas may also hydrolyse host cell phospholipids, activating particular signaling cascades or the 
release of cytolytic lysophospholipids which are able to disrupt the integrity of the host cell membrane.  
Additionally, apart from upsetting the normal functions of the host cells, mycoplasmas deliver potent 
hydrolytic enzymes when they enter or fuse to host cells [Rottem, 2003]. Examples include endonucleases 
of M. penetrans, which degrade host cell DNA, and phosphoprotein phosphatase which may interfere with 
host cell signal transduction. Fusion of the mycoplasma membrane (components) to the host cell membrane 
may also alter receptor recognition sites, and influence the stimulation and expression of cytokines, 
upsetting cross-talk between host cells. 
Recent studies by Hopfe and Heinrich [Hopfe and Heinrich, 2008] indicate that the ecto-ATPase OppA 
protein in M. hominis induces the release of ATP from HeLa cells and that OppA subsequently hydrolyzes 
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this ATP. The degradation of extra-cellular ATP to adenosine inhibits the growth of numerous cell types 
and may even induce apoptosis. This correlates with previous findings by Zhang and Lo [cited by Hopfe 
and Heinrich, 2008] that M. hominis and M. salivarium accelerates apoptosis and inhibits proliferation of 
32 D cells. Hopfe and Heinrich [2008] hypothesize that M. hominis is an extra-cellular colonizing pathogen 
and suggest that this pathogen enhances necrosis and apoptotic cell death in HeLa cells, while OppA 
promotes apoptosis only, in contrast to invasive mycoplasmas such as M. fermentans and M. penetrans, 
which have been shown to prevent apoptosis and stimulate cell proliferation. 
2.7.6 Epidemiology 
No information is currently available on the epidemiology of Ms01, but most avian species are infected by 
a unique species of mycoplasma [Bigland, 1969; Kleven, 2008]. Examples of minor mycoplasmal 
pathogens include M. columbinum, and M. columbinasale which infect pigeons, M. anatis which infects 
ducks and M. imitans, which is pathogenic to several avian species and closely related to M. gallisepticum 
[Kleven, 2008].  
M. gallisepticum is the most significant mycoplasmal pathogen infecting chickens and turkeys [Kleven, 
2008]. Although M. gallisepticum may also infect other avian species including ostriches, the gallinaceous 
species are known to be most at risk [Cline et al., 1997; Kleven, 2008]. M. gallisepticum occurs worldwide. 
However, as a result of the intense control programs utilized by developed countries, key poultry breeds, as 
well as turkey and broiler production in Western Europe, North America and several other developed 
countries, are now free of this pathogen [Bradbury, 2005; Kleven, 2008; Kleven, 1998]. However, even in 
developed countries, M. gallisepticum is still a regular occurrence in big multi-age commercial egg 
production flocks [Kleven, 2008]. 
M. synoviae is another species of Mycoplasma which infects both chickens and turkeys [Kleven, 2008]. M. 
synoviae infections occur in layers, turkeys and commercial broilers all around the world. Breeding flocks 
are, however, generally free of infection [Dufour-Gesbert et al., 2006]. M. meleagridis infects turkeys only, 
whilst M. iowae is a newly discovered pathogen infecting young turkeys and turkey embryos [Kleven, 
2008]. 
2.7.7 Clinical Signs 
The virulence and clinical manifestations of poultry Mycoplasma species vary widely, perhaps as a result of 
the high intraspecies variability between strains, as well as the ability of mycoplasmas to interact with other 
disease-causing organisms and environmental factors [Pretorius, 2009; Kleven, 2008]. However, when a 
bird becomes infected with a pathogenic mycoplasma species, the infection lingers for the lifetime of the 
host, despite severe antibiotic medication and a strong immune response [Kleven, 2008]. The course of 
avian mycoplasmosis is often prolonged and symptoms of the disease typically develop after 6 to 21 days 
in experimentally infected poultry. However, the incubation period is variable in naturally infected birds 
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and may result in birds remaining asymptomatic for days or months, until they become stressed [Avian 
mycoplasmosis, 2007]. 
M. gallisepticum infections result in what is commonly referred to as ‘chronic respiratory disease’ in 
chickens and ‘infectious sinusitis’ in turkeys [Bigland, 1969; Kleven, 2008]. Infectious sinusitis in turkeys 
is characterized by severe upper and lower respiratory disease, whereas in chickens, depending on the 
infecting strain as well as other factors, infections with M. gallisepticum may vary from asymptomatic to 
severe, with more severe respiratory symptoms being seen where birds are concurrently infected with E. 
coli, infectious bronchitis virus (IBV), pneumovirus infection, Newcastle disease virus (NDV), Hemophilus 
paragallinarum, avian influenza and other pathogens [Kleven, 2008; Avian mycoplasmosis , 2007; Ley, 
2008]. Infections by M. gallisepticum are characterized by a build up of inflammatory exudates in the 
trachea, an exfoliation of ciliated epithelial cells and a severe inflammatory response in the pulmonary air-
sacs [Collier et al., 2006; Bajwa et al., 1996]. Respiratory symptoms may include tracheal rales, sneezing, 
coughing, dyspnea and nasal discharges. Lesions include airsacculitis, tracheitis, sinusitis and conjunctivitis 
[Kleven, 2008]. More severe disease symptoms are often seen in turkeys and often include swelling of the 
paranasal (infraorbital) sinus [Avian mycoplasmosis, 2007; Ley, 2008]. Another common occurrence in 
turkeys is conjunctivitis accompanied by a frothy exudate, a condition which occurs only occasionally in 
chickens. When the birds are concurrently infected with E. coli, lesions frequently include perihepatitis and 
pericarditis [Kleven, 2008]. M. gallisepticum infections result in decreased feed conversion, poor growth 
rate, decreased egg production in adults and hatchability losses [Bradbury, 2005; Kleven, 2008; 
Abdulmoumen and Roy, 1995]. Mortality may be considerable where birds are concurrently infected with 
E. coli. M. gallisepticum infections contribute to the downgrading or condemnation of the meat at poultry 
processing plants [Bradbury, 2005; Collier et al., 2006]. 
Infections by M. synoviae are characterized by a comparatively mild respiratory infection and/or 
airsacculitis and infectious synovitis [Kleven, 2008; Dufour-Gesbert et al., 2006; Lockaby et al., 1998]. 
Synovitis frequently occurs as a swelling of the joints accompanied by poor growth and lameness [Kleven, 
2008]. In this condition, a thick gelatinous fluid frequently fills the synovial membranes of the feet, 
mandibles, hock and breast, in response to inflammation of the joint synovial membrane [Bigland, 1969]. 
There are, however, considerable differences in the virulence of different strains of M. synoviae and the 
virulence of the infecting strain may determine how severe the resulting disease will be [Kleven, 2008; 
Lockaby et al., 1998]. A small number of strains seem to be rather virulent, whereas several strains of M. 
synoviae seem to be non-pathogenic and result in little or no disease.  
Ostrich mycoplasma infections are primarily associated with the respiratory tract, resulting in inflammation 
of the air sacs, trachea and nose, as well as in severe lung lesions [Botes et al., 2005; Pretorius, 2009; Air 
sac infection, 2006]. Swollen sinuses, nasal exudates, rattle sounds in the throat, foamy eyes and excessive 
swallowing or shaking of the head are clinical signs associated with the ostrich specific mycoplasmas. 
Direct and indirect consequences of ostrich mycoplasma infections include erosion disease; increased 
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treatment costs; downgrading of carcasses; and increased susceptibility to secondary infections, for 
example E. coli. 
2.7.8 The effect of concurrent infections 
In 1969, Bigland described M. gallisepticum as “an organism of moderate pathogenicity which often acts as 
an opportunist, waiting for other conditions to lower the defenses of the bird then acting synergistically to 
bring on the typical syndrome of chronic respiratory disease” [Bigland, 1969]. This statement resulted from 
early studies involving M. gallisepticum, where scientists became aware that infection of healthy birds did 
not always result in chronic respiratory disease. It came to their attention that additional factors, which 
include stress causing conditions such as bad ventilation, overcrowding, feed and water starvation, and 
reactions to vaccinations against NDV, fowl pox, IBV and infectious laryngotracheitis were often required, 
in conjunction with M. gallisepticum infection, to bring about chronic respiratory disease. Concurrent 
infections involving mycoplasmas, viruses and bacteria are now well recognized and additional agents 
which have since been found to be involved include reovirus, Heamophilus gallinarium, adenovirus and 
molds [Bradury, 1984].  
It is now known that concurrent infection with even the mild or vaccine strains of IBV or NDV may 
promote the multiplication of mycoplasmas and amplify the severity of respiratory disease [Bradury, 1984]. 
The resulting infection may, however, be influenced by the breed, resistance and age of the birds, as well as 
the sequence of infection, the route and dose of infection, and the tropism and virulence of the infecting 
organisms. Amplification of pathogenicity, interference between pathogens or simply co-existance may be 
causative agents of the ensuing disease. It is thought that viral damage to the mucous epithelium may 
improve the habitat for the mycoplasma infection and a study by Hopkins and Yoder [cited by Bradury, 
1984], where a tissue reaction to IBV appears to predispose M. synoviae to air sac lesion production, 
supports this theory. Humidity and environmental temperature may, however, influence the extent to which 
the lesions are formed. 
Bacterial disease may also be involved and pathogenic strains of E. coli are frequently at the forefront of 
such infections [Bigland, 1969; Bradury, 1984]. Concurrent (mycoplasma) infections with NDV or IBV are 
known to enhance the vulnerability of the host to E. coli bacteraemia, resulting in perihepatitis, airsacculitis 
and pericarditis. It also appears as if previous infection with M. gallisepticum or M. gallisepticum and NDV 
or IBV may aid in the bacterial invasion of the air sacs [Bajwa et al., 1996, Bradury, 1984]. Concurrent E. 
coli infections are characterized by aggravated clinical symptoms as well as increased morbidity and 
mortality, and are often associated with adverse management conditions, especially in broiler houses with a 
lot of dust in the air [Bradury, 2005; Bigland, 1969; Kleven, 2008; Bajwa et al., 1996]. In addition to E. 
coli, bacteria such as Pseudomonas aeruginosa, Avibacterium paragallinarum, Bordetella avium and 
Pasteurella species have been implicated in mycoplasma-associated clinical conditions in South African 
feedlot ostriches [Botes et al., 2005].  
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2.7.9 Factors contributing to avian mycoplasma infections 
Stress, adverse weather conditions, lack of biosecurity and poor hygiene are factors which add to the 
incidence and severity of mycoplasma infections [Pretorius, 2009; Kleven, 1998]. In 1984, Yoder et al. 
[cited by Mohammed et al., 1987] suggested that mycoplasmal disease is augmented by an intricate 
interaction that takes place between temperature and humidity. This is evident during winter months in the 
Western Cape, when windy and wet weather amplifies the severity of ostrich mycoplasma infections due to 
the increased susceptibility of ostriches to secondary infections [Pretorius, 2009; Kleven, 1998]. A higher 
incidence of ostrich mycoplasma infections is, however, observed during autumn and spring, when 
fluctuations in temperature occur. Moldy feed, dirty water troughs, change in feed, high population 
densities, transport of birds, as well as other unhygienic and stress-causing conditions are also thought to 
contribute to ostrich mycoplasma infections. An increased risk of spread occurs with poor biosecurity 
programs, for example when birds from various sources are mixed. A lack of ventilation to decrease the 
amount of dust and ammonia, increased human contacts, the presence of wild birds, the absence of frequent 
stirring and replacement of manure to reduce moisture content, and the absence of bird-proofing are factors 
that have been linked to the spread and severity of other avian mycoplasmas [Mohammed et al., 1987; 
Kleven, 1998]. 
2.7.10 Diagnosis 
Confirmation of mycoplasma infections requires laboratory diagnosis, since several different poultry 
pathogens display similar clinical signs [Kleven, 2008]. Mycoplasmas should, however, be considered in 
the preliminary diagnosis if there is a drop in egg production or lesions and respiratory symptoms occur. 
The fact that mycoplasmal infections are frequently associated with additional pathogens should also be 
kept in mind.  
Serological procedures are usually the means by which mycoplasmosis is diagnosed [Kleven, 2008]. The 
easiest and most commonly utilized test is the serum plate agglutination (SPA) test. An enzyme-linked 
immunosorbent assay (ELISA) may also be performed and either ELISA or SPA tests of 10-30 serum 
samples should always be included in early diagnostic efforts. Positive SPA or ELISA results are usually 
confirmed using the very precise and dependable hemagglutination inhibition (HI) tests. However, as a 
result of the problems associated with acquiring suitable antigen, HI tests are not accessible in several 
regions of the world. Nonetheless, the best diagnostic technique for a mycoplasma infection is isolation and 
identification of the organism [Avakian and Kleven, 1990; Kleven, 2008]. The majority of laboratories 
around the world, however, lack this capability, and culture techniques are frequently substituted by the 
polymerase chain reaction (PCR), a technique which is commonly used in many laboratories.  
2.7.11 Prevention and Control  
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The method of control which is generally favored against M. gallisepticum is the use of all-in, all-out 
management techniques, the exclusive use of M. gallisepticum-free breeder sources for replacements, and 
the implementation of strict biosecurity measures to ensure that flocks are kept free of infection [Collier et 
al., 2006; Kleven, 2008]. Similarly, there is as yet no means with which ostrich mycoplasma infections can 
be prevented, except for maintaining good biosecurity practices [Olivier, personal communication]. 
However, ostriches infected with mycoplasmas frequently do not show any symptoms, but may act as 
carriers of mycoplasmal disease, making disease control difficult. In addition, the ability of these pathogens 
to conceal themselves from the host’s immune system makes mycoplasmas difficult to eradicate. 
2.7.11.1 Antibiotics  
There is no known course of medication which is able to eradicate M. gallisepticum and M. synoviae from a 
flock [Kleven, 2008]. However, antibiotics such as chloramphenicol and related products, tetracyclines, 
fluoroquinolones, ethromycin, tiamulin, tylosin and its derivatives; and other antibiotics whose actions are 
not based upon the inhibition of cell wall synthesis, have proven relatively effective, with the most 
effective results obtained when the medication is applied prophylactically. Similarly, advocin, tylosin, 
doxycline and oxytetracyclin are typically used to manage ostrich mycoplasma infections, but are not able 
to eradicate the mycoplasmas [Olivier, personal communication]. In addition, when antibiotics are used for 
extended periods of time, mycoplasmas tend to become resistant [Kleven, 2008]. The development of an 
effective vaccine thus appears to be the most promising avenue of control. 
2.7.11.2 Vaccines 
In literature it is stated that although mycoplasma “vaccines provide some protection against disease, 
almost universally, they fail to prevent colonization, and disease outbreaks still occur at unacceptable 
frequencies” [Minion, 2002]. Thus, while there are vaccines available which aid in the reduction of 
symptoms associated with avian mycoplasma infections, no conventional vaccine has yet been able to 
completely thwart infection during field challenge [Collier et al., 2006; Kleven, 2008]. There are no 
vaccines currently available for use against M. meleagridis infection and inactivated, oil-emulsion vaccines, 
which are generally applied intramuscularly or subcutaneously, are thought to be the safest vaccines for use 
against M. gallisepticum. Oil emulsion vaccines are, however, associated with the formation of granulomas 
and abcesses when applied subcutaneously to ostriches [Pretorius, 2009].  
2.8 DNA Vaccines  
Since its initial description by Edward Jenner more than 200 years ago, vaccination has become one of the 
most versatile and effective medical tools with which infectious pathogens of humans and animals can be 
combated [Liu, 2003; Saurez and Shultz-Cherry, 2000; Babiuk, 2002]. One of the greatest triumphs of 
medical science was the successful elimination of an entire wild-type of disease (smallpox) from the planet, 
an accomplishment largely attributed to the ability of vaccines to, instead of treating the disease directly, 
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(as other therapeutics, for example antibiotics do), teach the body to protect itself against the wild-type 
pathogen. It is a principle which is eloquently expressed in an old Chinese saying: ‘Give a man a fish and 
you feed him for a day. Teach a man to fish and you feed him for a lifetime’.  
Vaccines are usually composed of attenuated, but still infectious microorganisms (live attenuated vaccines) 
or of whole inactivated microorganisms or purified components thereof (inactivated vaccines) [Gregersen, 
2001]. Since live attenuated vaccines imitate natural infection, they are able to stimulate long-lasting 
immune responses after only a single application, whereas inactivated vaccines typically require booster 
injections and immunopotentiating adjuvants in order to stimulate sufficient humoral protection.  
Despite the various successes accomplished by their use, vaccines against many pathogens throughout the 
world, for example tuberculosis, malaria and human immunodifficiency virus (HIV), remain unavailable or 
ineffective [Guranathan et al., 2000]. While efficient antibody responses are generated by all currently 
licensed vaccines, one of the obstacles to successful vaccinations against the abovementioned organisms is 
that protection is only afforded by a cellular immune response, a response which is only efficiently 
achieved with the use of live attenuated vaccinations. A major disadvantage of live attenuated vaccines is, 
however, the existence of a narrow and delicate balance between (over) attenuation and (lack of) efficacy, 
and between replication competence and lack of pathogenicity [Gregersen, 2001]. Thus, while some live 
attenuated vaccines may be available, widespread use is barred by practical constraints such as 
manufacturing and safety concerns [Guranathan et al., 2000]. The observation that a recently developed 
group of vaccines, referred to as DNA vaccines, are able to induce both humoral and cellular immune 
responses, without the concern of “reversion back to virulence”, has therefore resulted in a lot of 
excitement within the vaccine development community [Oshop et al., 2002]. 
2.8.1 History 
The science behind the use of DNA vaccines, also referred to as third generation vaccines, was initiated 
more than fifty years ago when both Stasney et al. [cited by Abdulhaqq and Weiner, 2008] and Ito [cited by 
Abdulhaqq and Weiner, 2008] demonstrated in separate studies that when mice were injected with mouse-
derived tumor DNA, it not only resulted in the induction of tumors, but also precipitated seroconversion 
[Gregersen, 2001; Abdulhaqq and Weiner, 2008]. An increase in investigations into the in vivo expression 
of injected plasmid and linear DNA occurred in the 1980s and activity was demonstrated in several animal 
models. Such studies included a demonstration that growth hormone and insulin genes could result in the 
manufacture of these hormones in rats and that hepatitis could be induced in chimpanzees through the use 
of Hepatitis B Virus DNA. Support for the possibility of immune response induction using this in vivo 
delivery platform, came from studies conducted by Seeger et al. [cited by Abdulhaqq and Weiner, 2008], 
who established that Ground Squirrel Hepatitis Virus (GSHV) surface antigen was produced in 
experimental animals injected intrahepatically with GSHV genomic DNA [Shedlock and Weiner, 2000; 
Abdulhaqq and Weiner, 2008].  
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Table 2.1 The differences between inactivated, live attenuated and DNA vaccines, as tabulated by Gregersen [2001]. 
 
 
These early studies, while essential in showing that injected DNA could be expressed in vivo, frequently 
depended upon particular DNA preparations to aid transfection [Abdulhaqq and Weiner, 2008]. Examples 
of such preparations include calcium phosphate precipitation or liposome encapsulation. The first 
demonstration that transfection of murine muscle cells could occur when a purified DNA plasmid which 
encoded a reporter gene was injected into the muscle tissue of an animal subject, came from Wolf et al. 
[cited by Oshop et al., 2002] in 1990 [Guranathan et al., 2000; Stevenson and Rosenburg, 2001]. This study 
provided the basis for the concept that ‘naked plasmid DNA’ could be used to express proteins which are 
foreign to the host, as a means of immunization [Oshop et al., 2002; Guranathan et al., 2000]. This was 
confirmed by Tang et al. in 1992 [cited by Shedlock and Weiner, 2000], when they showed that Human 
Growth Hormone-specific antibodies were produced in mice after ‘genetic immunization’ with the Human 
Growth Hormone gene [Saurez and Shultz-Cherry, 2000; Shedlock and Weiner, 2000; Abdulhaqq and 
Weiner, 2008]. The immunoprotective capabilities of DNA vaccines were illustrated simultaneously in 
different studies by Fynan et al. [cited by Guranathan et al., 2000] and Ulmer et al. [cited by Guranathan et 
al., 2000] one year later, with the use of hemaglutinin and the influenza virus respectively, and in the same 
year Robinson et al. [cited by Guranathan et al., 2000] demonstrated that DNA vaccines could be used to 
elicit a protective immune response against influenza in chickens.  
These initial studies launched the field of DNA vaccines and were followed by several investigations in 
which different DNA constructs were used in an extensive array of animal disease models [Abdulhaqq and 
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Weiner, 2008]. The ability of DNA vaccines to stimulate appropriate immune responses is now being 
clinically investigated [Stevenson and Rosenburg, 2001; Abdulhaqq and Weiner, 2008]. 
2.8.2 Composition 
2.8.2.1 Identification and characterization of the antigenic gene 
The identification of an appropriate candidate gene is usually the first step in the development of a DNA 
vaccine. Proteins associated with the virulence of pathogens as well as structures of a pathogen which 
interact with the host are usually recognized by the host immune response, and consequently responsible 
for immune response induction [Heinrich, 1993]. Genes which encode such structures are referred to as 
antigenic or immunogenic genes.  
Several studies have identified ABC transporters as good targets for vaccine development against 
pathogenic bacteria [Tanabe et al., 2006]. These studies have established the immunogenic character of the 
OppA protein [Nowalk et al., 2006]. One study in particular, which focused on the production of a subunit 
vaccine against Yersinia pestis, assessed the potential of several ABC transporters in the induction of 
protective immunity in a mouse model of infection [Tanabe et al., 2006]. This study found that a significant 
increase in survival rate occurred in mice immunized against the OppA protein, when compared to the 
controls as well as the other proteins investigated. Immunoglobulin G (IgG) titers measured suggested that 
antibody to OppA was responsible for the protection afforded.  
2.8.2.2 Eukaryotic Expression Vectors 
In addition to an immunogenic gene of a pathogen of choice, a DNA vaccine usually comprises a specially 
modified bacterial plasmid [Donelly et al., 1997; Saurez and Shultz-Cherry, 2000; Guranathan et al., 2000; 
Oshop et al., 2002]. This plasmid, which is specifically designed for optimal expression in eukaryotic cells, 
is commonly known as a eukaryotic expression vector. A eukaryotic expression vector, such as can be seen 
in Figure 2.6, typically comprises (a) an origin of replication to allow for the production of high yields of 
plasmid in E. coli, (b) a strong eukaryotic promotor to drive the expression of the target gene in eukaryotic 
cells, (c) an antibiotic resistance gene to allow for antibiotic selective growth of E. coli, and (d) a 
polyadenylation or termination signal sequence to stabilize mRNA transcripts [Donelly et al., 1997; Saurez 
and Shultz-Cherry, 2000; Guranathan et al., 2000]. The immune response induced by a DNA vaccine relies 
to a large extent on the components of the expression vector employed [Guranathan et al., 2000]. It is thus 
required that the regulatory elements of the plasmid be optimized according to the expressing cell type 
[Oshop et al., 2002]. An important consideration during the optimization of DNA vaccine efficacy is 
therefore the choice of a suitable expression vector which allows for optimal expression of the 
antigenicgene in eukaryotic host cells.  
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Figure 2.6 An example of a eukaryotic expression vector (pCIneo, Promega) which may be utilized as part a typical 
DNA vaccination strategy. 
The majority of the promotors utilized in eukaryotic expression vectors are derivatives of the immediate 
early human cytomegalovirus gene or are derived from other virus genes such as simian virus 40 
[Guranathan et al., 2000; Gregersen, 2001]. A number of studies conducted to determine the best promoter 
for use in plasmids employed during avian DNA vaccinations, have found the cytomegalovirus promoter to 
be the better choice between the group of promoters evaluated (including the Rous Sarcoma virus, simian 
virus 40, chicken beta actin and cytomegalovirus) [Oshop et al., 2002]. Some promoters, for example the 
myocyte-specific desmin promoter, may be also used to limit antigen expression to a particular cell type, 
thus enabling a cell type of interest to be targeted directly. In addition, bicistronic vectors containing two 
genes whose transcription is regulated by a single promoter, and alternatively, vectors expressing multiple 
genes which are each regulated by an individual promotor and termination signal, may also be utilized 
[Gregersen, 2001].  
The polyadenylation termination signals utilized in eukaryotic expression vectors are usually obtained from 
bovine growth hormone or specific viruses [Gregersen, 2001]. A study evaluating the effect of the 
termination signal on avian DNA vaccines found no significant difference between the bovine growth 
hormone signal and a synthetic poyadenylation signal [Oshop et al., 2002]. Also, the single study 
conducted to investigate the best plasmid conformation for use (super coiled compared to linear) found that 
the linear plasmid had greater effectiveness. All other avian DNA vaccination studies were, however, 
conducted using super coiled plasmids and most produced high efficacy. Antibiotics such as neomycin, 
kanamycin or ampicillin are the most frequently utilized for plasmid selection [Gregersen, 2001]. Good 
DNA vaccination efficacy in avians may thus be achieved by using one of several common eukaryotic 
expression vectors containing the cytomegalovirus promoter and bovine growth hormone termination 
signal [Oshop et al., 2002].  
When the immunogenic target gene has been inserted into the eukaryotic expression vector, it is replicated 
(cloned) in bacteria, purified and delivered to the host using one of several routes.  
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2.8.3 Administration 
No particular formulations are required in order to make eukaryotic expression vectors appropriate for their 
intended utilization [Gregersen, 2001]. Most experimental DNA vaccines are applied merely as a 
physiological saline solution, making it possible for any laboratory to conduct investigations into the use of 
trial DNA vaccine products without the concern of having to prepare acceptable buffers, stabilizers or 
adjuvants. 
DNA vaccines are usually administered in doses of around 100 μg to mice, between 0.25 and 750 μg 
(depending on the route of administration) to chickens, while doses of more than 1000 μg have been 
administered to calves and monkeys [Gregersen, 2001; Oshop et al., 2002; Pretorius, 2009]. Suggestions 
have, however, been made that the amount of DNA required to induce an immune response is more 
dependent on the route of administration than on the size of the vaccinated animals. It is, however, 
imperative that vaccination occurs before field challenge.  
The possible routes of vaccine delivery in the avian include intramuscular injection, intra-dermal injection, 
gene gun inoculation (uses plasmid-coated gold beads to force DNA into epidermal cells), orally, 
intranasally, ocularly, intravenously, topically, intratracheally, intraperitoneally, subcutaneously, 
intrabursally, epidermally, in ovo to the developing embryo and in utero [Oshop et al., 2002]. Additional 
delivery routes which have been studied in other animal models include injections into thyroidal tissues and 
into lymph follicles [Gregersen, 2001]. Although vaccination by means of the gene gun has been shown to 
require less DNA to elicit a response in chickens, making it more efficient, this method is not economically 
feasible [Oshop et al., 2002]. A study by Fynan et al. [cited by Oshop et al., 2002], however, evaluated 
several of the above routes of plasmid delivery in the avian and found that none produced better efficacy 
than the intramuscular injection. Thus, due to its efficacy and simplicity, DNA vaccines are most frequently 
delivered to avian species by means of the intramuscular injection [Gregersen, 2001].  
Several other routes through which DNA vaccines may be administered to various animal models are 
currently being investigated [Gregersen, 2001]. Such techniques include aerosol applications, formulation 
into biodegradable nanoparticles, liposome formulations, inoculations together with cholera toxin, 
formulation into bioadhesive polymers, and through the use of microbial carriers which cannot replicate, 
for example specific viruses or enteric bacteria such as Salmonella typhimurium, into which plasmids 
encoding antigen are inserted. Interestingly, Fan et al. [cited by Oshop et al., 2002] also illustrated in 1999 
that fairly satisfactory humoral and cellular immune responses were generated when purified expression 
plasmids encoding the hepatitis B surface antigen, applied to the skin in aqueous solution, were taken up by 
hair follicles. This finding suggests that DNA vaccines may be administered by any means. However, not 
all modes of administration illustrate the high degree of reliability required for the standardized 
administration of vaccines, which often occurs under variable circumstances. As yet, the only conclusion 
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that can be drawn is that the character and the strength of the immune response generated are influenced by 
the species studied, the route of administration, the dose and the boosting scheme used.  
2.8.4 Optimization of DNA vaccines 
The identification of an immunogenic plasmid and antigen is rarely effective enough to immediately 
qualify as a vaccine [Gregersen, 2001]. Modifications of the plasmid framework, the antigen’s 
configuration and/or the antigen’s expression characteristics may improve immunity and protection. The 
antigen may prove more effective with or without its membrane anchor sequence, or when jointly 
expressed with a specific ligand, and even after optimization, single antigen may not sufficiently stimulate 
protective responses under practical circumstances, and may require antigen combinations, either in the 
same plasmid or by mixing different expression plasmids. 
Particular nucleotide sequences may be used to influence the immune response induced by a potential DNA 
vaccine [Guranathan et al., 2000]. Synthetic oligodeoxynucleotides (ODNs) with sequences modeled after 
those found in bacterial DNA have been found to stimulate the secretion of IFN-γ by natural killer cells. In 
addition, the unmethylated cytidine-phosphate-guanosine (CpG) dinucleotide motif, a specific motif which 
is 20 times more common in bacterial than in mammalian DNA, was also found to have a prominent role in 
enhancing the immune response, following DNA vaccinations. Unmethylated CpG motifs activate the 
innate immune response by binding to Toll-like receptor 9 (TLR9), triggering a signal transduction 
pathway which induces the secretion of proinflammatory cytokines, including IL-6, IL-12, IL-18, tumour 
necrosis factor (TNF)-ά, IFN- ά and IFN-γ, from macrophages and dendritic cells [Guranathan et al., 2000; 
Kim et al., 2001; Takeshita et al., 2004]. IL-12 and IL-18 subsequently activate natural killer cells. Also, 
binding of CpG motifs to TRL9 up regulates major histocompatibility complex (MHC) type I, MHC-II, 
CD80 and CD86 molecule expression and stimulates maturation of dendritic cells. In addition, CpG/TRL9 
interaction directly activates proliferation and antibody production by B-lymphocytes, and directly or 
indirectly activates T-lymphocytes, depending on their baseline activation state.  
Genes encoding cytokines and co-stimulatory molecules have also been used successfully to enhance or 
steer the immune response generated in a particular direction, through the expression of the said genes with 
a particular antigen [Gregersen, 2001]. An interesting example is the expression of ubiquitin, which targets 
proteins to the proteasome, thus leading to the rapid degradation of the expressed antigen before its release 
into the extracellular compartment, and subsequent stimulation of B-lymphocytes. Such investigations 
found that the antibody response which would otherwise have been generated was diminished or lost, but 
that cytoxic T-lymphocyte responses were still obtained.  
Although DNA vaccines are usually administered free of any enhancers or adjuvants when administered 
intramuscularly to avians, attempts have been made to enhance the immune response generated with the aid 
of adjuvants, such as cationic lipids, calcium phosphate, bupivacaine, sucrose, hypertonic solutions, 
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polybrene, DEAE dextran and cardiotoxin [Oshop et al., 2002]. Such studies found that the use of cationic 
lipids proved most successful. 
2.8.5 Immune response generated 
Despite the fact that the amount of antigen produced following DNA vaccination usually ranges from 
picograms to nanograms, a sustained and broad-based immune response is often generated [Guranathan et 
al., 2000; Oshop et al., 2002]. The type of antigen presenting cell transfected and the immune enhancing 
properties of the DNA itself (i.e. CpG motifs) are thought to play a role in the induction of the host immune 
response.  
Although the precise mechanism by which DNA vaccines initiate an immune response has not been fully 
elucidated, several theories have been suggested as to how this might occur [Oshop et al., 2002]. It has 
been suggested that myocytes are the cells which are predominantly transfected, even though dentritic cells 
and to a large extent monocytes, may also be transfected [Oshop et al., 2002; Gregersen, 2001, Abdulhaqq 
and Weiner, 2008]. The myocytes take up the plasmid DNA, although not very efficiently, to then translate 
and transcribe the encoded genetic information into a protein [Gregersen, 2001].  
It is thought that the antigenic proteins produced by the myocytes are presented to the immune system in 
their native form and that the process by which the antigen is presented is akin to what occurs during 
natural infection [Oshop et al., 2002, Abdulhaqq and Weiner, 2008]. Gregersen states that the “newly 
synthesized protein is processed through the proteasome complex and small peptides of the same are bound 
to MHC-I molecules” [Gregersen, 2001]. The same author then goes on to explain that the peptide-MHC-I 
complex would be presented to CD8+ T-lymphocytes resulting in differentiation and priming of peptide-
specific CD8+ cytotoxic T-lymphocytes. Any cell bearing the same peptide on its surface would then be 
targeted for destruction.  
There is a general consensus that dentritic cells and other antigen presenting cells are vital to the activation 
of adaptive immunity and that these cells sooner or later obtain the antigen for presentation to the CD4+ 
helper T-lymphocytes and CD8+ cytotoxic T-lymphocytes at the tissue-draining lymph nodes [Guranathan 
et al., 2000; Gregersen, 2001; Abdulhaqq and Weiner, 2008]. It is also thought that dendritic cells may 
directly prime the cytotoxic T-lymphocytes by expressing the antigen endogenously [Guranathan et al., 
2000; Abdulhaqq and Weiner, 2008]. Exogenous acquisition of antigen by the dendritic cells may occur in 
several ways, and these may include attainment of the antigen through a process referred to as “nibbling” 
from actively expressing myocytes, or through direct attainment through the phagocytosis of dying or dead 
cells [Guranathan et al., 2000; Gregersen, 2001; Abdulhaqq and Weiner, 2008]. In addition, dendritic cells 
may present the attained antigen via the MHC-II pathway, thus stimulating the helper T-lymphocytes which 
control B-lymphocyte responses. B-lymphocytes will subsequently produce antibody which specifically 
recognizes the antigen of interest.  
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In some studies, the skin has been implicated as an organ which plays a key role in the generation of an 
immune response subsequent to intradermal vaccination or gene gun inoculations [Guranathan et al., 2000; 
Gregersen, 2001, Oshop et al., 2002]. These studies have shown that very effective dendritic antigen 
presenting cells present in the epidermis, referred to as Langerhans cells, as well as dendritic cells present 
in the dermis of the skin are able to induce MHC-II immune responses resulting in strong helper T-
lymphocyte responses and subsequent antibody production by B-lymphocytes [Figure 2.7].  
 
Figure 2.7 A brief outline of the principal upon which DNA vaccination is based [Oshop et al., 2002]. 
2.8.6 Advantages of DNA vaccines 
DNA vaccines boast a number of important advantages when compared to the use of other currently 
available vaccines [Saurez and Shultz-Cherry, 2000; Oshop et al., 2002]. One of the most important 
features is the inherent safety associated with the use of DNA vaccines when compared to inactivated viral 
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vaccines and live attenuated vaccines, which are used at the constant risk of causing pathogenic infection in 
vivo [Abdulhaqq and Weiner, 2008]. Since DNA vaccines are able to induce both humoral as well as cell 
mediated immune responses, their use imitates that of live attenuated vaccines, but eliminates the safety 
concerns which are associated with the use of such vaccines [Saurez and Shultz-Cherry, 2000; Oshop et al., 
2002; Guranathan et al., 2000]. A summary of the advantages associated with the use of DNA vaccines is 
provided in Table 2.2. 
The design and production of DNA vaccines is reasonably straightforward and represents another important 
advantage [Abdulhaqq and Weiner, 2008]. In addition, DNA vaccines are decidedly more appropriate for 
mass production and circulation in both developed and developing countries, since they are fairly 
temperature insensitive and remarkably stable, thus eliminating requirement for a cold chain [Guranathan et 
al., 2000; Abdulhaqq and Weiner, 2008]. The plasmids used for DNA vaccinations are also not 
immunogenic themselves, thus there is no risk of producing a heterologous immune response to the 
plasmid of choice, after a boost [Abdulhaqq and Weiner, 2008]. Lastly, several open reading frames from 
one or more pathogenic genes may be introduced into the expression vector to allow for a better or 
specifically directed immune response, resulting in nearly infinite possibilities in which genetic inserts and 
plasmids may be modified. 
Table 2.2 Advantages of using DNA vaccines, as tabulated by Shedlock and Weiner [2000]. 
Immunogenicity 
 Can induce both humoral and cellular immune responses 
 Low effective dosages (micrograms) in animal models 
Safety 
 Unable to revert to virulence, unlike live vaccines 
 Efficacy does not require the use of toxic treatments, unlike some killed vaccines 
Engineering 
 Plasmid vectors are simple to manipulate and can be tested rapidly 
 Combination approaches are easily adapted 
Manufacture 
 Conceptually low cost and reproducible large-scale production and isolation 
 Produced at high frequency in bacteria and easily isolated 
Stability 
 More temperature-stable than conventional vaccines 
 Long shelf-life 
Mobility 
 Ease of storage and transport 
 Likely not to require a cold chain 
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Chapter 3 - Cloning, expression and purification of the Ms01 OppA protein 
3.1 Introduction 
Ostrich mycoplasma infections cause significant losses to the South African ostrich industry each year. 
Mycoplasmosis is primarily a disease of the respiratory system, initially infecting the air sacs of the lungs 
and later spreading to the trachea and upper respiratory passages [Bajwa et al., 1996]. Characterized 
initially by depression and decreased feed consumption, and later by sneezing, coughing and nasal 
discharges, the disease often results in decreased feed conversion, decreased viability, downgrading of 
carcasses and death of ostriches. Mycoplasmas are able to employ the minimal genetic information in their 
tiny genome to not only execute the essential functions for their replication, but also to damage the host 
cells in intimate proximity and obtain molecules, such as amino acids and nucleic acid precursors, for their 
own biosynthesis and survival. The lack of effective antibiotic and vaccine therapies with which to 
eradicate the mycoplasmas from South African ostriches has prompted a search for new alternatives. To 
this end, an immunogenic gene, specifically the oppA gene, was identified in Ms01 and isolated, with the 
aim of developing a DNA vaccine with which to combat ostrich mycoplasma infections. 
The oligopeptide transporter system has been identified in a variety of bacteria, and has been shown to be 
involved in a range of cellular processes, including nutrient accumulation and virulence [Tanabe et al., 
2006]. Such studies also identified the OppA lipoprotein as a good candidate for vaccine development. The 
oppA gene, which encodes the OppA lipoprotein, is referred to as the P100 gene in M. hominis and was 
documented as an important adhesion-related protein present in its cell membrane [Heinrich et al., 1993; 
Heinrich et al., 1999]. Most mycoplasmas, including M. hominis, must adhere to host cells in order to 
successfully colonize the host and cause infection [Rottem, 2003]. Since lipoproteins are known to play a 
central role in the interactions between mycoplasmas and eukaryotic cells, these proteins are thought to 
trigger the pathogenic mechanisms of mycoplasmas [Pilo et al., 2007]. Lipoproteins are also considered 
valuable targets for sensitive and specific sero-diagnosis, since these proteins are usually strongly antigenic 
and antibodies can be readily detected in the serum of infected hosts.  
In 2009, Pretorius [2009] isolated the DNA of an ostrich-infecting mycoplasma, Ms01, after which a major 
part of the genome was sequenced using GS 120 sequencing. A total of 64 contiguous sequences were 
generated and from these sequences the oppA gene was identified, isolated by PCR from Ms01 DNA, 
cloned and modified by site-directed mutagenesis [Pretorius, 2009]. The Ms01 oppA gene was subsequently 
subcloned into three different DNA vaccine vectors and purified. In this study, the three resulting DNA 
vaccines were amplified and then injected into ostriches as part of a vaccination trial. Serological analysis 
of the antibody responses generated would, however, require the use of a purified immunogenic protein for 
use in enzyme-linked immunosorbent assay of antibody levels. To this end, a strategy was followed in 
which the oppA gene was to be subcloned into a prokaryotic expression vector and expressed in E. coli. 
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Expression of the protein was attempted after cloning of the oppA gene into the pET14b prokaryotic 
expression vector. Additionally, the oppA gene was cloned into the pGEX-4T-1 prokaryotic expression 
vector in an attempt to express the OppA protein as a fusion product with GST in order to enable the 
purification of this fusion product by means of affinity chromatography.  
3.2 Materials and Methods 
3.2.1 Cloning of oppA gene into pGEM-T easy vector 
3.2.1.1 General Strategy 
Primers were designed into which specific endonuclease restriction cut sites were incorporated on the 5’ 
and 3’ ends of the PCR amplification product, as can be seen in Figure 3.1. Following PCR amplification of 
the Ms01 oppA gene, adenine overhangs were created on the 3’ ends of the oppA amplification product by 
means of polyA-tailing, after which the oppA gene was cloned into the pGEM®-T Easy cloning vector.  
3.2.1.2 Primer design 
Primers for the PCR amplification of the oppA gene were designed using Primer Designer (v1.01) based on 
the complete sequences of the Ms01 oppA gene that was previously sequenced by Pretorius (2009). NcoI 
and BamHI endonuclease restriction sites are present in the cloning region of the pET14b and pGEX-4T-1 
prokaryotic expression vectors, respectively, but not within the gene sequence of the oppA gene as 
modified by site-directed mutagenesis by Pretorius [8]. The NcoI and BamHI endonuclease restriction sites 
were thus added to the 5’ ends of the respective primers for later insertion of the modified oppA gene into 
the pET14b and pGEX-4T-1 vectors. The primers, which are shown in Table 3.1, were synthesized by 
Integrated DNA Technologies (IDT), Cape Town, South Africa.  
3.2.1.3 Polymerase Chain Reaction 
A pGEM®-T easy vector containing the modified (by prior site-directed mutagenesis) Ms01 oppA gene was 
provided by Benita Pretorius, Department of Biochemistry, Stellenbosch University. The oppA gene was 
amplified, using the P100-AmpF and P100-AmpR primers (Table 3.1), in 50 μl volumes containing 10 μl 
of 5x High Fidelity reaction buffer (Kapa Biosystems, Cape Town, South Africa), 1 μl of 1 U/μl HiFi 
proofreading Taq DNA polymerase (Kapa Biosystems), 1.5 μl of 10 mM deoxynucleotide triphosphates 
(dNTPs) (Kapa Biosystems), 0.5 μl of 25 mM MgCl2 (Kapa Biosystems), 1.5 μl of each primer (20 μM), 
250 ng of purified DNA and 29 μl of Milli-Q® deionized water. Amplifications were performed using a 
Labnet Thermal Cycler, with an initial denaturation step at 95°C for 2 minutes, followed by 25 cycles of 
denaturation at 98°C for 20 seconds, annealing at 50°C for 15 seconds and extension at 68°C for 90 
seconds. A final extension step was performed at 68°C for 5 minutes.  
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Figure 3.1 A diagrammatic illustration of how the Ms01 oppA gene was cloned into the pGEM®-T Easy vector. 
Primers were designed with NcoI restriction endonuclease cut sites added to the 5’ ends of the forward and reverse 
primer. These primers were used to amplify the Ms01 oppA gene present in the pCIneo eukaryotic expression vector, so 
as to obtain linear Ms01 oppA amplification product with NcoI restriction endonuclease cut sites on the 5’ and 3’ ends. 
Adenine overhangs were created on the 3’ ends of the oppA amplification product by means of polyA-tailing. The bonds 
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pGEM®-T Easy plasmid could then be utilized to facilitate cloning of the oppA gene into the pGEM®-T Easy plasmid. 
Restriction endonuclease cut sites are indicated with red arrows. 
3.2.1.4 Agarose gel electrophoresis 
In order to determine whether the PCR yielded the desired DNA product, the amplicon was analyzed on a 
1% (w/v) agarose gel (Molecular Grade Agarose D1-LE, Whitehead Scientific, Cape Town, South Africa) 
in 1x TAE buffer (0.04 M Tris acetate, 0.002 M EDTA, pH 8), to which 0.175 μg/ml of ethidium bromide 
was added for visualization of the DNA product under ultraviolet light. Ten microliters of PCR product, 
mixed with 2 μl of loading buffer [50% (v/v) glycerol, 50 mM EDTA, 100 mM Tris-base, 0.1% (v/v) 
bromophenol blue] was loaded onto the gel and run at 100 V for 50 minutes. A DNA Ladder (Fermentas, 
Inqaba Biotech, Pretoria, South Africa) was used to determine the approximate size and concentration of 
the amplicon.  
3.2.1.5 Purification of PCR product 
The PCR product was purified and concentrated using a GSFTM PCR DNA and Gel Purification Kit (GE 
Healthcare, Cape Town, South Africa) according to the manufacturer’s instructions. Agarose gel 
electrophoresis was subsequently performed as previously described (section 3.2.1.4), using 2 μl of purified 
PCR product, in order to confirm that enough PCR product was available for further use. The concentration 
of the purified PCR product was determined using a NanoDrop ND-2000 Spectrophotometer. 
3.2.1.6 Polyadenylation of the Ms01 oppA gene 
The amplification product generated during the PCR was used as template for polyadenine-tailing (polyA -
tailing). A reaction containing 1 μl of 10x reaction buffer (Super-Therm, JMR Holdings, USA), 6 μl of 
purified PCR product, 1 μl of 2 mM dATP (Bioline), 0.8 μl of 25 mM MgCl2 (Super-Therm), 1 μl of 5 U/µl 
Taq DNA polymerase (Super-Therm) and 0.2 μl of Milli-Q® water, was incubated at 70°C for 25 minutes. 
The PCR product was subsequently purified and concentrated using the DNA Clean and ConcentratorTM -5 
Kit (ZYMO Research, USA) as previously described.  
3.2.1.7 Cloning of the Ms01 oppA gene into the pGEM®-T easy vector 
The polyadenylated PCR product was cloned into the pGEM®-T Easy cloning vector (Promega, USA) 
using the pGEM® -T Easy Vector Kit, in a reaction mixture containing 5 µl of 2x Ligase buffer, 2 µl of 
polyadenylated PCR product, 50 ng of pGEM®-T Easy vector, 1 µl of 3 U/ µl T4 DNA Ligase, and Milli-
Q® water for a final volume of 10 µl. The reaction mixture was incubated at 24°C for 1 hour. Ligation 
reaction controls consisted of (a) a background reaction mixture containing no insert and (b) a positive 
control reaction containing control insert provided with the kit. 
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3.2.1.8 Transformation of E. coli JM109 cells with recombinant pGEM®-T Easy plasmids  
Agar plates containing Luria-Bertani (LB) medium were prepared according to the blue/white screening 
protocol of the pGEM®-T Easy Vector System (Promega). Plates were sterilized under ultraviolet (UV) 
light for 20 minutes. Thirty milliliters of sterilized LB/agar medium (15 g agar/ml LB medium), to which 
48 μl of 0.1 M IPTG (Bioline), 24 μl of 50 mg/ml X-Gal (Bioline) and 15 μl of 100 mg/ml ampicillin 
(Sigma) was added, was subsequently poured into plates for setting. Two microliters of ligation reaction 
was added to 50 μl of competent E. coli JM109 cells (1 x 107 cfu/μg DNA) (Promega) and incubated on ice 
for 20 minutes. The cell suspension was then heat shocked in a water bath at 42°C for 45 seconds and again 
incubated on ice for 2 minutes. The addition of 950 μl of LB medium to the cell suspension followed, as 
well as 60 minutes of incubation at 37°C on an IKA® KS 260 Basic orbital shaker (150 rpm) to allow for 
growth of the transformed cells. The cells were plated onto the LB/agar plates and subsequently incubated 
at 37°C for 16 hours. The plates could then be inspected for the development of colonies. 
3.2.1.9 Diagnostic PCR 
Successfully transformed colonies were identified with the aid of blue/white screening (as described in the 
Promega pGEM® -T Easy Vector System protocol), and subjected to a diagnostic PCR in order to identify 
the colonies containing the recombinant pGEM® -T Easy vector-insert construct. The T7 promotor (5’-
TAATACGACTCACTATAGGG-3’) and SP6 (5’-ATTTAGGTGACACTATAGAA-3’) primers were 
utilized in 10 μl reactions, containing 1 μl of 10x Reaction buffer (Super-Therm), 0.1 μl of 5 U/µl Taq 
DNA polymerase (Super-Therm), 0.4 μl of 5 mM dNTPs (Bioline), 0.5 μl of each primer (20 μM), 0.6 μl of 
25 mM MgCl2 (Super-Therm) and 6.9 μl of Milli-Q
® deionized water. A sterilized toothpick was used to 
scrape up cells from a colony of interest, after which the tip of the toothpick was placed into the PCR 
mixture and flicked 5 times to release some of the cells from the toothpick. The DNA contained within the 
cells of the chosen colony thus served as template DNA for the PCR. Amplification was performed with 25 
cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds. Initial denaturation occurred 
at 94°C for 5 minutes and final extension at 72°C for 7 minutes. Resulting PCR products were visualized 
using agarose gel electrophoresis, as described previously. A negative control reaction during which a blue 
colony was utilized as template DNA, as well as a positive control reaction during which previously 
purified plasmid known to contain insert of 700 bp was utilized as DNA template, was also performed. 
3.2.1.10 Isolation of the pGEM® -T Easy vector-insert construct 
Five milliliters of LB medium containing 5 μl of 100 mg/ml ampicillin (Sigma) was inoculated, using a 
sterilized toothpick, with a colony expected to contain the recombinant pGEM®-T Easy vector-insert 
construct. The inoculated medium was incubated for 16 hours at 37°C, on an IKA® KS 260 Basic orbital 
shaker, at 200 RPM, to allow the cells to grow. Plasmix Miniprep Kit (Talent, Italy) was used to isolate the 
pGEM®-T Easy vector-insert construct from the cultured cells according to the manufacturer’s instructions. 
The presence of the plasmid was confirmed using agarose gel electrophoresis, performed as previously 
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described. The successfully isolated recombinant pGEM®-T Easy plasmid containing the Ms01 oppA gene 
was then utilized as template for the subsequent DNA sequencing reaction. 
3.2.1.11 Sequencing of the pGEM®-T Easy plasmid insert 
In order to confirm that the oppA gene had been successfully inserted into the pGEM-T Easy plasmid, 
sequencing of the oppA gene insert was performed by means of cycle sequencing, with the aid of eight 
primers, each of which generated overlapping sequences in order to sequence the complete 2829 bp insert 
as illustrated in Figure 3.2. The internal primers utilized (P2F, P3F, P4F, P1R, P2R and P3R) are shown in 
Table 3.1. The T7 (5’-TAATACGACTCACTATAGGG-3’) and SP6 (5’-
ATTTAGGTGACACTATAGAA-3’) primers were used as external primers. Sequencing reactions were 
performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and was 
composed of 1 µl of Terminator mix, 3 µl of Half-dye buffer (Bioline), 300 ng of the isolated recombinant 
pGEM®-T Easy plasmid (refer to previous paragraph) and 3 µl of 3.3 µM of the respective primer 
solutions. Each of the eight individual reactions (each containing a different primer) was performed in 35 
cycles of 96°C for 10 seconds, 52°C for 30 seconds and 60°for 4 minutes, with a final extension of 60°C 
for 10 minutes, in a Labnet ThermoCycler. Sequencing reaction products were then analyzed, using an ABI 
PRISM® 373 DNA Sequencer, by the Core DNA Cycle Sequencing Facility at Stellenbosch University. 
The DNA sequences obtained were subsequently aligned using Chromas v1.45 (Technelysium Pty) and 
BioEdit (v 7.0.5.2, Hall) and inspected for mutations. Only when an Ms01 oppA sequence, free of all 
mutations except those induced by site-directed mutagenesis, was obtained, could the next step be 
continued with (Addendum A).  
 
Figure 3.2 A schematic illustration of the oppA gene (2829 bp) cloned into the pGEM®-T Easy plasmid (3015 bp) to 
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Table 3.1 Primers utilized during PCR and cycle sequencing reactions. NcoI and BamHI enodonuclease recognition 
sites, for the cloning of the Ms01 oppA gene into the pET14b and pGEX-4T-1 prokaryotic expression vectors, 
respectivlely, are underlined and the cut sites indicated with arrows. The initiation and termination codons of the Ms01 
oppA gene are indicated in bold. 
Primer name Primer sequence (5’-3’) Restriction enzyme 
P100-pET-AmpF 5’ – CCATGGTTATGAAAAAAAGCGCAAGACT – 3’ NcoI 
P100-pET-AmpR 5’ – CCATGGTTATTTATTGATTCTCCAATCA – 3’ NcoI 
P100-pGEX-AmpF 5’ – GGATCCATGAAAAAAAGCGCAAGACT – 3’ BamHI 
P100-pGEX-AmpR 5’ – GGATCCTTATTTATTGATTCTCCAATCA – 3’ BamHI 
T7  5’ – TAATACGACTCACTATAGGG – 3’ None 
T7 terminator 5’ – GCTAGTTATTGCTCAGCGG – 3’ None 
SP6  5’ – ATTTAGGTGACACTATAGAA – 3’ None 
pGEX-F 5’ – GGGCTGGCAAGCCACGTTTGGTG – 3’  None 
pGEX-R 5’ – CCGGGAGCTGCATGTGTCAGAGG – 3’  None 
P2F 5’ – CTAAAGATTTCTATTATTCATGGCTAAGAACAAATCAAACAATTG – 3’  None 
P1R 5’ – CTTCACCTTTTGAATTTACCCATTTTAAATTGTCTTTAAG – 3’  None 
P3F 5’ – GCTAAATTAGGTGTTTACTGGTATGGTGTAACAGCAAATAC – 3’  None 
P2R 5’ – CAATTGTTTGATTTGTTCTTAGCCATGAATAATAGAAATCTTTAG – 3’  None 
P4F 5’ – CTTTATTACAAGCTGCAATTAACTGGAATACAGTAGCAGATGTAAGAAC – 3’  None 
P3R 5’ – CTATTTGCTGTTACACCATACCAGTAAACACCTAATTTAGC – 3’  None 
 
3.2.2 Cloning of the Ms01 oppA gene into the pET14b and pGEX-4T-1 prokaryotic expression vectors 
Restriction endonucleases recognizing the endonuclease cut sites flanking the Ms01 oppA gene in the 
recombinant pGEM® -T Easy vector were used to cleave the gene from the pGEM®-T Easy vector-insert 
construct. The resultant sticky-ended oppA gene could then be cloned into the pET14b and pGEX-4T-1 
prokaryotic expression vectors as shown in Figure 3.3.  
The pGEM®-T Easy vector-insert construct, the pET14b vector (Novagen, USA) and the pGEX-4T-1 
vector (GE Healthcare) was each digested using NcoI (in case of pET14b) and BamHI (in case of pGEX-
4T-1) restriction endonuclease in a reaction containing 2 μl of 10x reaction buffer (Promega), 0.5 μl of 10 
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mg/ml 
Figure 3.3 A diagrammatic illustration of how the Ms01 oppA gene was cloned into the pET14b vector. NcoI 
restriction endonucleases were used to remove the oppA gene from the recombinant pGEM®-T Easy plasmid, as 
well as to digest and linearize the pET14b plasmid. The NcoI restriction endonuclease cut sites of the oppA gene and 
pET14b plasmid could then be bound together in a ligation reaction in order to produce the recombinant pET14b 
prokaryotic expression vector. Restriction endonuclease cut sites are indicated with red arrows. 
acetylated BSA, 2 mg of vector DNA, 2 μl of 10 U/μl NcoI (Promega) and Milli-Q® deionized water to a 
final volume of 20 μl. The reactions were incubated at 37°C for 2 hours. Restriction endonucleases and 
other reactants were removed from the digested DNA products using the DNA Clean and Concentrator TM-
5 Kit (ZYMO Research) according to the manufacturer’s instructions. In order to prevent the digested ends 
of linearized pET14b and pGEX-4T-1 plasmids from re-attaching, a phosphate group was removed from 






Isolated oppA gene 
5’- CATGG C            -3’ 
3’-              C GGTAC -5’ 
C            -3’ 











Stellenbosch University  http://scholar.sun.ac.za
 46 
alkaline phoshatase (SAP) (Promega), 0.5 μl of 10x SAP buffer (Promega) and 1.5 mg of digested vector. 
The reaction was incubated for 15 minutes at 37°C and inactivated for 15 minutes at 65°C. The 
dephosphorylated vectors were then purified and concentrated using the DNA Clean and Concentrator TM-5 
Kit (ZYMO Research) as previously described. The oppA gene was subsequently cloned into the pET14b 
and pGEX-4T-1 expression vectors in a reaction containing 1 μl of 10x Ligase buffer (Promega), 0.35 μl of 
3 U/μl T4 DNA Ligase (Promega), 100 ng of linearised vector DNA and 181.7 ng of oppA insert DNA. The 
ligation reactions were incubated for 16 hours at 4°C. Various insert to vector ratios were experimented 
with, including 5:1, 3:1, 1:1, 1:3 and 1:5 ratios. The equation illustrated below was used to calculate the 
concentration of DNA required to obtain these ratios. Negative controls consisted of reactions to which no 
insert was added. The transformation reaction was then performed as previously described. 
   








3.2.2.1 Diagnostic PCR 
In order to determine which colonies contained the recombinant pET14b and pGEX-4T-1 vector-insert 
constructs, a diagnostic PCR was carried out as previously described using the T7 promotor (5’-
TAATACGACTCACTATAGGG-3’) and T7 terminator (5-GCTAGTTATTGCTCAGCGG-3’) primers. 
Results were visualized using agarose gel electrophoresis, also described previously. 
3.2.2.2 Sequencing of the oppA gene in pET14b and pGEX-4T-1 vector-insert construct  
Colonies containing the recombinant pET14b and pGEX-4T-1 constructs were cultured in liquid medium, 
isolated using the Plasmix Miniprep Plasmid Isolation Kit (Invisorb, Invitek, Germany), and sequenced, as 
previously described, using the T7 promotor (5’-TAATACGACTCACTATAGGG-3’) and T7 terminator 
(5-GCTAGTTATTGCTCAGCGG-3’) external primers and the P2F, P1R, P3F, P2R, P4F and P3R primers 
as internal primers. Once an Ms01 oppA gene sequence in the correct orientation with regard to the 
transcription promoter and free of any mutations (except those induced by site-directed mutagenesis) was 
obtained, expression of the oppA gene could be attempted. 
3.2.3 Expression of the recombinant Ms01 OppA protein in E. coli BL21(DE3) pLysS cells using the 
pET14b and pGEX-4T-1 prokaryotic expression systems 
The recombinant pET14b and pGEX-4T-1 constructs (containing the Ms01 oppA gene) were cloned into 
competent BL21(DE3) pLysS cells (Novagen) using the transformation reaction described previously 
(PGEM®-T Easy transformation protocol). A diagnostic PCR was subsequently performed to confirm the 
success of the transformation reaction, and the results visualized using agarose gel electrophoresis as 
previously described. Two starter cultures, consisting of 5 ml of LB medium containing 250 μl of 20% 
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(m/v) glucose (Saarchem), 5 μl of 34 mg/ml chloramphenicol (Sigma-Aldrich) and 2.5 μl of 100 mg/ml 
ampicillin (Sigma), were respectively inoculated, using a sterile toothpick, with a colony of BL21(DE3) 
pLysS cells (Novagen) containing the recombinant pET14b plasmid, and a colony of BL21(DE3) pLysS 
cells (Novagen) containing the recombinant pGEX-4T-1 plasmid. The starter cultures were then incubated 
at 37°C for 16 hours on an IKA® KS 260 Basic orbital shaker at 200 RPM. The starter cultures were 
subsequently diluted fifty times in 10 ml of tryptone broth (TB) medium containing 1 ml of phosphate 
buffer (Merck), 0.5 ml of 20% (m/v) glucose (Saarchem), 10 μl of 34 mg/ml chloramphenicol (Sigma-
Aldrich) and 5 μl of 100 mg/ml ampicillin (Sigma) and allowed to continue growing at 37°C, under 
agitation, until an optical density (OD600) of 0.6 was reached. Induction was attempted using varying 
amounts of IPTG, ranging from 0.1 mM to 1 mM, and incubated at temperatures ranging between 20°C and 
37°C for up to 24 hours under agitation, with 500 μl samples being taken every hour. Controls consisted of 
BL21(DE3) pLysS cells containing (a) induced vector with no insert, (b) uninduced vector with the oppA 
gene insert, and in the case of expression with the pGEX system, (c) induced vector, not containing any 
insert. Following expression, samples were centrifuged (Beckman Model J2-21 Centrifuge, JA-20 rotor) at 
10 000 x g for 5 minutes, resuspended in TEN50 buffer (20 mM Tris, 1 mM EDTA, 0.2 mM DTT, 0.1% 
Triton X-100, 50 mM NaCl and 10% glycerol, pH 8) and stored at -80°C.  
3.2.3.1 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
In order to determine whether the OppA protein was successfully expressed, reducing SDS-PAGE was 
performed. Cell cultures were subjected to 3 cycles of freezing at -80°C for 10 minutes and thawing at 
37°C for 15 minutes in order to lyse individual cells and release the intracellular product into the medium. 
This was followed by five cycles of 3 second sonication and 20 seconds cooling of cells on ice. Samples 
containing 20 μl of cell lysis product, 12 μl of bromophenol blue (0.1% m/v) and 20 ml of loading buffer 
(0.125 M Tris-Cl, 4% m/v sodium dodecyl sulfate (SDS), 20% v/v glycerol, 10% v/v 2-mercaptoethanol, 
pH 6.8) were subsequently boiled for 3 minutes and immediately placed on ice. The samples were then 
loaded onto a reducing SDS gel composed of 4.5% stacking and 12% resolving gel, and electrophoresed at 
250 V, 20 mA, 100 W. Polyacrylamide gels were stained with staining buffer (0.125% Coomassie Briliant 
Blue R250, 50% v/v methanol, 10% v/v acetic acid) at room temperature on a rotary table (20 rpm) for 16 
hours. This was followed by 16 hours of destaining with Destain I solution (50% v/v methanol, 10% v/v 
acetic acid) at room temperature on a rotary table (20 rpm) for and 16 hours of further destaining under the 
above conditions, using Destain II solution (5% v/v methanol, 7% v/v acetic acid).  
3.2.3.2 Western Blot 
Prior to the western blot all samples were subjected to 12% reducing SDS-PAGE, as described before. The 
separated protein was then transferred to a 0.45 μm nitrocellulose membrane (Schleicher and Schuel) by 
means of 16 hours of electrophoresis (120 mA 100 W, 250 V) in electrophoresis buffer (0.05 M Tris, 0.2 M 
glycine and 20% v/v methanol, pH 8.3). Following protein transfer, the nitrocellulose membrane was 
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blocked with Casein buffer (154 mM NaCl, 0.5% w/v casein, 10 mM Tris HCl, 0.02% thiomersal, pH 7.6) 
for one hour at 37°C under agitation. Goat anti-GST antibody (GE Healthcare) was subsequently diluted 20 
000 times with Casein-Tween buffer (154 mM NaCl, 0.5% w/v casein, 10 mM Tris HCl, 0.05% v/v Tween 
20, 0.02% thiomersal, pH 7.6) and incubated with the nitrocellulose membrane for one hour at 37°C under 
agitation. The nitrocellulose membrane was then washed three times by means of incubation with PBS-
Tween (1.4 mM NaCl, 1% v/v Tween 20, pH 7.2) for ten minutes at 37°C under agitation. Rabbit anti-goat 
IgG peroxidase conjugate (Sigma-Aldrich) diluted 5 000 times with Casein-Tween buffer (154 mM NaCl, 
0.5% w/v casein, 10 mM Tris HCl, 0.05% v/v Tween 20, 0.02% thiomersal, pH 7.6) was subsequently 
added to and incubated with the nitrocellulose membrane for one hour at 37°C under agitation. This was 
followed by another washing step as previously described. Finally, substrate solution consisting of citrate 
buffer (0.1 M, pH 5), 0.05% w/v 2,2’-azino-bis(3ethylbenzthiazoline-6-sulphonic acid) (ABTS) and 0.05% 
v/v H2O2 was prepared and added to the nitrocellulose membrane. The substrate reaction, visualized with 
the appearance of green protein bands on the nitrocellulose membrane, was terminated after 30 minutes of 
incubation at room temperature by washing the membrane with distilled water. 
3.2.4 Protein Purification 
3.2.4.1 Ammonium sulphate precipitation 
An attempt was made to precipitate the recombinant OppA protein from the protein expression product of 
the recombinant pGEX-4T-1 vector containing the oppA gene. Therefore, 3 ml of phosphate buffered saline 
(PBS, pH 7.2) and subsequently 4.5 ml of saturated ammonium sulphate was added to 1.5 ml of lysed cell 
extract in a JA-20 centrifuge tube. Following incubation for 20 minutes at 4°C, the mixture was centrifuged 
(Beckman Model J2-21 Centrifuge, JA-20 rotor) at 4°C for 20 minutes at 27 216 × g. The supernatant was 
then decanted and the pellet redissolved in 3 ml of PBS. This was followed by the addition of a further 3 ml 
of saturated ammonium sulphate and incubation at 4°C for 20 minutes. Following centrifugation at 4°C for 
20 minutes at 27 216 × g, the pellet was redissolved in 1.5 ml of PBS and dialyzed overnight against 
carbonate buffer (0.1 M, pH 8.3) at 4°C. The carbonate buffer used for dialysis was replaced with fresh 
carbonate buffer 8 hours after the beginning of dialysis. The presence and size of the isolated protein was 
subsequently determined by SDS-PAGE, and the protein concentration was determined by measuring the 
absorbance at 280 nm using a Nanodrop ND-2000 Spectrophotometer. 
3.2.4.2 Glutathione affinity chromatography 
An attempt was made to purify the OppA protein from the protein expression product of the recombinant 
pGEX-4T-1 vector containing the oppA gene by means of affinity purification. Affinity purification was 
initiated by the swelling, washing and equilibration of the Glutathione-Agarose resin (Sigma-Aldrich), 
according to the manufacturer’s instructions. Following cell lysis, as described above, the soluble and 
insoluble fractions of the cell lysate were separated by centrifugation at 27 216 × g for 20 minutes. The 
soluble fraction of the cell lysate was subsequently pushed through a 0.45 μm Whatman® filter, as 
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recommended by the Sigma-Aldrich and GE Healthcare GST column purification protocols, to reduce the 
viscosity of the cell lysate and prevent the clogging of the purification column. Five milliliters of cell lysate 
was loaded onto the column and incubated overnight at 4°C on a rotary table (10 RPM). All subsequent 
steps were also performed at 4°C. A total of 5 ml of elution buffer (10 mM reduced glutathione, 50 mM 
Tris-HCl) was applied to the column, after which the column was closed and left to incubate for 30 
minutes. Multiple fractions were subsequently collected in 1 ml volumes, followed by the washing and 
storing of the column as recommended in the Sigma-Aldrich Glutathione-Agarose column purification 
protocol. Collected fractions were stored at 4°C and their protein content subsequently analyzed by means 
of SDS-PAGE (as previously described). 
3.3 Results 
3.3.1 Primer design, PCR amplification and agarose gel electrophoresis of the oppA gene 
The oppA gene was successfully amplified from the recombinant pCIneo vector by means of PCR, using 
the P100-AmpF and P100-AmpR primer pair, as shown by the presence of an amplicon of just under 3000 
bp (oppA gene of 2829 bp + 2 × restriction endonuclease cut sites of 6 bp each = 2841 bp DNA product) 
shown in Figure 3.5. An amplification product was obtained at all three annealing temperatures tested 
(50°C, 55°C and 60°C). It was thus decided that an annealing temperature of 50°C was most appropriate 
for amplifications in which the P100-AmpF and P100-AmpR primer pair were utilized. The amplicon was 
subsequently successfully purified as can be seen in Figure 3.6.  
3.3.2 Cloning the Ms01 oppA gene into the pGEM®-T easy vector  
The Ms01 oppA gene was successfully cloned into the pGEM®-T Easy plasmid, with transformation into E. 
coli JM109 cells yielding several white colonies amongst much fewer blue colonies. A diagnostic PCR 
performed on white colonies, using the T7 and SP6 primer pair, confirmed the success of the 
transformation reaction, with several colonies displaying the presence of insert, about 3000 bp in size 
(oppA gene of 2829 bp + 2 × restriction endonuclease cut sites of 6 bp each + 128 plasmid DNA = 2969 bp 
DNA product), in the multiple cloning site of the pGEM®-T Easy plasmid as shown in Figure 3.7.  
Isolation of the recombinant pGEM®-T Easy plasmid yielded the expected DNA product of just under 6000 
bp (2829 bp oppA gene + 3015 bp pGEM®-T Easy plasmid + 2 × restriction endonuclease cut sites = 5856 
bp recombinant pGEM®-T Easy plasmid) in size (separation on an agarose electrophoresis gel not shown). 
After analyzing 5 colonies containing the recombinant pGEM®-T Easy plasmid, a DNA sequence of the 
modified (by site-directed mutagenesis) Ms01 oppA gene, free of any mutations and flanked by the correct 
restriction endonuclease cut sites, was obtained. 
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Figure 3.5 PCR products obtained using the P100-AmpF and P100-AmpR primer pair. Amplification products were 
electrophoresed on a 1 % agarose gel, to which 0. 175 μg/ml ethidium bromide was added for visualization of the PCR 
product under UV light. Reactions were performed and analyzed in duplicate, with an annealing temperature gradient 
beginning at 50 °C and ending at 60 °C.  Lane 7: 5 μl DNA ladder mix (Fermentans) 
2.3.3 Cloning of the Ms01 oppA gene into the pET14b and pGEX -4T-1 vectors 
Restriction enzyme digestion of the pET14b, pGEX -4T-1 and recombinant pGEM®-T Easy plasmids was 
performed successfully. Complete digestion of the restriction endonuclease recognition sites in the 
recombinant pGEM-T Easy vector was obtained after one hour of incubation with restriction endonuclease, 
as deduced from the single solid band running slightly above the band of the undigested control sample, as 
shown in Figure 3.8. The ligation efficiency of the ligation reaction was initially evaluated through agarose 
gel electrophoresis of the ligation reaction product. Agarose gel electrophoresis of the ligation reaction 
product yielded two bands, corresponding to the size of the Ms01 oppA gene (2829 bp) and the expected 
size of the recombinant pET14b / pGEX-4T-1 vector (2829 bp oppA gene + 1 × restriction endonuclease 
cut site + 4671 bp pET14b / 4969 bp pGEX-4T-1 vectors = 7506 bp recombinant pET14b / 7804 bp 
recombinant pGEX-4T-1 plasmid ), leading to the deduction that although the concentration of plasmid was 
limiting, ligation had occurred efficiently, and that the transformation reaction could be proceeded with.  
Following numerous (more than 20) unsuccessful attempts and optimization, the Ms01 oppA gene was 
successfully cloned into the prokaryotic expression vectors (initially pET14b and later pGEX-4T-1), with 
several white colonies obtained on the LG/agar plates. The largest number of colonies were obtained on 
plates transformed using a 3:1 ligation reaction when the recombinant pET14b vector was utilized, and a 
5:1 ligation reaction when the recombinant pGEX-4T-1 vector was utilized. 
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Figure 3.6 Purified PCR products obtained using the P100-AmpF and P100-AmpR primer pair. Purification was 
performed using a GSFTM PCR DNA and Gel Purification Kit. The purified amplification products were 
electrophoresed on a 1% agarose gel, to which 0. 175 μg/ml ethidium bromide was added for visualization of the DNA 
under UV light. 
 
Figure 3.7 PCR products obtained following diagnostic PCRs in which the T7 and SP6 primer pair were utilized. 
The PCR products were electrophoresed on a 1% agarose gel to which 0.175 μg/ml ethidium bromide was added for 
visualization of the PCR product under UV light. Lane 1: 10 μl PCR product where a blue colony was used as template 
DNA (negative control). Lane 2: 10 μl PCR product where a plasmid known to contain an insert with a size of 700 bp 
was used as template DNA (positive control). Lanes 3 - 5: 10 μl PCR product where white colonies were used as 
template DNA. Lane 3 displayed an insert of the expected size and was thus considered to be a positive result. Lane 6: 
5 μl DNA ladder mix (Fermentas). 
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Figure 3.8 DNA products observed following restriction enzyme digestion of the pET14b plasmid. The digested DNA 
product was electrophoresed on a 1% agarose gel to which 0.175 μg/ml ethidium bromide was added for visualization 
of the DNA under UV light. Lane 1: DNA Ladder mix (Fermentans). Lane 2: Undigested pET14b plasmid. Lane 3: 
pET14b plasmid incubated with NcoI restriction enzyme for 1 hour. Lane 4: pET14b plasmid incubated with NcoI 
restriction enzyme for 2 hours. Lane 5: pET14b plasmid incubated with NcoI restriction enzyme for 3 hours. 
Transformation control (a), which was transformed with pET14b and pGEX-4T-1 expression vectors which 
did not contain any insert, yielded only blue colonies, whereas control (b), which was transformed using 
pET14b and pGEX-4T-1 vectors known to contain inserts, yielded mostly white colonies, as was expected. 
Diagnostic PCRs performed on well over 3000 colonies, thought to contain the recombinant pET14b and 
pGEX-4T-1 vectors, eventually showed the presence of the oppA gene in some colonies, with DNA product 
of about 3000 bp (2829 bp oppA gene + 1 × restriction endonuclease site + 216 bp vector DNA (pET14b) / 
150 bp vector DNA (pGEX-4T-1) = 3051 bp insert (pET14b)/ 2985 bp insert (pGEX-4T-1)) being 
obtained. Other colonies displayed band sizes of about 200 bp (216 bp vector DNA (pET14b) / 150 bp 
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Figure 3.9 PCR products obtained following diagnostic PCR in which the T7 and T7 terminator primer pair was 
used. The PCR product was electrophoresed on a 1% agarose gel to which 0.175 μg/ml ethidium bromide was added, 
for visualization of the DNA under UV light. Lane 1: 5 μl DNA ladder mix (Fermentas). Lane 2: 10 μl PCR product 
where a blue colony was used as template DNA (negative control). Lanes 3 - 12: 10 μl PCR product where white 
colonies were used as template DNA. Lanes 4, 7 and 11 displayed insert of the expected size (as indicated by the 
arrows) and were thus considered to be positive results. 
The recombinant plasmids were isolated and DNA product corresponding to the expected size of the 
prokaryotic expression vectors containing the Ms01 OppA protein (7506 bp recombinant pET14b / 7804 bp 
recombinant pGEX-4T-1 plasmid), could be seen on the respective agarose gels. Cycle sequencing yielded 
a DNA sequence in the correct orientation with regard to the transcription promoter, which could be 
aligned successfully with the modified Ms01 oppA DNA sequence previously sequenced [8].  
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3.3.4 Expression of the recombinant Ms01 oppA gene in E. coli BL21(DE3) pLysS cells using the 
pET14b prokaryotic expression system 
The transformation of the E. coli BL21(DE3) pLysS cells with the recombinant pET14b plasmid construct 
resulted in the formation of several colonies on the LB/agar plates. A diagnostic PCR and subsequent 
agarose gel electrophoresis revealed PCR products of around 3000 bp, which correspond to the size of the 
Ms01 oppA gene (2829 bp) (results not shown). 
BL21(DE3) pLysS cells were grown for six hours to an OD600 of 0.6. Cell samples taken hourly following 
induction of expression, appeared to contain a similar variation and quantity of protein products as the 
negative control when analyzed by means of reducing SDS-PAGE (Figure 3.10). A protein, around 130 
kDa in size (inclusing the GST tag), was expected. Even after several attempts at optimization (outlined 
and discussed in section 2.4), no additional bands or difference in protein band size could be observed 
between the expression samples and the expression controls.  
 
 
Figure 3.10 Reducing SDS-PAGE analysis of the protein product of BL21(DE3) pLysS cells containing the 
recombinant pET14b prokaryotic expression vector, following induction of expression. Lane 2: Cell sample taken 
before induction. Lane 3: Cell sample taken two hours after induction. Lane 4: Induced sample of cells containing 
pET14b with no insert (negative control) taken two hours after induction. Lane 5: Cell sample taken four hours after 
induction. Lane 6: Negative control taken four hours after induction. Lane 7: Cell sample taken 3 hours after induction. 
Lane 8: Cell sample taken two hours after induction. Lane 9: Uninduced cells containing the recombinant pET14b 
prokaryotic expression vector grown for four hours after the induction of other cell samples. Lane 1 and 10: RainbowTM 
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3.3.5 Expression of the recombinant Ms01 oppA gene in E. coli BL21(DE3) pLysS cells using the 
pGEX-4T-1 prokaryotic expression system 
The recombinant Ms01 OppA protein was successfully expressed in BL21(DE3) pLysS cells containing the 
recombinant pGEX-4T-1 plasmid, with a protein of about 150 kDa (100 kD OppA protein + 26 kDa protein 
= 126 kDa recombinantly expressed protein) becoming visible two hours after induction on a reducing 
SDS-PAGE gel. Expression for about eight hours after induction appeared to yield the highest 
concentration of recombinant OppA protein product, since longer expression resulted in a decrease in the 
protein product obtained, and was thus accepted to be the optimum expression time.  
3.3.6 Purification of the recombinant OppA protein 
3.3.6.1 Ammonium sulphate precipitation 
Purification of the recombinant OppA protein expressed using the pGEX-4T-1 prokaryotic expression 
system was initially attempted by means of ammonium sulphate precipitation. The objective of this 
technique, which involves the addition of saturated ammonium sulphate to the cell lysate following 
expression, is to precipitate highly expressed soluble protein, isolate, and re-dissolve the protein. Although, 
this technique appeared to be relatively successful, results from the SDS-PAGE gel, shown in Figure 3.11, 
did not allow accurate protein size determination. Furthermore, the SDS-PAGE analysis suggested that 
another highly expressed protein had been isolated (lane 3), instead of the recombinant OppA protein. In 
addition, the isolated protein product appeared to contain smaller sized proteins, indicating that it was not 
completely pure. It was thus decided to purify the recombinant OppA protein by means of glutathione-
agarose affinity purification. 
 
Figure 3.11 Reducing SDS-PAGE analysis of protein products of BL21(DE3) pLysS cells containing the recombinant 
pGEX-4T-1 plasmid, after expression and ammonium sulphate precipitation of the recombinant OppA protein. Lane 1: 
Induced sample of cells containing pGEX-4T-1 plasmid with no insert. Lane 2: Cell sample taken eight hours after 
induction of expression. Lane 3: Purified protein. Lane 4: Purified GST protein. Lane 5: PrecisionPlus ProteinTM All 
Blue Standard (Bio Rad). The arrow indicates the position of the Ms01 OppA protein. 
250 kDa 
150 kDa 
 10 kDa 
 25 kDa 
 37 kDa 
100 kDa 
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3.3.6.2 Affinity purification 
Glutathione affinity purification of the recombinant OppA protein proved successful, with a single protein 
of about 150 kDa (100 kD OppA protein + 26 kDa protein = 126 kDa recombinantly expressed protein) 
having been obtained on an acrylamide gel, seen in Figure 3.12. The presence of the recombinant protein 
was successfully confirmed by means of western blot using anti-GST antibodies as shown in Figure 3.13.  
 
 
Figure 3.12 Reducing SDS-PAGE analysis of the protein product of BL21(DE3) pLysS cells containing the 
recombinant pGEX-4T-1 plasmid, following expression and affinity purification of the recombinant OppA protein. 
Lane 1: Cell sample taken eight hours after induction of expression. Lane 2: Induced sample of cells containing pGEX-
4T-1 plasmid with no insert (control sample) taken two hours after induction. Lanes 3-6: Purified recombinant Ms01 
OppA protein. Lane M: PrecisionPlus ProteinTM All Blue Standard (Bio Rad). The arrow in lane 1 indicates the 
position of the expressed recombinant protein, while the arrow in lane 2 points to the expressed GST protein (positive 
control). The arrow in lane 3 indicates the position of the purified recombinant protein. 
3.4 Discussion 
From the results obtained in this study, it can be concluded that the cloning strategy employed for the 
insertion of the oppA gene into the selected expression vectors was successful. The primers designed to 
amplify the Ms01 oppA gene were successfully used to yield a PCR product with the expected band size of 
3000 bp. The cloning of the purified Ms01 oppA gene into the pGEM-T easy cloning vector appeared to be 
successful, based on the diagnostic PCRs which showed a PCR product of the expected band size. The 
subsequent plasmid isolation, where a plasmid of the expected size was visualized on an agarose gel, and 
DNA sequencing reaction confirmed the presence of the Ms01 oppA gene flanked by the NcoI restriction 
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Figure 3.13 Western blot analysis of the purified protein. The top-left arrow indicates the position of the recombinant 
OppA protein, while the bottom-right arrow points to GST control. 
The NcoI restriction endonuclease was successfully used to cleave the gene from the cloning vector for 
subsequent subcloning, with a difference in band size being observed between the digested and undigested 
samples. The change in band size was thought to occur as a result of the linearization of the circular 
plasmids during digestion, resulting in slower migration of the digested linear DNA through the gel matrix, 
and causing the linear DNA to migrate more slowly in the gel than the circular DNA. 
Cloning of the Ms01 oppA gene into the pET14b and pGEX-4T-1 prokaryotic expression vectors yielded 
positive results, with the diagnostic PCR that followed transformation revealing the presence of an insert 
the size of the oppA gene (around 3000 kb). Insertion of the oppA gene into the correct position in the 
expression vectors was confirmed by analysis of the size of the recombinant vectors (with the expected 
sizes having been attained) and subsequent DNA sequencing. 
Despite numerous attempts at problem-solving and optimization, expression of the recombinant Ms01 
OppA protein could not be achieved using the pET14b system of expression. A subsequent literature study 
indicated that the mode of expression of recombinant proteins influences the production and physical 
properties of the polypeptide that is synthesized [Guan and Dixon, 1991]. The expression system utilized is 
also said to influence the level of expression obtained. Problems commonly associated with expression 
include protein insolubility, incorrect protein folding, protein aggregation (formation of inclusion bodies), 
plasmid instability and codon bias. All of the above factors were considered as possible causes of the 
problems experienced and investigated accordingly.  
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Studies investigating the structure of the OppA protein have confirmed it to be a soluble protein, thus 
protein insolubility was unlikely as a possible reason for the problems with expression [Garmory and 
Titball, 2004; Balan et al., 2008; Hopfe and Heinrich, 2008]. Proteins which are folded incorrectly are 
usually either broken down into their constituent amino acids by cytoplasmic proteases or precipitate into 
inclusion bodies [Baneyx, 1999]. Thus, incorrectly folded proteins may not be readily detected by means of 
SDS-PAGE, the detection technique used during this study. For this reason, incorrect protein folding could 
thus not be ruled out as a possible problem of expression. An attempt was thus made to express the protein 
at lower temperatures. Literature indicates this to be a measure of reducing inclusion body formation 
[Simionatto et al., 2010]. Inclusion bodies are amorphous protein aggregates which are thought to occur 
during situations which impair protein folding in vivo, resulting in the aggregation of protein folding 
intermediates [Sorensen and Mortensen, 2005]. The exact mechanism of formation is unknown, but 
Simionatto et al. [2010] suggests that inclusion bodies are formed when the protein translation rate exceeds 
the cells capacity to fold newly synthesized proteins. Expression at a lower temperature would therefore 
reduce the rate of protein translation and lessen the formation of inclusion bodies. However, even with 
expression performed at temperatures as low as 20˚C, no bands of the expected size could be observed on 
the SDS-PAGE gels after staining. Expression was also attempted using a higher concentration of IPTG for 
induction, as recommended in the pET system manual, but no increase in expression was detected. 
The plasmid stability of the recombinant pET14b vector was then investigated. Literature indicates that 
recombinant protein expression is always enhanced with higher plasmid stability and that plasmid stability 
may be influenced by various factors, including medium composition, type of insert and plasmid load [Xu 
et al., 2005]. A study conducted by Xu et al. [2005] found that the ratio of plasmid-containing cells 
decreased significantly (from 67.2% to 0.053%) with increasing numbers of multiple (heterologous) joined 
genes in the pET28a plasmid. This indicates that increased gene size may greatly reduce plasmid retention 
when using the pET expression system. Since the Ms01 oppA gene is a relatively large gene (2829 bp), its 
size could be viewed to be of serious concern in this regard. A diagnostic PCR was thus conducted with 
samples taken before, during and after protein expression to determine whether the recombinant pET14b 
plasmid was retained by the E. coli BL21(DE3) pLysS cells during expression. Positive results were 
obtained in each case indicating that at least some plasmid was retained by the induced cells even after 
expression. The percentage of expressing cells actually containing plasmid was, however, not determined.  
Xu et al. [2005] also found that the addition of glucose to the medium significantly increased retention of 
the pET28a recombinant plasmid by BL21(DE3) cells. Cells containing plasmid typically grow slower than 
cells which do not contain any plasmid, particularly when a recombinant strain is fully induced. This is the 
result of an increased metabolic burden on the cells due to the synthesis of the recombinant protein. This 
burden is likely to be increased with the size of the protein synthesized and probably accounts for the 
decrease in protein stability witnessed by Xu et al. [2005]. Nonetheless, even with the addition of glucose 
to the medium, no protein bands of the expected size were found on the SDS-PAGE gel after staining.  
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It has also been reported that plasmid stability can be improved by decreasing the strength of the promoter 
[Xu et al., 2005]. The pET14b expression system is the most powerful prokaryotic expression system to 
date and comprises a T7 promoter and T7 RNA polymerase that are so active that, when fully induced, 
most of the cell’s resources are converted to recombinant gene expression, such that the recombinant 
protein synthesized may comprise more than 50% of the cells protein within only a few hours [Novagen 
pET System manual]. This strong promoter may therefore have negatively affected plasmid stability and 
protein production, as has been shown in previous studies [Xu et al., 2005].  
Examination of the nucleotide sequence of the Ms01 OppA protein raised the additional concern that the 
occurrence of high numbers of rare codons was likely to be hampering expression of the recombinant 
protein. All cells, especially E. coli in this case, utilize a particular subset of 61 amino acid codons for the 
manufacturing of most mRNA molecules [Kane, 1995; Sorensen and Mortensen, 2005]. Rare codons are 
codons which are utilized by E. coli at a frequency of less than 1%. Rare codons usually occur in genes 
which are expressed at low levels, whereas major codons are typically found in highly expressed genes. 
While genes which contain a distribution of codons similar to that which is normally encountered by E. coli 
will usually be expressed without much difficulty, genes containing rare codons are likely to undergo 
translational problems resulting in a reduction in either the quantity or quality of the protein synthesized. 
The AGG and AGA codons occur at the lowest frequency in E. coli (0.14% and 0.21%, respectively) and 
were the first codons demonstrated to have a detrimental effect on protein expression [Kane, 1995]. Studies 
investigating the effect of the said codons on gene expression found that the expression additionally 
depended on the number and position of the codons within the mRNA. Thus, as the number of rare codons 
increased, the expression decreased, and the effects on the protein decreased as the codons approached the 
carboxyl-terminus. 
About 15% of the codons encountered in the Ms01 OppA are rare codons, with some occurring in clusters 
and others occurring singly [Addendum B]. The first rare codon to appear in the Ms01 OppA transcript 
occurs as a single AGA codon at position number six on the mRNA transcript. The other AGA codons 
occur at positions 83, 166, 223, 249, 254, 455, 485, 489, 550, 566, 637, 639, 667, 673, 680, 711, 739, 786, 
820, 821, 851 and 939. A tandem double repeat AGA codon also occurs at position 821. The AGA codon 
occurs in the Ms01 OppA transcript at a frequency that is ten times more than that which is normally 
encountered in E. coli mRNA transcripts. In addition, several other rare codons are placed throughout the 
length of gene, with several of these codons occurring in clusters, as is shown in Addendum B. Table 3.2 
gives an indication of the types and frequencies of all rare codons encountered in the Ms01 OppA protein.  
Two strategies may be employed to overcome codon bias during expression. The first is site-directed 
mutagenesis of the target sequence in order to generate codons which reflect the tRNA pool of E. coli 
[Sorensen and Mortensen, 2005]. This is, however, a time consuming process which may result in unstable 
mRNA transcripts. The second strategy is the co-transformation of E. coli with a plasmid possessing a gene 
which codes for the tRNA of the problematic codons. E. coli can be manipulated to match the codon usage 
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frequency in heterologous genes by increasing the copy number of the limiting tRNA species. The Rosetta-
gami B(DE3) pLysS cell line is an example of such a strain of E. coli, and as such possesses a plasmid to 
remedy problems experienced with codon bias. However, although such a cell line was initially considered 
as expression host, following the failed expression attempts using the BL21(DE3) pLysS cell line, a 
decision was taken against it, due to its failure to influence problematic expression resulting from codon 
bias during previous studies in this laboratory [Rothman, 2007]. Instead a fusion partner was considered for 
use.  
Table 3.2 A summary of the type and number of rare codons present in the Ms01 OppA mRNA transcript compared to 
the frequency at which these codons are typically observed in the mRNA transcripts of E. coli. The Ms01 OppA mRNA 
transcript comprises 929 codons. 
Rare codon 
Number of codons 
encountered in the Ms01 
OppA mRNA transcript 
Frequency of codons in a 
typical E. coli mRNA 
transcript 
Frequency of codons in 
Ms01 OppA transcript 
compared to that in E. 
coli 
AGA 23 / 943 codons 2.1 / 1000 codons 10 times more 
UGU 1 / 943 codons 4.7 / 1000 codons  
CCU 11 / 943 codons 6.6 / 1000 codons 1.5 times more 
UCA 44 / 943 codons 6.8 / 1000 codons 6 times more 
AGU 14 / 943 codons 7.2 / 1000 codons 2 times more 
UCG 1 / 943 codons 8 / 1000 codons  
AUA 10 / 943 codons 4.1 / 1000 codons 2 times more 
ACA 40 / 943 codons 6.5 / 1000 codons 6 times more 
CCA 23 / 943 codons 8.2 / 1000 codons 3 times more 
GGA 13 / 943 codons 7 / 1000 codons 2 times more 
CUA 6 / 943 codons 3.2 / 1000 codons 2 times more 
 
Although most fusion partners are employed for specific purification strategies, they may also be beneficial 
in vivo, where their use in protein expression has proven advantageous for a number of reasons. The most 
important reason, with regards to this study, is that amino-terminal fusion partners often facilitate the 
synthesis of otherwise poorly expressed proteins (specifically with regard to translation) [Baneyx, 1999; 
Sorensen and Mortensen, 2005]. This is thought to occur as a result of mRNA stabilization as well as the 
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occurrence of a higher efficiency of the translation of passenger proteins containing rare codons. Fusion 
partners have also been shown to protect passenger proteins from intra-cellular proteolysis and to enhance 
the solubility of the passenger proteins (lessen or eliminate inclusion body formation) [LaVallie and 
McCoy, 1994; Sorensen and Mortensen, 2005]. While several hypotheses have been presented to explain 
the successes observed with the use of fusion partners during expression, none have yet been substantiated. 
Some authors suggest that fusion proteins act as “intramolecular chaperones”, while others believe that 
fusion partners favour on-pathway isomerization reactions, thus promoting the acquisition of the correct 
protein structure [LaVallie and McCoy, 1994; Baneyx, 1999]. In addition, superior fusion partners also 
permit controlled transcription [LaVallie and McCoy, 1994]. This has been shown to minimize plasmid 
loss and hold off accumulation of mutations in passenger protein products. Thus, the use of a fusion partner 
during expression would enable a range of problems encountered during expression to be addressed 
simultaneously.  
The glutathione S-transferase (GST) gene fusion system is a multipurpose system for the expression, 
purification and detection of fusion proteins consisting of a Schistosoma japonicum GST moiety at the 
amino terminus and the target protein at the carboxyl terminus [GST gene fusion system handbook, GE 
Healthcare]. The pGEX vector is controlled by a Ptac promoter, a weaker promoter than the T7 promoter 
[Xu et al., 2005]. The pGEX system is one of the expression systems which have proven most successful 
for the synthesis of soluble, correctly folded proteins in the bacterial cytoplasm [LaVallie and McCoy, 
1994]. Several studies involving the expression of mycoplasma genes have been able to successfully 
express these proteins with the utilization of the pGEX expression system [Rosati et al., 2000; Robino et 
al., 2007]. In addition, a previous study conducted in this laboratory accomplished successful expression of 
a gene containing rare codons after employing the pGEX expression system, when the pET expression 
system had failed [Rothman, 2007].  
Once the Ms01 oppA gene was successfully cloned into the pGEX-4T-1 vector, expression was attempted 
again. The initial observation made was that the pGEX-transformed cells grew much slower than was 
observed during utilization of the pET expression system, taking about 6 hours to reach an OD600 of 0.6 
compared to the 2.5 hours required by the pET-transformed cells. Expression utilizing the pGEX system 
proved successful, yielding a protein band of about 150 kDa. Although the expected size of the Ms01 OppA 
protein was around 100 kDa, the addition of the 26 kDa GST protein was expected to increase the size of 
the fusion protein product to about 130 kDa. The fact that the product obtained was slightly larger than 
expected was not a serious concern and could be attributed to an initial net positive charge of the 
recombinant protein (resulting from a protein composition of more positively charged than negatively 
charged amino acids), which probably decreased its overall negative charge during SDS-PAGE, resulting in 
slower migration of the protein through the gel matrix. This theory was, however, disproved when further 
investigation revealed the recombinant protein has an initial net negative charge. Western Blot analysis 
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with anti-GST antibodies, nevertheless, indicated that a GST moiety was present on the protein product 
obtained and served as a confirmation of successful expression. 
Although the reason for the success of the pGEX expression system compared to the pET expression 
system remains largely unknown, it may have been through the accumulation of various factors. These 
include gene size, incorrect protein folding, plasmid instability and codon bias. The weaker promoter of the 
pGEX system possibly aided in correct protein folding and to maintain plasmid stability, in combination 
with the GST fusion partner which may also have contributed to correct protein folding, as explained 
earlier in this chapter. The highly expressed GST fusion partner may also have enabled expression of the 
recombinant protein, despite codon bias and large gene size, as a result of mRNA stabilization and a higher 
efficiency of the pGEX gene fusion system in translating the rare codons in the Ms01 oppA gene. Also, 
while no protein was detected on SDS-PAGE gels when the pET expression system was employed, it does 
not exclude the possibility that expression did occur. The expression product was not tagged and thus could 
not be analysed using the Western Blot. Expression levels may thus simply have been too low to detect 
when the pET system was utilized. 
The subsequent purification of the Ms01 OppA protein was initially attempted by means of ammonium 
sulphate precipitation. Using this technique, large soluble proteins are precipitated out of solution and 
isolated, by adding saturated ammonium sulphate solution to the expressed cell extract. Although relatively 
pure protein could be isolated using this technique, the SDS-PAGE gels did not display even protein 
separation and were thus unreliable for use in determining the exact size of the protein isolated. This was 
likely the result of the high salt content of the protein samples analysed (even after dialysis) influencing the 
overall charge, and thus migration of the proteins through the gel matrix. Even so, close analysis of the 
isolated protein product suggested that the protein product was not sufficiently pure and that the isolated 
protein might in fact be another large, highly expressed protein present in the cell extract of the expressed 
cells. Thus, for the sake of accuracy and efficiency, it was decided that affinity purification would be the 
best method of purification. This decision proved to be right, as indicated by later SDS-PAGE analysis. 
Following successful affinity purification, a decision was made not to remove the affinity tag from the 
fusion protein, since the GST protein is much smaller than the Ms01 OppA protein and would not likely 
interfere with antibody detection of the Ms01 OppA protein during the ELISA. In addition, the ostriches 
were unlikely to have been in contact with the GST protein of Schistosoma japonicum so they were highly 
unlikely to react sero-positively to this protein. Interestingly, however, when left for a period of time, the 
recombinant protein samples degraded in a manner such that the GST moiety became detached from the 
OppA protein, while the OppA protein remained intact. This was determined by means of SDS-PAGE 
analysis, where a protein of about 100 kDa was observed, and confirmed by western blot analysis of the 
same sample, where only a protein of about 25 kDa could be detected, instead of the 150 kDa protein 
previously detected in this sample. The 100 kDa protein was thought to consist largely of the OppA protein, 
whereas the 25 kDa protein is probably the GST moiety. A probable explanation for the degradation of the 
Stellenbosch University  http://scholar.sun.ac.za
 63 
recombinant OppA protein is the co-purification of an E. coli protease(s) together with the expressed 
protein. While there are no specific references to proteases, the co-purification of host proteins with GST-
fusion proteins have been previously documented [GST gene fusion system handbook, GE Healthcare]. 
Since the BL21(DE3) pLysS cell line which was utilized for protein expression is a Lon and OmpT 
protease deficient cell line, the addition of protease inhibitors to the cell extract was deemed unnecessary 
[Sorensen and Mortensen, 2005; GST gene fusion system handbook, GE Healthcare]. It is therefore 
possible that a tiny amount (as judged by the very slow rate of protein degradation and the fact that it was 
not detected during the SDS-PAGE) of another active host protease may have co-purified with the 
recombinant OppA protein. The use of a protease deficient expression cell lines and/or the addition of 
protease inhibitors to the cell extract after expression are the generally employed measures with which 
unwanted degradation of the expressed protein is prevented. 
The successfully expressed and purified Ms01 OppA protein could now be utilized as the antigenic protein 
in the ELISA to enable analysis of the serum samples which were collected during the DNA vaccine trial.  
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4. An evaluation of the antibody responses elicited in ostriches by the pCIneo, 
VR1012 and VR1020 DNA vaccines 
4.1 Introduction 
The stringent nutritional requirements of mycoplasmas have made these organisms notoriously difficult to 
cultivate [Razin et al., 1998]. The current utilization of complex undefined media to this end, have hindered 
the preparation of mycoplasmal antigen which is free of any contaminating serum components, making 
traditional vaccine development strategies, in which the organism is cultivated and then inactivated, 
difficult. Although poultry vaccines against M. gallisepticum and M. synoviae were thought, until recently, 
to provide some protection against the Ms01, Ms02 and Ms03 ostrich-infecting mycoplasmas, a study by 
Pretorius [2009] found that these vaccines did not prevent ostrich-specific mycoplasma infections. This 
effectively means that no vaccine is currently available for use against mycoplasma infections in ostriches. 
In addition, despite the use of currently available antimicrobial agents, none are able to prevent or eliminate 
mycoplasmal disease from flocks, and outbreaks still occur at unacceptable frequencies in South African 
ostriches. As a result, the South African ostrich industry has launched a search for a more effective therapy 
with which to combat ostrich-specific mycoplasma infections.  
DNA vaccines represent a novel way in which protective immunity may be achieved in a host, and have 
been successfully utilized against various microorganisms in a number of different hosts [Saurez and 
Shultz-Cherry, 2000]. DNA vaccines stimulate both a humoral and cellular immune response by utilizing 
the genes encoding (immunogenic) proteins of pathogens, as an alternative to an attenuated pathogen, a live 
replicating vector or the protein itself [Donelly, 1997]. DNA vaccines consist of a plasmid containing a 
strong viral promoter; an immunogenic gene; possibly immunostimulatory sequences and a 
polyadenylation or transcription termination sequence, which is dissolved in saline and injected into the 
host. The plasmid does not integrate into the host chromosomal DNA and its lack of a eukaryotic origin of 
replication prevents it from replicating within the host. The host cells take up the DNA plasmid and 
subsequently manufacture the encoded protein, resulting in the generation of an immune response. 
However, the DNA plasmid that is taken up by the cell is broken down again and therefore only leads to a 
short-term production of the encoded vaccine protein, which means that a booster vaccination is required to 
establish long-term immune memory.  
Following DNA vaccine development and preparation, a technique was required to determine whether or 
not the DNA vaccines, as administered to the ostriches in this study, elicited an antibody response. For this 
purpose an indirect ELISA was developed. In its simplest form such an ELISA requires an immunogenic 
protein which will be recognized by a primary antibody (which should be present in the serum of animals 
exposed to the antigenic protein), an enzyme (such as horse radish peroxidase (HRP)) labeled secondary 
Stellenbosch University  http://scholar.sun.ac.za
 65 
antibody which will recognize the primary antibody and an enzyme substrate which reports upon the 
success of the reaction (Figure 4.1). 
 
 
Figure 4.1 A diagrammatic representation of an indirect ELISA [ELISA technical guide and protocols, Thermo 
Scientific]. Immobilization of the antigen may be achieved either by direct adsorbtion or by means of an antibody 
adsorbed to a microtiter plate. Following the blocking of non-specific binding to the plate, a primary antibody is used to 
probe for the antigen. Subsequently a secondary antibody labelled with a signal generating enzyme is added to detect 
the binding of the primary antibody. An appropriate enzyme substrate is then added (in the case of enzymatic 
detection), and the strength of the signal is proportional to the amount of antibody present in the sample. The 
maintenance of only high affinity binding events is ensured by washing the plate between steps.  
Since its initial description by Engval and Perlmann [cited by Jordan, 2002] more than 30 years ago, the 
ELISA has had an enormous impact in both basic scientific applications as well as in clinical diagnostics 
[Busolo et al., 1980; Jordan, 2002]. An ELISA is a simple and sensitive technique with which molecules 
recognized by an antibody are specifically and quantitatively detected [Jordan, 2002]. This technique, 
which is based upon the detection of specific antibodies against “solid phase” adsorbed antigens using 
enzyme-conjugated immunoglobulins, is one of several serological tests which have been developed for the 
detection of avian mycoplasma infections [Busolo et al., 1980; Abdulmoumen and Roy, 1995]. The ELISA 
offers more sensitivity than HI tests, in which false negatives are common, and more specificity than the 
serum plate agglutination test, in which false positives are common.  
As part of this study, an ELISA was developed and optimized for the detection of antibodies against the 
Ms01 OppA protein and the Ms01 whole organism. By comparison with the ELISA format illustrated 
above, this ELISA was modified to include an additional step in order to increase its sensitivity. Instead of 
only using an enzyme labelled secondary antibody, the secondary antibody was labelled with biotin, after  
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which an additional step was included which involved the addition of HRP enzyme labelled streptavidin, 
followed by substrate addition (Figure 4.2). The inclusion of this step increased the sensitivity of the 




Figure 4.2 A diagrammatic illustration of the modified indirect ELISA. Following immobilization of the antigen on the 
microtiter plate by direct adsorbtion and the blocking of non-specific binding to the plate, a primary antibody is used to 
probe for the antigen. A biotinylated secondary antibody is subsequently added to detect the binding of the primary 
antibody. A signal generating enzyme (horseradish peroxidase (HRP) in this case) conjugated to streptavidin PO is then 
added. Streptavidin PO binds to biotin with high affinity. The inclusion of this step decreases background binding and 
increases the sensitivity of the ELISA, resulting in an increased signal to noise ratio. Following the addition of the 
appropriate substrate, the strength of the signal detected is proportional to the amount of antibody present in the sample. 
The maintenance of only high affinity binding events is ensured by washing the plate between steps.  
A DNA vaccine trial was conducted in which the ability of recently developed DNA vaccines, the Ms01 
oppA gene cloned into pCIneo, VR1012 and VR1020 respectively, to elicit antibody responses against the 
ostrich-specific mycoplasma, Ms01, was evaluated. The antibody responses of six month old ostriches 
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4.2 Materials and Methods 
4.2.1 Vaccine preparation 
The three DNA vaccines utilized comprised the eukaryotic expression vectors, pCIneo, VR1012 and 
VR1020, into which the Ms01 oppA gene was cloned. The above recombinant eukaryotic expression 
vectors were obtained ready for use and vaccine preparation thus only required increasing the amount of 
vector available. For this purpose, single colonies of E. coli JM109 cells containing the respective 
recombinant eukaryotic expression vectors were used to inoculate aliquots of 5 ml of LB medium 
containing 2.5 μl of 100 mg/ml ampicillin respectively, and incubated for eight hours at 37°C. Each of 
these starter cultures were then transferred to 400 ml of LB medium containing 200 μl of 100 mg/ml 
ampicillin respectively, and incubated for a further 16 hours at 37°C. Isolation and purification of the 
respective recombinant eukaryotic expression vectors followed, using a Nucleobond® Endotoxin-free 
Plasmid DNA Purification Kit (Macherey-Nagel, Germany) as per the manufacturer’s instructions, with 
MilliQ® analytical quality water as eluting agent. The concentration of the isolated plasmids was then 
determined using a Nanodrop ND-2000. The purified recombinant eukaryotic expression vectors were then 
ready to be inoculated into ostriches as DNA vaccines.  
4.2.2 Vaccination trial 
Pre-immunization blood samples were collected from all ostriches on the first day (day 0) of the 
vaccination trial. Three groups consisting of ten birds each were immunized with 100 μg of pCIneo, 
VR1012 or VR1020 DNA vaccine in 1 ml of PBS by intra-muscular injection in the large upper thigh 
muscle, using a 25 G ×11/4" needle (Nipro) and 2 cc syringe (Promex), respectively. The control group (10 
birds) was not immunized. Blood samples were collected in 5 ml Vacuette® Z Serum Sep Clot activator 
tubes (Greiner-bio one) using Vacuette® 18 G ×1" multiple drawing blood collection needles (Greiner-bio 
one) from the main vein under the wing of the ostriches on a weekly basis, on days 7, 14, 21, 28 and 35. 
Following blood sample collection on day thirty-five, the vaccinated ostrich groups received an additional 
100 μg of the respective DNA vaccine in 1 ml intramuscularly. Once again, the control group received no 
vaccine. Blood samples were subsequently collected on days 42, 49, 58 and 64 as calculated from the first 
day of vaccination. The blood samples collected were incubated for 30 minutes at 37°C and subsequently at 
4°C overnight to facilitate the clotting process. Samples were then centrifuged at 5 000 x g for one minute 
to separate the clotted cell components of the blood from the serum. The serum obtained was removed 
using a 1 ml Gilson pipette and subsequently stored at -20°C for later use.  
4.2.3 Antigen preparation 
The concentration of the Ms01 OppA protein, prepared as described in the previous chapter, was 
determined using the Bradford protein determination assay. The Bradford reagent was prepared as 
described in the original publication [Bradford, 1976]. Bovine serum albumin (BSA) was utilized in the 
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preparation of a standard curve, ranging in concentration from 0 to 175 μg/ml. Five microliters of each 
standard solution was transferred, in triplicate, to a Greiner Bio-one 96-well microplate, after which 250 μl 
of Bradford reagent was added. Once the protein concentration was determined, the OppA antigenic protein 
was diluted, using carbonate buffer (50 mM NaHCO3, pH 9.6), to 1 μg/ml and used to coat Nunc
© 96-well 
microtiter plates.  
4.2.4 Secondary antibody purification and biotinylation 
Serum samples collected, on day 97, from a rabbit immunized with ostrich antibodies were provided by Dr 
Annelise Botes, Department of Biochemistry, Stellenbosch University. The presence and immunogenicity 
of rabbit anti-ostrich immunoglobin (Ig) in the collected serum was established in a previous investigation 
by an Honours student in this laboratory, Ms Amanda van Tonder [89]. Rabbit anti-ostrich antibodies were 
isolated from serum by means of ammonium sulphate precipitation, as described in Chapter 3. 
Biotinylation of the isolated rabbit anti-ostrich Ig was initiated with a 1:10 dilution of the isolated rabbit 
anti-ostrich Ig in carbonate buffer. Following protein concentration determination by measuring the 
absorbance at 280 nm on a Nanodrop ND-2000, the Ig was diluted with carbonate buffer to a final 
concentration of 5 mg/ml. Two mg of biotinomidocaproate N-hydroxysuccinimide ester (Sigma) was 
dissolved in 1 ml of N,N-dimethylformamide (DMF), and 250 μl added per 1 ml of Ig fraction of  the rabbit 
anti-ostrich Ig, with gentle stirring for 2 hours at room temperature. The biotinylated Ig was subsequently 
dialysed against PBS at 4°C for 8 hours followed by a change of PBS and further dialysis overnight. 
Glycerol was then added in a ratio of 1:1 to the biotinylated rabbit anti-ostrich Ig, which was subsequently 
stored at -20°C.  
4.2.5 Enzyme-linked immunosorbent assay (ELISA)  
4.2.5.1 Optimization 
Nunc© 96-well microtitre plates (Nunc, Denmark) were coated with 100 μl of Ms01 OppA protein ranging 
from 2.5 μg/ml to 0.125 μg/ml in concentration, or with 109 Ms01 cells/ml diluted 100, 1 000 and 10 000 
times, and incubated at 4°C for 16 hours. Plates were then blocked with 200 μl of casein buffer (154 mM 
NaCl, 0.5% w/v casein, 10 mM Tris HCl) for 2 hours at 37°C. Ostrich serum was diluted between 40 to 
5620 times in casein buffer containing Tween 20 (0.05% v/v Tween 20), after which 100 μl of diluted 
serum was added to each well, followed by incubation at 37°C for one hour. At least two birds from each 
group of ostriches were utilized to determine the optimal serum dilution for that group. Plates were then 
washed three times with PBS-Tween 20 (1.4 mM NaCl, 1% v/v Tween 20, pH 7.2). Biotinylated rabbit 
anti-ostrich antibody (5 mg/ml) was subsequently diluted 100 times in casein buffer containing Tween 20 
and 100 μl of the diluted antibody incubated for one hour at 37°C in each well. Plates were then washed as 
described. This was followed by the addition of 100 μl of HRP–Streptavidin conjugate, diluted 8000 times 
in casein buffer containing Tween 20, and subsequently incubated at 37°C for one hour. Plates were again 
washed as previously described. Substrate solution consisting of citrate buffer (0.1 M, pH 5), and substrate, 
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0.05% w/v 2,2’-azino-bis(3ethylbenzthiazoline-6-sulphonic acid) (ABTS) and 0.05% (v/v) H2O2 was 
subsequently prepared, of which 100 μl was added to each well, and readings taken on a Labsystems 
Multiscan Original spectrophotometer at A405 at five minute intervals for 30 minutes. Results were 
presented graphically, with the antigen dilution/serum dilution plotted on the x axis and the absorbance 
values obtained plotted on the y axis.  
4.2.5.2 Detection of humoral antibodies to the Ms01 OppA protein in ostrich serum 
The ELISA was performed as described above, with Nunc© 96-well micrititre plates coated with 100 μl of 
1 μg/ml Ms01 OppA protein and 106 Ms01 cells, respectively. Ostrich serum diluted 160 times in casein 
buffer containing Tween 20 was utilized as primary antibody. As coating controls, wells were coated with 
the respective antigen, but not incubated with serum. As negative serum controls, wells were not coated 
with antigen. Results were presented graphically, with the absorbance values (Y axis) obtained plotted 
against time (X axis).  
4.2.5.3 Comparative analyses 
The results obtained from the ELISA using the Ms01 OppA protein as coating antigen were compared to 
those obtained from the ELISA using the Ms01 whole organism as coating antigen. In addition, 
comparisons were drawn between the antibody responses observed in ostriches of similar weight in the 
same group as well as in different groups. An unexpected avian influenza outbreak during the trial also 
necessitated a careful analysis of the antibody responses obtained during the trial.  
4.3 Results 
4.3.1 Optimization studies 
Before a new ELISA can be attempted, the optimum concentration of antigen and antibody for use in the 
ELISA, must be determined. To determine the optimal concentration of antigen for use in the ELISA, the 
absorbance values obtained at different coating concentrations of antigen were plotted against a serum 
dilution series with serum samples diluted between 1/40 and 1/5 120 times (Figures 4.3 and 4.4). The 
antigen coating concentration was optimized utilizing serum samples from one of the ostriches in the 
VR1012 vaccinated group.  
Based on the results obtained using the OppA protein as coating antigen, a concentration of 1 μg/ml Ms01 
OppA protein was chosen as the optimal coating concentration for subsequent ELISAs. Based on the 
results obtained using the Ms01 whole cells as coating antigen, a concentration of 106 Ms01 whole cells/ml 
was chosen as the optimal coating concentration for the subsequent ELISAs. Furthermore, although the day 
0 serum should not give any absorbance readings in both of these ELISAs, antibodies were consistently 
detected in the serum of the prebleeds of the ostriches included in this trial and this will be placed into 
context in the discussion that follows this section.  
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Figure 4.3 Optimization of coating concentrations using the Ms01 OppA protein as antigen. ELISA plates were 
coated with OppA protein concentrations ranging between 2.5 μg/ml to 0.125 μg/ml. Serum samples taken on day 0 
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Figure 4.4 Optimization coating concentrations using Ms01 whole cells as coating antigen. Serum samples taken 
from a VR1012 vaccinated ostrich (ostrich 209) on day 0 and day 35 were used for the serum dilution series.  
A serum dilution series was subsequently used in the ELISAs to determine if a single serum dilution could 
be used to assess the relative levels of antibodies in sera. Serum samples taken from an ostrich in each of 
the groups throughout the trial, were serially diluted between 1/40 and 1/5120 times. The A405 values 
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obtained when the ELISA was performed on plates coated with 1 μg/ml Ms01 OppA protein (Figures 4.5, 




































Figure 4.5 Serum dilution analysis of serum samples collected from a pCIneo DNA vaccinated ostrich (ostrich 416). 
The ostrich was vaccinated on day 0 and day 35 with 100 μg of pCIneo DNA vaccine, administered intramuscularly. 
































Figure 4.6 Serum dilution analysis of serum samples collected from a pCIneo DNA vaccinated ostrich (ostrich 416). 
The ostrich was vaccinated on day 0 and day 35 with 100 μg of pCIneo DNA vaccine, administered intramuscularly. 
The ELISA plate was coated with 106 Ms01 whole cells/ml.  
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Figure 4.7 Serum dilution analysis of serum samples collected from a VR1012 DNA vaccinated ostrich (ostrich 454). 
The ostrich was vaccinated on day 0 and day 35 with 100 μg of VR1012 DNA vaccine, administered intramuscularly. 
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Figure 4.8 Serum dilution analysis of serum samples collected from a VR1012 DNA vaccinated ostrich (ostrich 454). 
The ostrich was vaccinated on day 0 and day 35 with 100 μg of VR1012 DNA vaccine, administered intramuscularly. 
The ELISA plate was coated with 106 Ms01 whole cells/ml.  
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Figure 4.9 Serum dilution analysis of serum samples collected from a VR1020 DNA vaccinated ostrich (ostrich 404). 
The ostrich was vaccinated on day 0 and day 35 with 100 μg of VR1020 DNA vaccine, administered intramuscularly. 
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Figure 4.10 Serum dilution analysis of serum samples collected from a VR1020 DNA vaccinated (ostrich 404). The 
ostrich was vaccinated on day 0 and day 35 with 100 μg of VR1020 DNA vaccine, administered intramuscularly. The 
ELISA plate was coated with 106 Ms01 whole cells/ml.  
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A decrease in the A405 values obtained could consistently be observed with each step in the dilution series. 
Thus, the more diluted the serum, the lower the A405 values obtained. A serum dilution of 1/160 was 
determined to be optimal for use with all four groups of ostriches. In all the serum samples of the ostriches 
tested, high absorbance values were observed on day 0, indicating that anti-Ms01 antibodies were already 
present in the sera of the birds before the vaccination trial was started.  
4.3.2 Serum analysis of the pCIneo, VR1012 and VR10120 DNA vaccine trials 
4.3.2.1 Antibody responses of ostriches measured by the ELISA using the Ms01 OppA protein as coating 
antigen 
The antibody responses elicited by ostriches vaccinated with the pCIneo, VR1012 and VR1020 DNA 
vaccines were presented as the individual titre values (A405) obtained for each ostrich in each group. The 
individual immune responses of the ostriches in each of the four groups, analyzed using the ELISA in 


































Figure 4.11 The antibody response elicited in ostriches vaccinated with the pCIneo DNA vaccine, as determined by an 
ELISA utilizing 1 μg/ml Ms01 OppA protein as coating antigen. 100 μg of pCIneo DNA vaccine was administered to 
ostriches on day 0 and day 35 through intramuscular injection. Ostriches which died during the trial are indicated with 
an asterisk (*). Ostriches diagnosed with avian influenza during the trial are marked with a quotation mark (“). 


































Figure 4.12 The average antibody response elicited in ostriches vaccinated with the VR1012 DNA vaccine, as 
determined by an ELISA utilizing 1 μg/ml Ms01 OppA protein as coating antigen. 100 μg of VR1012 DNA vaccine 
was administered to ostriches on day 0 and day 35, through intramuscular injection. Ostriches which died during the 
trial are indicated with an asterisk (*). Ostriches diagnosed with avian influenza during the trial are marked with a 

































Figure 4.13 The average antibody response elicited in ostriches vaccinated with the VR1020 DNA vaccine, as 
determined by an ELISA utilizing 1 μg/ml Ms01 OppA protein as coating antigen. 100 μg of VR1020 DNA vaccine 
was administered to ostriches on day 0 and day 35, through intramuscular injection. Ostriches which died during the 
trial are indicated with an asterisk (*). Ostriches diagnosed with avian influenza during the trial are marked with a 
quotation mark (“). 

































Figure 4.14 The anti-Ms01 OppA antibody titres observed in the individual ostriches of the control group, 
as determined by an ELISA utilizing 1 μg/ml Ms01 OppA protein as coating antigen. Ostriches in the control group 
did not receive any vaccine. Ostriches which died during the trial are indicated with an asterisk (*).Ostriches diagnosed 
with avian influenza during the trial are marked with a quotation mark (“). 
4.3.2.2 Antibody responses measured by the ELISA using Ms01 whole cells as coating antigen 
ELISAs using Ms01 whole cells as coating antigen were performed on each group of ostriches in an 
attempt to corroborate and compare results with those obtained using the ELISA in which the Ms01 OppA 
protein was used as coating antigen. The antibody responses elicited by ostriches vaccinated with the 
pCIneo, VR1012 and VR1020 DNA vaccines were represented as the individual titre values (A405) obtained 
for each ostrich in each group. The individual immune responses of the ostriches in each of the three 
experimental and one control groups, analyzed using the ELISA in which Ms01 whole cells were used as 
coating antigen, are shown in Figures 4.15, 4.16, 4.17 and 4.18, respectively.  
If the antibody titre values, as measured with the OppA ELISA and the Ms01 whole cell ELISA, of each 
individual ostrich within all the groups are compared, then firstly, it is apparent that considerable variation 
occurs over time. Although average values of antibody titres at each time point were calculated, the error 
margins were very large, and at no point could significant differences between titre values be observed. As 
a result, the titre values of each bird in each group were shown, and not averages and error bars as the error 
bars would have been very large. Secondly, there do not appear to be any general trends in any of the 
groups over time, i.e. an increase over time as a consequence of immunization was not observed. This 
applies to the ELISA results obtained using the Ms01 OppA protein as coating antigen as well as the 
ELISA results obtained using Ms01 whole cell as coating antigen.  


































Figure 4.15 The antibody response elicited in ostriches vaccinated with the pCIneo DNA vaccine, as determined by an 
ELISA utilizing 106 Ms01 whole cells/ml as coating antigen. 100 μg of pCIneo DNA vaccine was administered to 
ostriches on day 0 and day 35 through intramuscular injection. Ostriches which died are indicated with an asterisk (*). 


































Figure 4.16 The antibody response elicited in ostriches vaccinated with the VR1012 DNA vaccine, as determined by 
an ELISA utilizing 106 Ms01 whole cells/ml as coating antigen. 100 μg of VR1012 DNA vaccine was administered to 
test ostriches through intramuscular injection on day 0 and day 35. Ostriches which died are indicated with an astrix 
(*). Ostriches diagnosed with avian influenza during the trial are marked with a quotation mark (“). 

































Figure 4.17 The antibody response elicited in ostriches vaccinated with the VR1020 DNA vaccine, as determined by 
an ELISA utilizing 106 Ms01 whole cells/ml as coating antigen. 100 μg of VR1020 DNA vaccine was administered to 
test ostriches through intramuscular injection on day 0 and day 35. Ostriches which died are indicated with an asterisk 
































Figure 4.18 The anti-Ms01 OppA antibody titres observed in the individual ostriches of the control group, as 
determined by an ELISA utilizing 106 Ms01 whole cells/ml as coating antigen. Ostriches in the control group did not 
receive any vaccine. Ostriches which died during the trial are indicated with an asterisk (*). Ostriches diagnosed with 
avian influenza during the trial are marked with a quotation mark (“). 
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Unexpectedly high antibody titers were observed in a number of birds at the start of the trial, as determined 
by both ELISAs. However, high titre values of some birds were determined using the one ELISA but not in 
the other, for example bird 202 on day 35, where a high outlier titre value of bird 202, as determined with 
the ELISA using Ms01 OppA protein as coating antigen, did not show a high value using the ELISA in 
which Ms01 whole cells were used as coating antigen. The antibody responses of individual birds 
fluctuated, with no observed increase in antibody titres over time. In addition, high outliers frequently 
occurred in all groups of ostriches in the trial. As a result of this apparent variation in titre values using the 
two ELISAs, an attempt was made to try to establish general trends in which the results obtained with the 
two ELISAs did correlate and which gave explicable results. Firstly, the titre values of all birds that died 
during the trial were investigated, and secondly, the effects of an outbreak of avian influenza were 
investigated.  
4.3.2.3 The possible role of mycoplasma infections on the vaccination trial 
Although the ostriches in the trial were not properly inspected for symptoms of mycoplasma infections 
before the immunization trial was started nor at any given time point during the trial, symptoms of 
mycoplasma infection were noted in at least one ostrich prior to its death, and included foaming eyes and 
mucus exudates (ostrich 207). As mycoplasma infections prior to the start of the vaccination trial could 
have had a significant effect on the results of the trial, a careful investigation was made of the titres of the 
birds that died during the trial.  
One bird (ostrich 204) that was vaccinated with the pCIneo vaccine, showed a decrease in its antibody titre 
on day 7, as determined by both the Ms01 OppA protein ELISA and the Ms01 whole cell ELISA, prior to 
its death. Two ostriches (ostrich 401 and 481) that were vaccinated with the VR1012 DNA vaccine died. 
Ostrich 401 died following a slight decrease in its antibody titre on day 21, as determined by both the Ms01 
OppA protein ELISA and the Ms01 whole cell ELISA, while ostrich 481 died following a decrease in its 
antibody titre on day 14, as determined by the Ms01 OppA protein ELISA, and an increase in antibody 
titre, as determined by the Ms01 whole cell ELISA. Two birds (ostrich 206 and 207) vaccinated with the 
VR1020 DNA vaccine died. Ostrich 207 died following a decrease in antibody titre on day 14, while 
ostrich 206 died following a slight decrease in antibody titre on day 49, as determined by both the Ms01 
OppA protein ELISA and the Ms01 whole cell ELISA. Three ostriches (ostrich 483, 456 and 421) in the 
control group died during the DNA vaccination trial. A decrease in the antibody titre of ostrich 483 was 
observed on day 35, as determined by both the Ms01 OppA protein ELISA and the Ms01 whole cell 
ELISA, prior to the death of the ostrich. Ostrich 456 died following a slight increase in antibody titre on 
day 28, as determined by the Ms01 OppA protein ELISA, and a decrease in antibody titre, as determined by 
the Ms01 whole cell ELISA. Although not statistically analyzed, the general trend that was observed was 
that birds which died showed a drop in the antibody titre, as determined by both the ELISA using Ms01 
cells as coating antigen as well as the ELISA using the Ms01 OppA protein as coating antigen.  
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4.3.2.4 An avian influenza outbreak during the vaccination trial 
A state veterinarian inspected the birds that were included in the vaccination trial, as well as breeding birds 
that were housed in adjacent pens at regularly intervals. Six weeks after the initiation of the trial, the 
veterinarian suspected that some of the birds had been infected with avian influenza and placed the whole 
flock under quarantine. As blood samples had been collected for the vaccination trial, these blood samples 
were used for the detection of antibodies against avian influenza as an indication of infection. Pathologists 
use the appearance of antibodies as an indication of whether ostriches have been infected with avian 
influenza, because the virus can only be detected for a very short period after infection, whilst antibody 
levels in the serum of infected birds remain there for longer periods. The technical term of 
“seroconversion” is used if the diagnosis is based on antibody levels and this is the standard practice for the 
detection of avian influenza in the outbreak that is currently infecting ostriches in South Africa.  
Four pCIneo vaccinated birds (ostrich 343, 406, 427 and 461) tested sero-positive for avian influenza on 
day 64 of the trial, after having tested negative in all the weeks prior to week 7 of the trial. Similarly, four 
VR1012 vaccinated ostriches (ostrich 208, 322, 434 and 487) tested sero-positive for avian influenza 
during the trial, with ostrich 208 and 322 testing positive for the first time on day 35, while ostrich 434 and 
487 tested positive for the first time on day 64. Three VR1020 vaccinated ostriches (ostrich 205, 321 and 
404) tested sero-positive for avian influenza during the vaccination trial. Ostrich 404 first tested positive for 
the virus on day 35 (having tested negative in all prior weeks of the trial), whereas ostrich 205 and 321 
tested positive for the virus for the first time on day 64. Four ostriches (ostrich 202, 465, 469 and 474) in 
the control group tested sero-positive for avian influenza. Ostrich 202 tested positive for the virus for the 
first time on day 42, while ostrich 465, 469 and 474 first tested positive for avian influenza on day 64 of the 
trial.  
Thus, to summarize, on day 35 of the DNA vaccination trial two ostriches in the VR1012 vaccinated group 
and one ostrich in the VR1020 vaccinated group tested sero-positive for avian influenza, after having tested 
negative on all previous days of the trial. More birds became infected as the trial progressed, to the point 
where 15 birds tested positive at the end of the trial on day 64 (one bird which tested positive on day 35 and 
42, tested negative on day 63, but was included in the final count). None of the birds which tested positive 
for avian influenza died during the trial and it should be emphasized that all eight birds which did die 
during the trial, tested negative for avian influenza. The antibody response curves of birds which tested 
positive for avian influenza were equally as erratic as those observed for birds which tested negative to the 
virus (as determined by both the Ms01 OppA protein ELISA and the Ms01 whole cell ELISA). Also, no 
consistent similarities, for example a decrease in the antibody titre, could be detected in the Ms01 antibody 
responses of birds which tested positive for avian influenza. For this reason, the titre values of the birds 
which tested positive for avian influenza were not removed from the graphs of the titre values shown 
before.  
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Number of birds 
Taking part in the trial 
10 10 10 10 40 
Number of birds which died during the 
trial 
2 2 1 3 8 
Number of birds which became infected 
with avian influenza during the trial 
4 3 4 4 15 
Number of birds which died of avian 
influenza during the trial 
0 0 0 0 0 
 
4.3.2.5 Ostrich weight comparisons 
Due to the high variation in the weights of ostriches in each of the respective vaccination groups, an 
analysis was conducted to compare the antibody responses obtained for specific ostriches in each group, 
with the weight of the individual ostriches, as measured on day 35 of the trial (Addendum C). No 
correlations between the weights of ostriches and the antibody response measured could be detected in any 
of the vaccinated groups, with ostriches as heavy as 95 kg displaying similar responses to ostriches 
weighing 53 kg, and ostriches of similar weights sometimes displaying very different antibody responses.  
4.3.2.6 Comparison between Ms01 OppA protein ELISA results and Ms01 whole cell antigen ELISA 
results 
Since no increase in the antibody titres of vaccinated ostriches occurred over time, a direct comparison 
between the ELISA results obtained when the Ms01 OppA protein was used as coating antigen and when 
the Ms01 whole organism was used as coating antigen, was made by plotting these values against each 
other and investigating the relationship between them (Figures 4.19, 4.20, 4.21 and 4.22). The groups of 
birds that were vaccinated with the different vaccines were analyzed separately. The objective with this 
analysis was to detect whether vaccination of the ostriches caused an alteration in the ratio of the antibodies 
against Ms01 (as selectively induced by the vaccine) as opposed to a general increase in the level of 
antibodies against the whole Ms01 organism (as induced by infection with Ms01 or other mycoplasmas 
prior to or during the vaccination trial).  
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Figure 4.19 A comparison of the antibody response curves generated following analyses of the pCIneo vaccinated 
ostriches by means of the Ms01 OppA protein ELISA and Ms01 whole organism ELISA. 100 μg of pCIneo DNA 
vaccine was administered to ostriches on day 0 and day 35 through intramuscular injection. Correlation statistics are 
shown on the graph.  
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Figure 4.20 A comparison of the antibody response curves generated following analyses of the VR1012 vaccinated 
ostriches by means of the Ms01 OppA protein ELISA and Ms01 whole organism ELISA. 100 μg of VR1012 DNA 
vaccine was administered to ostriches on day 0 and day 35 through intramuscular injection. The correlation statistics 
are shown on the graph.  
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Figure 4.21 A comparison of the average antibody response curves generated following analyses of the VR1020 
vaccinated ostriches by means of the Ms01 OppA protein ELISA and Ms01 whole organism ELISA. 100 μg of VR1020 
DNA vaccine was administered to ostriches on day 0 and day 35 through intramuscular injection. The correlation 
statistics are shown on the graph.  
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Figure 4.22 A comparison of the antibody response curves generated following analyses of the control ostriches by 
means of the Ms01 OppA protein ELISA and Ms01 whole organism ELISA. No DNA vaccine was administered to the 
control ostriches. The correlation statistics are shown on the graph.  
Although a negative relationship was observed between the results of the ELISA using the Ms01 OppA 
protein as coating antigen and the ELISA using the Ms01 whole cells as coating antigen for the pCIneo 
vaccinated group, a positive relationship between the two ELISAs was observed for all three of the 
remaining groups (the VR1012 and VR1020 vaccinated group and the control group). The y intercept of  
the three vaccinated groups and the control group was above 0, indicating that the ELISA using Ms01 
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whole cells as coating antigen was detecting antibodies against a greater number of antigens, and not only 
the antibodies against the Ms01 OppA protein as measured by the ELISA using the Ms01 OppA protein as 
coating antigen. The gradient of the trend lines in all the vaccinated groups as well as the control groups 
was below 0.5, however, and thus failed to establish a direct relationship between the Ms01 OppA antibody 
response measured by the ELISA using the Ms01 OppA protein as coating antigen and that measured by 
the ELISA using the Ms01 whole cells.  
4.4 Discussion 
The ELISA technique is commonly used in many laboratories to detect and diagnose various diseases in 
humans and animal species, including avian mycoplasmosis [50, 91]. However, before utilization, any 
ELISA must first be optimized as was done in this study. The optimal coating concentration was 
determined to be 1 μg/ml of Ms01 OppA protein and 106 Ms01 cells/ml, while the optimal serum dilution 
was determined to be 1/160. The absorbance values obtained at a serum dilution of 1/160 resulted in the 
achievement of a high signal to background ratio and additionally, were mostly in the middle of linear 
portion of the serum dilution curve and would thus allow any increases or decreases in antibody titre to be 
easily observed. Specific binding of the respective antibodies to their antigen was confirmed with very low 
to negative absorbance values being observed in wells which did not contain any antigen (serum control 
wells) as well as in wells which were coated with antigen, but to which no serum was added (antigen 
control wells).  
However, a basic flaw in these optimizations was the apparent lack of a negative signal indicating the 
absence of antibodies in any of the sera of the birds that were tested and particularly the general absence of 
antibodies in the birds at the start of the trial. The crucial question therefore really was if the ELISA was 
not showing nonspecific binding instead of indicating antibody levels to Ms01 or whole mycoplasma cells. 
The ELISAs outlined above had not been developed at the time that the vaccination trial was started, and it 
was assumed that the ostriches that had not been vaccinated would test negative for antibody levels to the 
Ms01 OppA protein or Ms01 whole cells. However, the ELISA results indicated that significant antibody 
levels were present in the birds prior to the vaccination trial. In order to check that the ELISA was indeed 
specific and capable of measuring antibody levels against the Ms01 OppA protein in animal sera, a test was 
performed by Amanda van Tonder, from our research group, in which ELISA plates were coated with the 
Ms01 OppA protein at the same concentration as in the ELISAs described above. Two serum samples from 
a rabbit, one prior to vaccination with the recombinant OppA protein and one taken at the end of a series of 
vaccinations, were used with appropriate secondary antibodies and an equivalent detection system. In this 
trial it was found that the serum sample from the rabbit taken prior to vaccination gave a negative ELISA 
reading, i.e. an absorbance value of 0 at a serum dilution of 1:20 and greater, whilst the serum sample from 
the rabbit taken after vaccination gave a high absorbance value which was found to drop if the serum was 
serially diluted. This result can be explained because rabbits do not harbour ostrich mycoplasmas and 
should therefore not possess antibody levels against them, whilst after vaccination they produced antibodies 
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which could be detected with the ELISA. From this result the deduction can therefore be made that the 
ELISA described above, in which the Ms01 OppA protein was used as coating antigen, is capable of 
measuring antibody levels in ostrich serum and that the ostriches used in these trails already possessed 
significant antibody levels prior to the start of the vaccination trial.  
The high antibody titre observed in the vast majority of samples on day 0 suggested that most of the 
ostriches used in the trial had already been exposed to the Ms01 organism prior to the initiation of the 
vaccination trail, and that they possessed antibody levels against the Ms01 organism. This appears likely, 
since no studies have yet been conducted to assess the prevalence of Ms01 within South Africa, but a 
reportedly high prevalence of respiratory disease (probably due to mycoplasma infections) in South African 
feedlot ostriches suggests high prevalence [Pretorius, 2009]. The fact that at least one of the ostriches 
which died during the DNA vaccination trial (ostrich 207), displayed symptoms associated with ostrich 
mycoplasma infection, in addition to high antibody titres, indicates that prior exposure to the Ms01 
organism likely occurred.  
It is, however, also possible that the ostriches used in the trial may have been infected with another ostrich-
infecting mycoplasma prior to or during the trial, resulting in cross-reactivity in the ELISAs, as suggested 
by Abdelmoumen and Roy [Abdulmoumen and Roy, 1995]. According to these authors, the sharing of 
epitopes amongst avian mycoplasma species make serological diagnosis of avian mycoplasmas less than 
reliable, and that the mycoplasma ELISA is subject to nonspecificity of the reagents and cross-reactions 
amongst a variety of mycoplasma species. This view is, however, contradictory to what was found in an 
unpublished ostrich mycoplasma cross-reactivity study conducted at Onderstepoort Veterinary Institute 
[Pretorius, 2009]. Serological cross-reactivity tests conducted by the latter indicated that antibodies to the 
Ms01 organism do not recognize Ms02 and Ms03, and that although antibodies to Ms02 partially cross-
reacts with Ms03, they do not recognize Ms01. The fact that Ms02 and Ms03 are more closely related to 
each other than to Ms01 support these findings. Some cross-reactivity can, however, not be discounted.  
In the light of the above finding that the ostriches were likely exposed to the Ms01 organism or 
alternatively the Ms02 and/or Ms03 organisms before the trial, the ELISA results should be interpreted 
somewhat differently. However, before interpreting the results, it is necessary to consider how an ostrich 
would typically respond to a successful vaccine. A primary antibody response, representing a slight 
increase in antibody titre, would initially be seen following vaccination on day 0. A peak in the antibody 
titre is usually observed during the primary antibody response, followed by a gradual decrease in titre. A 
boost vaccination is then administered a few weeks after the initial vaccination, resulting in a secondary 
antibody response. The antibody titre observed in the secondary immune response is typically many-fold 
higher than that seen in the primary immune response. This was also documented in the response to 
Newcastle Disease Virus vaccines and to two chicken mycoplasma vaccines in ostriches [Blignaut, 2000; 
Pretorius, 2009].  
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As a result of the erratic antibody responses observed during the trial, no apparent primary and/or 
secondary antibody response could be detected against any of the DNA vaccines analyzed in this trial. The 
erratic immune responses and frequent outliers observed in all groups throughout the trial may be explained 
by the fact that the trial was coincidentally conducted during a period in which the ostrich mycoplasma 
infections are prevalent. The trial was conducted towards the end of winter and the beginning of spring, a 
period marked by weather conditions fluctuating between extremely cold, wet and windy weather, and 
more moderate sunny conditions. The incidence and severity of mycoplasma infections in ostriches are 
known to increase during such conditions [Pretorius, 2009]. The immunomodulatory capabilities of 
mycoplasmas consist of a “complex network of synergistic and antagonistic influences induced by 
mycoplasmas on the immune system” [Rottem, 2003], which allows mycoplasmas to either stimulate or 
suppress the immune system and probably accounts for the erratic immune responses observed in this trial 
[Rottem, 2003]. Mycoplasmas are able to induce the suppression or polyclonal stimulation of T and B 
lymphocytes (of which the B lymphocytes are responsible for antibody production), amongst other things 
[Razin et al., 2009; Rottem, 2003; Bradbury, 2005]. Also, although no direct effect could be detected, the 
avian influenza virus most likely had an effect on the immune responses of ostriches infected with the 
virus, if for no other reason than the stress caused to the animal by the infection. Hence, one or the 
cumulative effect of the above possibilities may have resulted in the erratic immune responses observed 
during the trial. In addition, immunosuppression or a weakened immune system caused by an ostrich 
mycoplasma infection (in addition to the other stress-causing factors mentioned below) probably made the 
ostriches more vulnerable to other infections, and may thus be linked to the avian influenza outbreak which 
occurred during the trial. This possibility is supported by the fact that M. gallisepticum infections in 
chickens and turkeys have been linked to concurrent infections with viruses such as avian influenza, 
infectious pneumovirus, IBV and NDV [Dufour-Gesbert et al., 2006; Mohammed et al., 1987; Nili and 
Asasi, 2003; Yang et al., 2009]. Moreover, the birds were very likely stressed due to the harsh weather 
conditions experienced during the trial, the weekly collection of blood samples, the new location to which 
the birds were moved prior to the initiation of the trial. Stress is known to not only be one of the 
contributing factors to mycoplasma infections, but to have a negative effect on the immune system by itself 
(which is why stressed birds are predisposed to mycoplasma infections) [Pretorius, 2009].  
Since the Ms01 organism has more epitopes than the Ms01 OppA protein, it was expected that if the 
ostriches used in the trial were indeed exposed to the Ms01 organism prior to or during the trial, that a Y-
intercept of larger than zero would be obtained in a comparison between the results obtained using the 
Ms01 whole cell ELISA and the Ms01 OppA ELISA. This was indeed found to be the case. This meant that 
the ELISA in which Ms01 whole cells were used as coating antigen was detecting antibodies against a 
greater number of antigens, than the ELISA in which Ms01 OppA protein was used as coating antigen. In 
addition, since the Ms01 OppA protein is one of the antigens present on the Ms01 organism, a direct 
relationship was expected between the Ms01 whole cell ELISA and the Ms01 OppA ELISA. However, 
although a positive relationship could be observed in three of the four groups which took part in the 
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vaccination trial, no direct relationship could be established in any of the groups. A possible explanation for 
this may be that the Ms01 OppA protein, which is a membrane protein, is partially masked on the Ms01 
whole cell. Alternatively, this might be explained by the fact that the Ms01 OppA protein antibody 
response is much more sensitive to change, since it represents only a portion of the entire antibody response 
to the Ms01 organism. Any change which occurred in the Ms01 OppA protein antibody response (whether 
it be in response to the DNA vaccines or for any other reason) may thus have been heavily diluted by other 
Ms01-specific antibodies in the serum, and perhaps not even detected by the Ms01 whole cell ELISA, while 
the same response would easily be detected by the Ms01 OppA ELISA and consequently cause differences 
in the antibody response trends to be observed between the two ELISAs. Finally, the finding that no 
correlation occurred between the weights of ostriches immunized and the antibody response obtained, 
suggests that: 1) the antibody responses elicited by the DNA vaccines are not dependant on the size of the 
vaccinated animal or 2) that no vaccine induced antibody response occurred in the ostriches.  
The results obtained during the vaccination trial did not show conclusively that the pCIneo, VR1012 and 
VR1020 DNA vaccines were effective in eliciting antibodies against the Ms01 organism and further studies 
will be required to evaluate whether they can be used to combat ostrich mycoplasma infections. It is 
imperative that in such studies it first be established that birds utilized during the vaccination trial were not 
previously exposed to the Ms01 organism. The ELISA developed for use in this trial provides a means with 
which to do this. In addition, measures should be taken to ensure that birds are exposed to as little stress as 
possible by, for example, not relocating the birds prior to or during the trial, minimizing handling and blood 
collection times, and ensuring that birds are kept in optimal housing conditions. It is obvious that when 
ostriches are exposed to avian influenza other vaccination trials are immediately invalidated. However, 
although the results achieved in the vaccination trial of this study were jeopardized by the above mentioned 
factors, they were extremely valuable in establishing the conditions under which such trials will have to be 
undertaken in future. Future trials will have to include optimization studies in which the quantity of vaccine 
administered, the time of booster vaccination administration, and the use of adjuvants are investigated to 
establish whether the Ms01 oppA gene contained in the pCIneo, VR1012 and VR1020 DNA vaccines is 
effective in protecting ostriches against Ms01 ostrich mycoplasma infections. 
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Chapter 5 - Conclusions and future perspectives 
While mycoplasmas may still call to mind an image of a group of incapable or ambiguous organisms, 
mounting evidence have brought their pervasive and pathogenic potential to the fore as sophisticated, 
evolutionary advanced pathogens [Baseman and Tully, 1997]. The lack of effective antibiotic and 
vaccination therapies with which to combat these organisms bears testimony to this fact. Investigations into 
new vaccination strategies with which to combat mycoplasmas were inspired by the isolation of three 
ostrich-infecting mycoplasmas, Ms01, Ms02 and Ms03, which cause huge losses to the South African 
ostrich industry each year. Vaccination using genes which encode immunogens, rather than the immunogen 
itself, has provided new possibilities for vaccine research, development and application, and thus stirred 
new hopes in the war against resilient pathogens [Gregersen, 2001]. Preliminary studies were conducted in 
which the ability of three such DNA vaccines, pCIneo, VR1012 and VR1020, to elicit antibody responses 
against the Ms01 OppA protein in ostriches, was evaluated. Since adherence is considered an essential step 
in the pathogenesis of mycoplasmas, the cytoadherence-related OppA protein was considered a good 
candidate for vaccine development. However, in order to assess the efficacy of the DNA vaccination trial, 
the development of an ELISA which probes for antibodies against the Ms01 OppA protein, was required. 
Thus, the Ms01 oppA gene was amplified, cloned, expressed and the resultant protein purified for use as 
coating antigen in the ELISA. Protein expression problems, as a result of the codon bias and large size of 
the Ms01 oppA gene, were overcome with the aid of a protein expression system utilizing a weaker 
promoter and a highly expressed GST purification tag. The identity of the expressed OppA protein was 
confirmed by means of SDS-PAGE and western blot, with the specific binding of serum antibodies to the 
antigen during the subsequent ELISA serving as additional confirmation.  
The ability of the pCIneo, VR1012 and VR1020 DNA vaccines to elicit antibody responses against the 
Ms01 OppA protein in ostriches could neither be confirmed nor rejected, due to the probable prior exposure 
of the ostriches used in the trial, to the Ms01 and/or Ms02 and Ms03 organisms. An important deduction to 
be made from this trial, however, is that there is probably a high prevalence of the ostrich-infecting 
mycoplasmas in the South African ostrich industry. It might thus be a good idea to formally evaluate the 
prevalence of the Ms01, Ms02 and Ms03 organisms in South African ostriches. In addition, mycoplasma 
infected ostriches are probably predisposed to other infections such as avian influenza (as witnessed during 
this trial). Although there is no indication in the modest amount of literature currently available on the 
ostrich-infecting mycoplasmas that avian influenza has been linked to ostrich mycoplasma infections, avian 
influenza has previously been linked to mycoplasma infections of poultry [Bradury, 1984; Nili and Asasi, 
2002; Nili and Asasi, 2003; Kleven, 2008]. Mycoplasmas and avian influenza both colonize the mucosal 
surfaces of birds (often causing respiratory infections) and thus occupy a similar niche. It might thus also 
prove useful to conduct a formal study to investigate whether or not mycoplasma infected ostriches are 
predisposed to avian influenza. Considering the results of the current avian influenza outbreak on the South 
African ostrich industry, as well as those in 2004 and 2006, such an investigation might not only serve to 
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illuminate some obscurities about the ostrich infecting mycoplasmas, but may also be of aid in the battle 
against future avian influenza outbreaks in South Africa.  
Furthermore, during vaccine development, the route of vaccine administration is known to be a key factor 
in the generation of immune responses. Since the mucosal surfaces serve not only as the portal of entry, but 
also as the target tissue of the ostrich infecting mycoplasmas, mucosal immunity in the host would be 
desirable [Oshop et al., 2002]. In recent years, DNA vaccines have been efficiently delivered in attenuated 
gram positive and gram negative intracellular bacteria such as Salmonella, Shigella and Listeria [Yang et 
al., 2009; Du et al., 2005; Pan et al., 2009]. This strategy enables administration of DNA vaccines via 
mucosal surfaces as well as delivery of the plasmid DNA directly to the antigen presenting cells which can 
elicit strong humoral and cellular immune responses against the pathogens from which the target gene was 
derived. Salmonella, in particular, has been successfully used to immunize against intracellular pathogens 
including NDV, hepatitis B virus and human immuno-deficiency virus (HIV). Moreover, secretory IgA 
(which is primarily responsible for mucosal immunity) specific for the antigens against which immunity 
was desired has been detected in the secretions of chickens vaccinated in this way. The possibility that 
Ms01 may be an intracellular organism, which may require a cellular immune response, makes the use of 
Salmonella as carrier for Ms01 DNA vaccines particularly promising. Also, a recent avian influenza 
vaccine study involving chickens found that the use of a Salmonella-delivered primary DNA vaccine and 
secondary (booster) inactivated vaccine induced strong immune responses and fully protected chickens 
from a high dose virus challenge [Pan et al., 2009]. Similar studies conducted on mammals, involving the 
use of an intramuscularly-delivered primary DNA vaccine and secondary protein-based vaccine, obtained 
similarly positive results [Oshop et al., 2002]. The use of a Salmonella-delivered primary Ms01 OppA 
DNA vaccine and a secondary protein-based vaccine may thus serve as a good starting point for future 
Ms01 vaccination trials.  
However, before any future DNA vaccination trials are initiated, the ostriches utilized should first be 
serologically tested for prior exposure to the ostrich infecting mycoplasmas. If possible, only ostriches 
which test negative for previous exposure to ostrich infecting mycoplasmas should be utilized in such a 
trial. In addition, ostriches used in such a trial should be tested for additional infections such as Salmonella 
infections. Birds found to be infected with any organisms should then be treated with an appropriate 
antibiotic three weeks before initiation of the vaccination trial. In order to minimize stress on the birds, 
birds should not be moved to a testing facility prior to the vaccination trial, but tested on the farm on which 
they grew up. Additionally, handling of birds should be minimized by not collecting blood samples more 
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Addendum A 
Alignment of the DNA sequences of the oppA gene cloned into the pET14b and pGEX-4T-1 prokaryotic 
expression vectors, with that of the modified oppA DNA sequence generated by Pretorius [2009]. 
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Addendum B 
The Ms01 oppA gene sequence. Rare codons are highlighted. 
 
atg aaa aaa agc gca AGA ctt tta tta tta ggt gct tta CCA tta gca gcc tta 
gca gct CCA tta gtt gct gcg gca TGT aat AGT aaa TCA gcc CCT TCG cag aac 
act gct tta gct aaa cag cag ttc gtt act gaa ATA aac gca ACA CCA ACA ttt 
gat gct tat ACA tat gat AGT TCA gct TCA tat ggt GGA tat tct TCA aat gct 
agc tac caa cac ACA TCA ggt atg tta gtt AGA gaa caa ggt gtt aat gaa att 
caa att gat ACA gtg acc TCA gac act GGA aaa gtt TCA aac tat att act aaa 
CCA gct ttc TCA aaa tat ACA tta TCA tta gca aaa gct gta gtt tta act tta 
ACA gat ggc ACA gtt gta gtt tac gat aat gat gat gct gaa gtt gtt CCT gca 
CCA gat tta act tat gta gat gct gca ggt gaa act aaa aaa gct tat TCA TCA 
gca tat caa AGA tta AGT TCA gca aat TCA aaa TCA att aat AGT caa gaa ttt 
gca gaa aac ttg aaa aaa gct aaa ACA tta caa tat gta ctt aaa gac aat tta 
aaa tgg gta aat TCA aaa ggt gaa gaa act aaa tat caa att gtt CCT aaa gat 
ttc tat tat TCA tgg CTA AGA ACA aat caa ACA att ggt aat gtt cgt cat gat 
gaa gaa aaa AGT GGA ggt TCA gaa caa tta gac aat gaa gtt AGA gat gca tta 
gca AGA CCT aac AGT cgt gta ttt ACA gat ACA AGT gaa tac TCA aat gaa tat 
gtt tta aaa atc ttt ggt tta gat aca gta aaa tta aat gaa gaa AGT gaa ttc 
gtt aaa aaa gtt gct CCA AGT gca aat tta GGA gat gta ACA gct gta acc ttc 
caa GGA tta ACA ggt gaa ggt gct aaa gtt caa atg aat caa ttt ttt gat caa 
tta atg cat gac tat ACA ttc tat CCA gct CCA TCA caa tac att gat gat atg 
aat gca ACA aat ggt tac aaa tta act aat tac caa ggc gat gta act gat aaa 
gtt tct gca CTA gaa act aaa TCA aaa gca atg gat aaa AGT aaa tta act gct 
aaa tta ggt gtt tac tgg tat ggt gta ACA gca aat AGT ACA ttg tat TCA GGA 
CCA tac tat gca caa ggc ttt gta AGT ggt caa TCA gaa ATA ttt aaa aag aat 
act cac ttt gca gaa aaa gcc ttt gca gaa tct aaa aat ACA gtt aat gaa att 
att ACA aac tat caa caa aaa acc tta agc CCT gaa gaa ttt aat ACA aac atc 
ttt aac tta tat AGA caa ggt act ACA TCA act act CCA tat TCA TCA tta act 
gaa gct caa aaa caa atc gtt aac caa gac CCA caa GGA ttt ggt att AGA tta 
ttc aaa AGA gaa aat act aat TCA gct CCT tat gat ATA atc caa act CCA ttt 
gtg ttt aac aat gtt act gca gat tac TCA ttt aac gat gct tat gct caa tta 
atg tat ggt aaa ACA ATA gaa gaa tta aaa gcc GGA aaa ggt ACA GGA gat gct 
tat att tac GGA ACA ggt tta AGT ttt AGA act tta tta caa gct gca att aac 
tgg aat ACA gta gca gat gta AGA ACA aac ggt gtt TCA gaa gct tgg ttg gcg 
aaa tta gcc gat ggt ggt aat att ggt GGA aaa gac caa gaa TCA TCA gca gaa 
aaa ACA CCA ttt gat gta aaa gat aaa att aat gca ttg aaa gct gta aat aaa 
gat aaa caa tta gtg gac ttc ggt ggc aat tta GGA aaa gat CTA aac CCA TCA 
gaa aac gat gct gct gtt AGA gac AGA tct aat gtc aac gac aaa ATA aaa TCA 
gct ggt tat gaa aaa att aaa gaa gct gta aaa gca tta tta gat gag ttt 
gaa AGA ACA cat caa aat gtt AGA ccg gca gat ggt aaa tat AGA ttc act TCA 
ttc tat CCA ttt att aat caa TCA aaa gaa ttt ggt gaa TCA tta aaa ttt gtt 
aaa gag gct ATA gaa GGA tta gat tct AGA att caa tta gat tta gta ttc ttt 
act gat aat aaa gat CCT aat tat gtt gca tat ATA aac caa GGA gca aat GGA 
ACA AGA aac gtt ggt tgg AGT tat gac tat aac TCA ATA ggt TCA ggt tat gat 
ggt tta TCA tgg aat tgg CCA tta ttc CCA act CTA att aaa att ggt gtt gaa 
aaa gat AGT cat CCA gaa ttt gct act gca ttt CCA AGA atc gct aaa tta gca 
gaa gat tta tta gct tat caa gaa caa CCA ggt cac gaa ttt gta tct TCA gta 
CCA ttt aaa gaa tta tac aaa gta gaa CCA AGA AGA tac ACA gta ttg CCT 
act CTA tta gct TCA aat gtt ACA aaa aat tct gta ACA gat aaa tat gag ctt 
gtt tta ACA gaa aaa aat AGA CCA ATA CCT tat aaa CCA caa ggt aat aag caa 
gta act gat att tat caa tac TCA gcg gtt ttc tgg aac caa tac gta gca gac 
aaa ACA aat gat tat tta act gaa tta atg gaa gaa CTA ACA ACA ttt tta ggt 
att gaa tat TCA TCA gca act ATA ACA aaa gca aaa gat TCA ttt gtt aac gtt 
tta gta caa aaa ggt tat gta gca CCT tac ACA gta aat aat agt gtt gac atg 
tat gtt gat tgg AGA atc aat aaa taa   
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Addendum C 
Ostrich weights as measured on day 35 of the DNA vaccination trial. 
 
Ostriches vaccinated 
with the pCIneo 
DNA vaccine 
Ostriches vaccinated 
with the VR1012 
DNA vaccine 
Ostriches vaccinated 
with the VR1020 
DNA vaccine 
Ostriches which did 















204 dead 208 62 205 58.5 201 55 
343 79.5 209 56 206 57 202 79 
363 92 322 65 207 dead 203 46.8 
427 58 434 58.5 321 93 329 64 
461 85.5 475 62.5 424 48.5 421 dead 
468 63.5 478 67 443 62.5 465 69.5 
477 85 487 72 451 56.5 469 48.2 
490 76.5 481 dead 467 56 474 63.5 
406 63.5 401 dead 491 53.5 456 56 
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Addendum D 
The raw data obtained during the serological analyses of the ostriches in the DNA vaccination trial, as 
determined by the ELISA using the Ms01 OppA protein as coating antigen, follows on the next page. This 
is directly followed by the raw data obtained when the ELISA using Ms01 whole cells as coating antigen, 
was used for the serological analyses. The data are arranged in three columns, each containing the ostrich 
identification number, treatment (Trt), time and response (Rsp) on each page. Columns are read from top to 
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ELISA using the OppA 
protein as antigen:  
 
Ostrich Trt Time  Resp 
204 1 0 0.395 
343 1 0 0.214 
363 1 0 0.527 
427 1 0 2.139 
461 1 0 0.284 
468 1 0 0.866 
477 1 0 - 
490 1 0 - 
406 1 0 0.319 
416 1 0 0.481 
209 2 0 0.830 
322 2 0 0.275 
434 2 0 0.625 
475 2 0 0.266 
478 2 0 0.234 
487 2 0 0.288 
481 2 0 0.340 
401 2 0 0.635 
454 2 0 0.470 
208 2 0 0.061 
205 3 0 0.307 
206 3 0 0.178 
321 3 0 0.653 
424 3 0 0.395 
443 3 0 0.772 
451 3 0 1.225 
467 3 0 0.960 
491 3 0 0.250 
404 3 0 0.052 
201 4 0 0.440 
202 4 0 0.379 
203 4 0 0.089 
329 4 0 0.563 
465 4 0 0.029 
469 4 0 0.475 
474 4 0 0.279 
456 4 0 0.166 
483 4 0 0.195 
204 1 7 0.000 
343 1 7 0.201 
363 1 7 0.327 
427 1 7 0.192 
461 1 7 0.467 
468 1 7 0.152 
477 1 7 0.377 
490 1 7 0.372 
406 1 7 0.262 
416 1 7 0.302 
209 2 7 0.182 
322 2 7 0.322 
434 2 7 0.253 
475 2 7 0.122 
478 2 7 0.000 
487 2 7 0.106 
481 2 7 0.438 
401 2 7 0.423 
454 2 7 0.485 
208 2 7 0.000 
205 3 7 0.248 
206 3 7 0.000 
321 3 7 0.000 
424 3 7 0.150 
443 3 7 0.140 
451 3 7 0.115 
467 3 7 0.000 
491 3 7 0.114 
404 3 7 0.133 
201 4 7 0.376 
202 4 7 0.373 
203 4 7 0.209 
329 4 7 0.081 
465 4 7 0.057 
469 4 7 0.000 
474 4 7 0.195 
456 4 7 0.120 
483 4 7 0.101 
204 1 14 - 
343 1 14 0.224 
363 1 14 0.300 
427 1 14 0.061 
461 1 14 0.824 
468 1 14 0.472 
477 1 14 0.000 
490 1 14 0.032 
406 1 14 0.245 
416 1 14 0.399 
209 2 14 0.000 
322 2 14 0.168 
434 2 14 0.153 
475 2 14 0.047 
478 2 14 0.000 
487 2 14 0.191 
481 2 14 0.265 
401 2 14 0.436 
454 2 14 0.288 
208 2 14 0.077 
205 3 14 0.000 
206 3 14 0.282 
321 3 14 0.000 
424 3 14 0.050 
443 3 14 0.229 
451 3 14 0.133 
467 3 14 0.000 
491 3 14 0.190 
404 3 14 0.000 
201 4 14 0.394 
202 4 14 0.309 
203 4 14 0.111 
329 4 14 0.017 
465 4 14 0.020 
469 4 14 0.000 
474 4 14 0.310 
456 4 14 0.162 
483 4 14 0.170 
204 1 21 - 
343 1 21 0.342 
363 1 21 0.136 
427 1 21 0.000 
461 1 21 0.439 
468 1 21 0.466 
477 1 21 0.000 
490 1 21 0.199 
406 1 21 0.207 
416 1 21 0.258 
209 2 21 0.000 
322 2 21 0.116 
434 2 21 0.145 
475 2 21 0.051 
478 2 21 0.000 
487 2 21 0.071 
481 2 21 - 
401 2 21 0.396 
454 2 21 0.291 
208 2 21 0.091 
205 3 21 0.000 
206 3 21 0.000 
321 3 21 0.000 
424 3 21 0.000 
443 3 21 0.060 
451 3 21 0.113 
467 3 21 0.290 
491 3 21 0.232 
404 3 21 0.025 
201 4 21 0.467 
202 4 21 0.416 
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203 4 21 0.340 
329 4 21 0.087 
465 4 21 0.062 
469 4 21 0.000 
474 4 21 0.229 
456 4 21 0.185 
483 4 21 0.148 
204 1 28 - 
343 1 28 0.257 
363 1 28 0.335 
427 1 28 0.000 
461 1 28 0.068 
468 1 28 0.319 
477 1 28 0.162 
490 1 28 0.215 
406 1 28 0.370 
416 1 28 0.281 
209 2 28 0.000 
322 2 28 0.083 
434 2 28 0.145 
475 2 28 0.167 
478 2 28 0.000 
487 2 28 0.066 
481 2 28 - 
401 2 28 - 
454 2 28 0.357 
208 2 28 0.202 
205 3 28 1.197 
206 3 28 0.019 
321 3 28 0.000 
424 3 28 0.000 
443 3 28 0.129 
451 3 28 0.051 
467 3 28 0.000 
491 3 28 0.154 
404 3 28 0.079 
201 4 28 0.403 
202 4 28 0.214 
203 4 28 0.125 
329 4 28 0.085 
465 4 28 0.217 
469 4 28 0.000 
474 4 28 0.672 
456 4 28 0.191 
483 4 28 0.185 
204 1 35 - 
343 1 35 0.237 
363 1 35 0.151 
427 1 35 0.000 
461 1 35 0.616 
468 1 35 0.817 
477 1 35 0.000 
490 1 35 0.253 
406 1 35 0.233 
416 1 35 0.176 
209 2 35 0.000 
322 2 35 0.205 
434 2 35 0.215 
475 2 35 0.123 
478 2 35 0.000 
487 2 35 0.075 
481 2 35 - 
401 2 35 - 
454 2 35 0.260 
208 2 35 0.000 
205 3 35 0.008 
206 3 35 0.031 
321 3 35 0.211 
424 3 35 0.000 
443 3 35 0.105 
451 3 35 0.093 
467 3 35 0.438 
491 3 35 0.167 
404 3 35 0.000 
201 4 35 0.337 
202 4 35 0.188 
203 4 35 0.152 
329 4 35 0.122 
465 4 35 0.128 
469 4 35 0.000 
474 4 35 0.606 
456 4 35 0.106 
483 4 35 0.009 
204 1 42 - 
343 1 42 0.213 
363 1 42 0.129 
427 1 42 0.000 
461 1 42 0.118 
468 1 42 0.462 
477 1 42 0.014 
490 1 42 0.164 
406 1 42 0.218 
416 1 42 0.121 
209 2 42 0.000 
322 2 42 0.303 
434 2 42 0.097 
475 2 42 0.080 
478 2 42 0.000 
487 2 42 0.031 
481 2 42 - 
401 2 42 - 
454 2 42 0.266 
208 2 42 0.134 
205 3 42 0.000 
206 3 42 0.088 
321 3 42 0.000 
424 3 42 0.000 
443 3 42 0.431 
451 3 42 0.305 
467 3 42 0.048 
491 3 42 0.181 
404 3 42 0.000 
201 4 42 0.383 
202 4 42 0.401 
203 4 42 0.452 
329 4 42 0.205 
465 4 42 0.000 
469 4 42 0.000 
474 4 42 0.310 
456 4 42 0.232 
483 4 42 0.000 
204 1 49 - 
343 1 49 0.376 
363 1 49 0.075 
427 1 49 0.000 
461 1 49 0.148 
468 1 49 0.558 
477 1 49 0.021 
490 1 49 1.086 
406 1 49 - 
416 1 49 0.242 
209 2 49 0.000 
322 2 49 0.007 
434 2 49 0.045 
475 2 49 0.067 
478 2 49 0.000 
487 2 49 0.043 
481 2 49 - 
401 2 49 - 
454 2 49 0.055 
208 2 49 0.244 
205 3 49 0.000 
206 3 49 0.075 
321 3 49 0.000 
424 3 49 0.011 
443 3 49 0.368 
451 3 49 0.128 
467 3 49 0.347 
491 3 49 0.212 
404 3 49 0.000 
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201 4 49 0.459 
202 4 49 0.480 
203 4 49 1.350 
329 4 49 0.147 
465 4 49 0.813 
469 4 49 0.000 
474 4 49 0.658 
456 4 49 - 
483 4 49 - 
204 1 58 - 
343 1 58 0.179 
363 1 58 0.000 
427 1 58 0.000 
461 1 58 0.656 
468 1 58 0.619 
477 1 58 0.000 
490 1 58 0.248 
406 1 58 0.293 
416 1 58 0.188 
209 2 58 0.000 
322 2 58 0.027 
434 2 58 0.112 
475 2 58 0.070 
478 2 58 0.000 
487 2 58 0.138 
481 2 58 - 
401 2 58 - 
454 2 58 0.314 
208 2 58 0.532 
205 3 58 0.000 
206 3 58 0.000 
321 3 58 0.000 
424 3 58 0.201 
443 3 58 0.261 
451 3 58 0.059 
467 3 58 0.233 
491 3 58 0.309 
404 3 58 0.000 
201 4 58 0.494 
202 4 58 0.359 
203 4 58 0.232 
329 4 58 0.404 
465 4 58 0.114 
469 4 58 0.000 
474 4 58 0.695 
456 4 58 - 
483 4 58 - 
204 1 64 - 
343 1 64 0.429 
363 1 64 0.575 
427 1 64 0.414 
461 1 64 0.915 
468 1 64 0.735 
477 1 64 0.234 
490 1 64 0.591 
406 1 64 0.083 
416 1 64 0.104 
209 2 64 0.000 
322 2 64 0.129 
434 2 64 0.159 
475 2 64 0.097 
478 2 64 0.000 
487 2 64 0.094 
481 2 64 - 
401 2 64 - 
454 2 64 0.431 
208 2 64 0.608 
205 3 64 0.042 
206 3 64 0.022 
321 3 64 0.000 
424 3 64 0.000 
443 3 64 0.049 
451 3 64 0.279 
467 3 64 0.100 
491 3 64 0.230 
404 3 64 0.035 
201 4 64 0.533 
202 4 64 0.431 
203 4 64 0.608 
329 4 64 0.042 
465 4 64 0.022 
469 4 64 0.000 
474 4 64 0.000 
456 4 64 - 
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ELISA using Mso1 whole 
cells as antigen: 
 
Ostrich Trt Time Resp 
204 1 0 1.214 
343 1 0 1.336 
363 1 0 1.741 
427 1 0 0.946 
461 1 0 1.767 
468 1 0 1.868 
477 1 0 1.659 
490 1 0 2.16 
406 1 0 2.088 
416 1 0 2.034 
209 2 0 1.393 
322 2 0 1.625 
434 2 0 2.427 
475 2 0 1.066 
478 2 0 2.038 
487 2 0 1.491 
481 2 0 1.535 
401 2 0 1.893 
454 2 0 - 
208 2 0 0.612 
205 3 0 1.727 
206 3 0 1.286 
321 3 0 0.968 
424 3 0 0.618 
443 3 0 0.948 
451 3 0 1.206 
467 3 0 0.996 
491 3 0 1.194 
404 3 0 0.561 
201 4 0 0.996 
202 4 0 0.1 
203 4 0 1.121 
329 4 0 1.257 
465 4 0 1.599 
469 4 0 2.625 
474 4 0 1.71 
456 4 0 2.027 
483 4 0 2.316 
204 1 7 0.923 
343 1 7 1.307 
363 1 7 1.68 
427 1 7 1.104 
461 1 7 0.959 
468 1 7 1.793 
477 1 7 1.16 
490 1 7 1.678 
406 1 7 1.662 
416 1 7 1.963 
209 2 7 1.525 
322 2 7 1.655 
434 2 7 1.693 
475 2 7 1.122 
478 2 7 1.636 
487 2 7 1.579 
481 2 7 1.253 
401 2 7 1.52 
454 2 7 0.643 
208 2 7 0.231 
205 3 7 1.107 
206 3 7 0.531 
321 3 7 0.914 
424 3 7 0.507 
443 3 7 0.51 
451 3 7 0.884 
467 3 7 0.638 
491 3 7 1.48 
404 3 7 0.473 
201 4 7 0.649 
202 4 7 0.611 
203 4 7 1.146 
329 4 7 0.989 
465 4 7 1.408 
469 4 7 1.253 
474 4 7 1.233 
456 4 7 1.451 
483 4 7 1.271 
204 1 14 - 
343 1 14 1.096 
363 1 14 1.477 
427 1 14 1.285 
461 1 14 0.96 
468 1 14 1.571 
477 1 14 0.912 
490 1 14 0.849 
406 1 14 1.625 
416 1 14 1.995 
209 2 14 1.092 
322 2 14 1.806 
434 2 14 1.906 
475 2 14 0.853 
478 2 14 1.575 
487 2 14 1.348 
481 2 14 1.34 
401 2 14 1.551 
454 2 14 0.535 
208 2 14 0.645 
205 3 14 1.525 
206 3 14 0.804 
321 3 14 0.874 
424 3 14 0.776 
443 3 14 0.718 
451 3 14 1.265 
467 3 14 0.924 
491 3 14 1.635 
404 3 14 0.383 
201 4 14 0.674 
202 4 14 0.393 
203 4 14 1.142 
329 4 14 0.823 
465 4 14 1.169 
469 4 14 1.63 
474 4 14 1.09 
456 4 14 1.448 
483 4 14 1.454 
204 1 21 - 
343 1 21 0.853 
363 1 21 1.504 
427 1 21 0.63 
461 1 21 0.471 
468 1 21 1.147 
477 1 21 1.269 
490 1 21 0.583 
406 1 21 1.372 
416 1 21 1.91 
209 2 21 0.912 
322 2 21 1.691 
434 2 21 2.343 
475 2 21 0.883 
478 2 21 1.223 
487 2 21 1.459 
481 2 21 - 
401 2 21 1.317 
454 2 21 0.374 
208 2 21 0.492 
205 3 21 1.393 
206 3 21 1.125 
321 3 21 0.771 
424 3 21 1.023 
443 3 21 0.665 
451 3 21 1.162 
467 3 21 1.213 
491 3 21 1.437 
404 3 21 0.33 
201 4 21 0.404 
202 4 21 0.323 
Stellenbosch University  http://scholar.sun.ac.za
 108 
203 4 21 0.952 
329 4 21 0.837 
465 4 21 1.24 
469 4 21 1.102 
474 4 21 1.262 
456 4 21 1.411 
483 4 21 1.3 
204 1 28 - 
343 1 28 0.765 
363 1 28 1.741 
427 1 28 0.593 
461 1 28 0.683 
468 1 28 1.172 
477 1 28 1.168 
490 1 28 0.791 
406 1 28 1.274 
416 1 28 1.853 
209 2 28 1.472 
322 2 28 1.672 
434 2 28 2.202 
475 2 28 1.357 
478 2 28 1.29 
487 2 28 2.22 
481 2 28 - 
401 2 28 - 
454 2 28 0.481 
208 2 28 0.685 
205 3 28 1.107 
206 3 28 0.834 
321 3 28 1.249 
424 3 28 0.906 
443 3 28 0.858 
451 3 28 1.05 
467 3 28 0.985 
491 3 28 0.722 
404 3 28 0.588 
201 4 28 0.538 
202 4 28 0.211 
203 4 28 0.907 
329 4 28 1.229 
465 4 28 1.707 
469 4 28 1.643 
474 4 28 1.472 
456 4 28 1.851 
483 4 28 1.078 
204 1 35 - 
343 1 35 1.693 
363 1 35 1.701 
427 1 35 1.354 
461 1 35 1.552 
468 1 35 1.507 
477 1 35 1.421 
490 1 35 0.82 
406 1 35 1.027 
416 1 35 1.717 
209 2 35 1.618 
322 2 35 1.296 
434 2 35 2.295 
475 2 35 0.636 
478 2 35 1.317 
487 2 35 1.066 
481 2 35 - 
401 2 35 - 
454 2 35 0.379 
208 2 35 0.457 
205 3 35 1.294 
206 3 35 0.625 
321 3 35 0.919 
424 3 35 0.952 
443 3 35 0.599 
451 3 35 1.228 
467 3 35 1.124 
491 3 35 1.461 
404 3 35 0.404 
201 4 35 0.444 
202 4 35 0.128 
203 4 35 1.329 
329 4 35 0.978 
465 4 35 1.362 
469 4 35 1.368 
474 4 35 1.585 
456 4 35 1.255 
483 4 35 1.168 
204 1 42 - 
343 1 42 1.156 
363 1 42 1.696 
427 1 42 1.096 
461 1 42 0.728 
468 1 42 1.243 
477 1 42 1.235 
490 1 42 0.484 
406 1 42 1.569 
416 1 42 1.503 
209 2 42 0.425 
322 2 42 1.424 
434 2 42 2.126 
475 2 42 0.581 
478 2 42 0.93 
487 2 42 1.443 
481 2 42 - 
401 2 42 - 
454 2 42 0.466 
208 2 42 0.841 
205 3 42 1.048 
206 3 42 0.865 
321 3 42 0.982 
424 3 42 0.771 
443 3 42 0.754 
451 3 42 0.991 
467 3 42 1.073 
491 3 42 0.938 
404 3 42 0.383 
201 4 42 0.592 
202 4 42 0 
203 4 42 1.777 
329 4 42 0.81 
465 4 42 1.136 
469 4 42 1.371 
474 4 42 1.62 
456 4 42 1.061 
483 4 42 1.138 
204 1 49 - 
343 1 49 1.071 
363 1 49 1.529 
427 1 49 0.532 
461 1 49 0.86 
468 1 49 1.35 
477 1 49 1.57 
490 1 49 1.035 
406 1 49 1.584 
416 1 49 1.508 
209 2 49 0.329 
322 2 49 1.374 
434 2 49 2.075 
475 2 49 0.637 
478 2 49 1.114 
487 2 49 1.374 
481 2 49 - 
401 2 49 - 
454 2 49 0.606 
208 2 49 0.295 
205 3 49 1.063 
206 3 49 0.698 
321 3 49 1.121 
424 3 49 0.574 
443 3 49 0.446 
451 3 49 0.854 
467 3 49 0.768 
491 3 49 0.743 
404 3 49 - 
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201 4 49 0.511 
202 4 49 0.333 
203 4 49 0.93 
329 4 49 0.795 
465 4 49 1.035 
469 4 49 0.819 
474 4 49 0.986 
456 4 49 - 
483 4 49 - 
204 1 58 - 
343 1 58 1.026 
363 1 58 1.685 
427 1 58 0.806 
461 1 58 1.848 
468 1 58 1.334 
477 1 58 1.554 
490 1 58 0.572 
406 1 58 1.475 
416 1 58 1.802 
209 2 58 0.82 
322 2 58 1.434 
434 2 58 1.994 
475 2 58 0.924 
478 2 58 1.368 
487 2 58 2.19 
481 2 58 - 
401 2 58 - 
454 2 58 0.734 
208 2 58 0.453 
205 3 58 1.046 
206 3 58 0.359 
321 3 58 1.079 
424 3 58 1.177 
443 3 58 0.686 
451 3 58 1.089 
467 3 58 1.163 
491 3 58 1.099 
404 3 58 0.32 
201 4 58 0.48 
202 4 58 0.257 
203 4 58 1.084 
329 4 58 0.801 
465 4 58 1.089 
469 4 58 0.796 
474 4 58 1.679 
456 4 58 - 
483 4 58 - 
204 1 64 - 
343 1 64 0.624 
363 1 64 0.93 
427 1 64 0.933 
461 1 64 1.611 
468 1 64 1.859 
477 1 64 1.779 
490 1 64 1.348 
406 1 64 1.319 
416 1 64 1.578 
209 2 64 0 
322 2 64 0.861 
434 2 64 1.961 
475 2 64 0.738 
478 2 64 1.337 
487 2 64 1.124 
481 2 64 - 
401 2 64 - 
454 2 64 0.651 
208 2 64 0.44 
205 3 64 1.272 
206 3 64 - 
321 3 64 0.991 
424 3 64 0.993 
443 3 64 0.781 
451 3 64 1.069 
467 3 64 0.999 
491 3 64 1.437 
404 3 64 0.209 
201 4 64 0.345 
202 4 64 0.498 
203 4 64 1.264 
329 4 64 0.759 
465 4 64 1.562 
469 4 64 0.603 
474 4 64 1.886 
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